EP1313710A1 - Pyrazole derivatives and their use as protein kinase inhibitors - Google Patents

Pyrazole derivatives and their use as protein kinase inhibitors

Info

Publication number
EP1313710A1
EP1313710A1 EP01958287A EP01958287A EP1313710A1 EP 1313710 A1 EP1313710 A1 EP 1313710A1 EP 01958287 A EP01958287 A EP 01958287A EP 01958287 A EP01958287 A EP 01958287A EP 1313710 A1 EP1313710 A1 EP 1313710A1
Authority
EP
European Patent Office
Prior art keywords
pyrazol
cyclobutyl
phenyl
acetamide
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01958287A
Other languages
German (de)
French (fr)
Inventor
Christopher B. Pfizer Global Rch. & Dev. COOPER
Christopher J. Pfizer Global Rch. & Dev. HELAL
Mark A. Pfizer Global Research and Dev. SANNER
Travis T. Pfizer Global Research and Dev. WAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1313710A1 publication Critical patent/EP1313710A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the subject invention relates to pyrazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system.
  • the compounds of the present invention act as inhibitors of cyciin-dependent protein kinase enzymes cdk5 (cyciin-dependent protein kinase 5) and cdk2 (cyciin-dependent protein kinase 2).
  • the compounds of the present invention also are inhibitors of the enzyme GSK-3 (glygocen synthase kinase-3) enzyme.
  • cdk5 serine/threonine kinase cdk5 along with its cofactor p25 (or the longer cofactor, p35) has been linked to neurodegenerative disorders, and inhibitors of cdk5/p25 (or cdk5/p35) are therefore useful for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, stroke, or Huntington's disease.
  • Treatment of such neurodegenerative disorders using cdk5 inhibitors is supported by the finding that cdk5 is involved in the phosphorylation of tau protein (J. Biochem, 117, 741-749 (1995)).
  • cdk5 also phosphorylates Dopamine and Cyclic AMP-Regulated Phosphorprotein (DARPP-32) at threonine 75 and is thus indicated in having a role in dopaminergic neurotransmission (Nature, 402, 669-671 (1999)).
  • DARPP-32 Cyclic AMP-Regulated Phosphorprotein
  • the serine/threonine kinase cdk2 is essential for normal cell cycling and plays a critical role in disorders arising from abnormal cell cycling, a common characteristic of many oncological disorders. Inhibitors of cdk2 are therefore useful for the treatment of various types of cancer and other diseases or conditions related to abnormal cell growth (Meijer, et al., Properties and Potential-applications of Chemical Inhibitors of Cyciin-dependent Kinsases, Pharmacology & therapeutics, 82 (2-3), 279-284 (1999); Sausville, et al., Cyciin-dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target, Pharmacology & therapeutics 82 (2-3) 285-292 (1999)).
  • GSK-3 is a serine/threonine protein kinase. It is one of several protein kinases which phosphorylate glycogen synthase (Embi, et al., Eur. J. Biochem. 107:519-527 (1980); Hemmings, et al., Eur. J. Biochem. 119:443-451 (1982)). GSK-3 exists in two isoforms, and ⁇ , in vertebrates, reported as having a monomeric structure of 49kD and 47kD respectively. Both isoforms phosphorylate muscle glycogen synthase (Cross, et al., Biochemical Journal 303: 21-26 (1994)).
  • GSK-3 has been implicated in numerous different disease states and conditions. For example, Chen, et al, Diabetes 43: 1234-1241 (1994) have suggested that an increase in GSK-3 activity can be important in Type 2 diabetes. Increased GSK-3 expression in diabetic muscle is also though to contribute to the impaired glycogen synthase activity and skeletal muscle insulin resistance present in Type 2 diabetes (Nikoulina, et al., Diabetes 49: 263-271 (2000)). Also, a higher activity of a type 1 protein phosphatase measured in immotile sperm was attributed to higher GSK-3 activity and was indicated as responsible for holding the sperm motility in check (Vijayaraghavan, et al. Biology of Reproduction 54: 709-718 (1996)).
  • GSK-3 activity has also been associated with Alzheimer's disease and mood disorders such as bipolar disorder (WO 97/41854).
  • GSK-3 has furthermore been implicated in hair loss, schizophrenia, and neurodegeneration, including both chronic neurodegenerative diseases (such as Alzheimer's, supra) and neurotrauma, for example stroke, traumatic brain injury, and spinal cord trauma.
  • R 1 is a straight chain or branched (C.
  • R 4 is a straight chain or a branched (C r C 8 )alkyl, a straight chain or a branched (C 2 - C 8 )alkenyl, a straight chain or branched (C 2 -C 8 alkynyl), (C 3 -C 8 )cycloalkyl, (C 4 -C 8 )cycloalkenyl, (3-8 membered) heterocycloalkyl, (C 5 -C 11 )bicycloalkyl, (C C ⁇ bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C 6 -C 14 )aryl, or (5-14 membered) heteroaryl; and wherein R 4 is optionally substituted with from one to three
  • Amino-substituted pyrazoles can exist as mixtures of tautomeric isomers in equilibrium with one another.
  • the present invention includes all such tautomers of compounds of formula 1, and references herein to compounds of formula 1, unless otherwise indicated, encompass also the tautomers of compounds of formula 1.
  • Compounds of formula 1 of the invention are inhibitors of serine/threonine kinases, especially cyciin-dependent kinases such as cdk ⁇ and cdk2, and are useful for the treatment of neurodegenerative disorders and other CNS disorders, and of abnormal cell growth, including cancer.
  • the compounds of formula 1 are particularly useful in inhibiting cdk5.
  • the compounds of formula 1 are also useful as inhibitors of GSK-3.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyi.
  • alkynyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.
  • alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.
  • cycloalkyl includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above.
  • examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Bicycloalkyl groups are non-aromatic saturated carbocyclic groups consisting of two rings, wherein said rings share one or two carbon atoms.
  • bicycloalkyl groups include spiro groups and fused ring groups.
  • bicycloalkyl groups include, but are not limited to, bicyclo-[3.1.0]- hexyl, norbornyl, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[4.3]octyl, and spiro[4.2]heptyl.
  • Cycloalkenyl and “bicycloalkenyl” refer to non-aromatic carbocyclic cycloalkyl and bicycloalkyl moieties as defined above, except comprising one or more carbon-carbon double bonds connecting carbon ring members (an “endocyclic” double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an “exocyclic” double bond).
  • Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl and cyclobutenyl, and a non-limiting example of a bicycloalkenyl group is norbornenyl.
  • Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups that are substituted with one or more oxo moieties. Examples of such groups with oxo moieties are oxocyclopentyl, oxocyclobutyl, oxocyclopentenyl, and norcamphoryl.
  • aryl includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, and fluorenyl.
  • heterocyclic refers to non-aromatic cyclic groups containing one or more heteroatoms, prefereabiy from one to four heteroatoms, each selected from O, S and N.
  • Heterobicycloalkyl are non-aromatic two- ringed cyclic groups, wherein said rings share one or two atoms, and wherein at least one of the rings contains a heteroatom (O, S, or N).
  • Heterobicycloalkyl groups for purposes of the present invention, and unless otherwise indicated, include spiro groups and fused ring groups.
  • each ring in the heterobicycloalkyl contains up to four heteroatoms (i.e. from zero to four heteroatoms, provided that at least one ring contains at least one heteroatom).
  • the heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1 ,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3- dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]
  • Heteroaryl refers to aromatic groups containing one or more heteroatoms (O, S, or N), preferably from one to four heteroatoms.
  • a multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a "heteroaryl” group.
  • the heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,
  • a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • the terms referring to the groups also encompass all possible tautomers.
  • R 3 is -(CR 10 R 11 ) n -, and n is zero.
  • R 3 is -(CR 10 R 1 ) n -, n is zero, and R 4 is (C 6 -C 14 )aryl or (5-14 membered) heteroaryl, each optionally substituted as recited above.
  • a compound of formula 1 wherein R 1 is optionally substituted (C 3 -C 8 )cycloalkyl or optionally substituted bicycloalkyl.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, each optionally substituted as recited above (i.e.
  • a compound of formula 1 wherein R 1 is optionally substituted straight chain or branched (C.,-C B )alkyl or optionally substituted straight chain or branched (C 2 -C 8 )alkenyl.
  • compounds of formula 1 are provided, but wherein R 2 is hydrogen.
  • R 2 is hydrogen, and R 1 is as subdefined in the preceding paragraphs.
  • this invention provides a compound of formula 1 wherein R 4 is (C 6 -C 14 )aryl or (5-14 membered) heteroaryl, each optionally substituted.
  • R 4 is optionally substituted phenyl or optionally substituted pyridyl.
  • R 4 is naphthyl, quinolyl, or isoquinolyl, each optionally substituted.
  • R 4 is napthyl, quinolyl, or isoquinolyl, and is unsubstituted.
  • R 4 is pyrimidinyl, pyrazinyl, or pyridazyl, and in each case R 4 is optionally substituted.
  • R 4 is pyrimidinyl, pyrazinyl, or pyridazyl, and R 4 is unsubstituted.
  • Examples of preferred compounds of formula 1 are: (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine;
  • 6-chloro-pyridine-2-carboxylic acid (c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl ⁇ -amide; quinoline-2-carboxylic acid ⁇ c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl ⁇ -amide; pyrazine-2-carboxylic acid ⁇ c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl ⁇ -amide;
  • 6-methyl-pyridine-2-carboxylic acid (3- ⁇ 5-[2-(4-methoxy-phenyl)-acetylamino]-2H- pyrazol-3-yl ⁇ -cyclobutyl)-annide; 6-methyl-pyridine-2-carboxylic acid (3- ⁇ 5-[2-(4-chloro-phenyl)-acetylamino]-2H- pyrazol-3-yl ⁇ -cyclobutyl)-amide; and pharmaceutically acceptable salts of said compounds.
  • Salts of compounds of formula 1 can be obtained by forming salts with any acidic or basic group present on a compound of formula 1.
  • Examples of pharmaceutically acceptable salts of the compounds of formula 1 are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid, mandelic acid, sodium, potassium, magnesium, calcium, and lithium.
  • the compounds of formula 1 may have optical centers and therefore may occur in different enantiomeric and other stereoisomeric configurations.
  • the invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of formula 1, as well as racemic and other mixtures thereof.
  • the subject invention also includes isotopically-labeled compounds, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 l and 125 l.
  • Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • Isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. 11 C and 18 F isotopes are particularly useful in PET (positron emission tomography), and 1 5 l isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • Isotopically labeled compounds of formula 1 of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
  • This invention also includes compounds of the formula
  • n 1
  • This invention also provides a pharmaceutical composition for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective in inhibiting abnormal cell growth, and a pharmaceutically acceptable carrier.
  • This invention also provides a pharmaceutical composition for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective to inhibit cdk2 activity, and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting abnormal cell growth.
  • This invention also provides a method for treating a diseases or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective to inhibit cdk2 activity.
  • the disease or condition comprising abnormal cell growth is in one embodiment cancer.
  • the cancer may be a carcinoma, for example carcinoma of the bladder, breast, colon, kidney, liver, lung, for example small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin, for example squamous cell carcinoma; a hematopoietic tumor of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumor of myeloid lineage, for example acute and chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia; a tumor
  • the disease or condition comprising abnormal cell growth is benign.
  • diseases and conditions include benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, fungal infection, and endotoxic shock.
  • This invention also provides a pharmaceutical composition for treating a neurodegenerative disease or condition in a mammal, including a human, comprising a compound of formula 1 in an amount effective in treating said disease or condition, and a pharmaceutically acceptable carrier.
  • This invention also provides a pharmaceutical composition for treating a neurodegenerative disease or condition in a mammal, including a human, comprising a compound of formula 1 in an amount effective in inhibiting cdk5 activity, and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating a neurodegnerative disease or condition in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdk5 activity.
  • This invention also provides a method for treating a neurodegenerative disease or condition in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in treating said disease or condition.
  • the neurodegenerative disease or condition which is treated is selected from Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, neurodegeneration associated with bacterial infection, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age- related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myoto ⁇ ic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, and subacute sclerosing panencephalistis.
  • Huntington's disease Huntington's disease
  • stroke spinal cord trauma
  • traumatic brain injury traumatic brain injury
  • multiinfarct dementia
  • This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising a compound of formula 1 in an amount effective in treating said disease or condition and a pharmaceutically acceptable carrier.
  • This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising a compound of formula 1 in an amount effective to inhibit cdk ⁇ and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdk ⁇ activity.
  • This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in treating said disease or condition.
  • the disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission is selected from Parkinson's disease; schizophrenia; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance- induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; personality disorder of the schizoid type; drug addiction, including narcotic (e.g.
  • a major depressive episode a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features or with melancholic features or catatonic features, a mood episode with postpartum onset; post-stroke depression, major depressive disorder, dysthymic disorder, minor depressive disorder, premenstrual dysphoric disorder, post-psychotic depressive disorder of schizophrenia, a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia, a bipolar disorder, for example bipolar I disorder, bipolar II disorder, cyclothymic disorder; anxiety; attention deficit and hyperactivity disorder; and attention deficit disorder.
  • This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by decreasing cdk5 activity in a mammal, including a human, which composition comprises a compound of formula 1 in an amount effective in inhibiting cdk ⁇ activity and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by decreasing cdk5 activity in a mammal, including a human, which method comprises administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdk ⁇ activity.
  • the compounds of formula 1 have activity in inhibiting GSK- 3.
  • the compounds of formula 1 therefore can be expected to be useful in treating diseases and conditions the treatment of which can be effected or facilitated by inhibition of GSK-3.
  • Diseases and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include neurodegenerative diseases and conditions.
  • Neurodegenerative diseases and conditions are discussed above and include, but are not limited to, for example Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, cerebral ischemia, AIDS-related dementia, neurodegeneration associated with bacterial infection, multiinfarct dementia, traumatic brain injury, and spinal cord trauma. Therefore, compounds of formula 1 are effective in treating neurodegenerative diseases and conditions based on both cdk5 activity and GSK-3 activity.
  • GSK-3 diseases and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include psychotic disorders and conditions, for example schizophrenia, schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type.
  • the treatment of such diseases and conditions can also be effected or facilitated by altering dopamine mediated neurotransmission. Therefore, compounds of formula 1 are effective in treating such disorders and conditions based on both cdk ⁇ activity and GSK-3 activity.
  • disorders and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include mood disorders and mood episodes, for example a major depressive episode, a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features or with melancholic features or catatonic features, a mood episode with postpartum onset; post-stroke depression, major depressive disorder, dysthymic disorder, minor depressive disorder, premenstrual dysphoric disorder, post-psychotic depressive disorder of schizophrenia, a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia, a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymic disorder.
  • a major depressive episode for example a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features or with melancholic features or catatonic features, a mood episode with postpartum onset
  • post-stroke depression major depressive disorder, dysthymic disorder
  • GSK-3 disorders and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 are male fertility and sperm motility; diabetes mellitus; impaired glucose 0 tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; spinal cord injury; hair loss, hair thinning, and balding; immunodeficiency; and cancer.
  • the present invention also provides a pharmaceutical composition for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example 0 muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which composition comprises a pharmaceutically acceptable carrier and an amount of a compound of formula 1 effective in treating said disease or condition.
  • a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailt
  • the present invention further provides a pharmaceutical composition for treating in a ⁇ mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, 0 abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which composition comprises a pharmaceutically acceptable carrier and an amount of a compound of formula 1 effective in inhibiting GSK-3.
  • a disease or condition selected from male fertility and sperm motility
  • diabetes mellitus impaired glucose tolerance
  • metabolic syndrome or syndrome X polycystic ovary syndrome
  • adipogenesis and obesity myogenesis and fra
  • the present invention also provides a method for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes ⁇ mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which method comprises administering to said mammal an amount of a compound of formula 1 ⁇ effective in treating said disease or condition.
  • a disease or condition selected from male fertility and sperm motility
  • diabetes ⁇ mellitus impaired glucose tolerance
  • metabolic syndrome or syndrome X polycystic ovary syndrome
  • adipogenesis and obesity myogenesis and
  • the present invention also provides a method for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline 0 in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which method comprises administering to said mammal an amount of a compound of formula 1 effective in inhibiting GSK-3.
  • the present invention further provides a method for inhibiting GSK-3 in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula 1 effective in inhibiting GSK-3.
  • the present invention further provides a pharmaceutical composition for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive 0 impairment, and age-related cognitive decline comprising a compound of formula 1 and a COX-II inhibitor together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive impariment, and age-related ⁇ cognitive decline which method comprises administering to said mammal a compound of formula 1 and a COX-II inhibitor, wherein the combined amounts of the compound of formula 1 and the COX-II inhibitor are effective in treating said disorder.
  • the compound of formula 1 and the COX-II inhibitor can be administered to the mammal at the same time and/or separately.
  • the compound of formula 1 and the COX-II inhibitor can be administered in a single 0 composition or in separate compositions.
  • a compound of formula 1 of the invention can be administered or formulated into a pharmaceutical composition with one or more anti-depressants or anxiolytic compounds for treatment or prevention of depression and/or anxiety.
  • this invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and an NK-1 receptor antagonist together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier.
  • This invention further provides a method for treating depression or anxiety in a mammal, including a human, which method comprises administering to said mammal a 5 compound of formula 1 and an NK-1 receptor antagonist, wherein the combined amounts of the compound of formula 1 and the NK-1 receptor antagonist are effective in treating depression or anxiety.
  • the compound of formula 1 and the NK-1 receptor antagonist can be administered to the mammal at the same time and/or at different times. Moreover, the may be administered together in a single pharmaceutical composition or in separate compositions.
  • This invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and a ⁇ HT 1D receptor antagonist together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier.
  • This invention further provides a method for treating depression or anxiety in a ⁇ mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and a 5HT 1D receptor antagonist, wherein the combined amounts of the compound of formula 1 and the 5HT 1D receptor antagonist are effective in treating depression or anxiety.
  • the compound of formula 1 and the 5HT 1D receptor antagonist can be administered to the mammal at the same time and/or at different times. Moreover, they may 0 be administered together in a single pharmaceutical composition or in separate compositions.
  • This invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and a SSRI together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier.
  • This invention further provides a method for treating depression or anxiety in a mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and a SSRI, wherein the combined amounts of the compound of formula 1 and the SSRI are effective in treating depression or anxiety.
  • the compound of formula 1 and the SSRI can be administered to the mammal at the same time and/or at 0 different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • This invention also provides a pharmaceutical composition for treating schizophrenia in a mammal, including a human, comprising a compound of formula 1 and an antipsychotic selected from ziprasidone, olanzapine, risperidone, L-74 ⁇ 870, sonepiprazole, RP 62203, NGD ⁇ 941 , balaperidone, flesinoxan, and gepirone, together in an amount effective in treating schizophrenia, and a pharmaceutically acceptable carrier.
  • an antipsychotic selected from ziprasidone, olanzapine, risperidone, L-74 ⁇ 870, sonepiprazole, RP 62203, NGD ⁇ 941 , balaperidone, flesinoxan, and gepirone
  • This invention further provides a method for treating schizophrenia in a mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and an antipsychotic selected from ziprasidone, olanzapine, risperidone, L-74 ⁇ 870, sonepiprazole, RP 62203, NGD 941 , balaperidone, flesinoxan, and gepirone, wherein the combined amounts of the compound of formula 1 and the antipsychotic are effective in treating schizophrenia.
  • the compound of formula 1 and the antipsychotic can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • This invention also provides a pharmaceutical composition for treating a disorder selected from Alzheimer's disease, mild cognitive impairment, and age-related cognitive decline in a mammal, including a human, comprising a compound of formula 1 and an acetylcholinesterase inhibitor together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • This invention further provides a method for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive impairment, and age-related cognitive decline, which method comprises administering to said mammal a compound of formula 1 and an acetylcholinesterase inhibitor, wherein the combined amounts of the compound of formula 1 and the acetylcholinesterase inhibitor are effective in treating said disorder.
  • the compound of formula 1 and the acetylcholinesterase inhibitor can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia comprising a compound of formula 1 and TPA (tissue plasminogen activator, for example ACTIVASE) together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia
  • TPA tissue plasminogen activator, for example ACTIVASE
  • This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and TPA, wherein the combined amounts of the compound of formula 1 and the TPA are effective in treating said disease or condition.
  • the compound of formula 1 and the TPA can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia in a mammal, including a human, comprising a compound of formula 1 and NIF (neutrophil inhibitory factor) together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia in a mammal, including a human, comprising a compound of formula 1 and NIF (neutrophil inhibitory factor) together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • NIF neurotrophil inhibitory factor
  • This invention further provides a method for treating in a mammal, including a human, a ⁇ disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and NIF, wherein the combined amounts of the compound of formula 1 and the NIF are effective in treating said disease or condition.
  • the compound of formula 1 and the NIF can be administered to the mammal at the 0 same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • This invention also provides a pharmaceutical composition for treating a disease or condition selected from Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced ⁇ dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age-related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower 0 lateral sclerosis, and subacute sclerosing panencephalistis in a mammal, including a human, comprising a compound of formula 1 and an NMDA receptor antagonist together in an amount effective in treating said disorder, and
  • This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from Huntington's disease, stroke, spinal cord trauma, ⁇ traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age-related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, 0 Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, and subacute sclerosing panencephalistis, which method comprises administering to said mammal a compound of formula 1 and an NMDA receptor antagonist, wherein the
  • This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct
  • dementia 5 dementia, epilepsy, pain, Alzheimer's disease, and senile dementia in a mammal, including a human, comprising a compound of formula 1 and a potassium channel modulator together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
  • This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, 0 multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and a potassium channel modulator, wherein the combined amounts of the compound of formula 1 and the potassium channel modulator are effective in treating said disease or condition.
  • the compound of formula 1 and the potassium channel modulator can be administered to the mammal at the 5 same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
  • treatment refers to reversing, alleviating, or inhibiting the progress of the disease or condition to which such term applies, or one or more symptoms of such disease or condition.
  • these terms also encompass, 0 depending on the condition of the patient, preventing the onset of a disease or condition or of symptoms associated with a disease or condition, including reducing the severity of a disease or condition or symptoms associated therewith prior to affliction with said disease or condition.
  • Such prevention or reduction prior to affliction refers to administration of the compound of the invention to a subject that is not at the time of administration afflicted with the disease or ⁇ condition.
  • Preventing also encompasses preventing the recurrence of a disease or condition or of symptoms associated therewith.
  • Abnormal cell growth refers to cell growth, either malignant (e.g. as in cancer) or benign, that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition).
  • benign proliferative diseases are psoriasis, benign prostatic 0 hypertrophy, human papilloma virus (HPV), and restinosis.
  • Neurodegenerative diseases and conditions refers to diseases and conditions having associated therewith degeneration of neurons. Conditions and diseases that are neurodegenerative in nature are generally known to those of ordinary skill in the art. ⁇ References herein to diseases and conditions "the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission” mean a disease or condition that is caused at least in part by dopamine neurotransmission, or a disease or condition that result in abnormal dopamine neurotransmission, thus contributing to symptoms or manifestations of the disease condition.
  • references herein to diseases and conditions "the treatment of which can be effected or ⁇ facilitated by decreasing cdk ⁇ activity" mean a disease or condition that is caused at least in part by cdk ⁇ activity, or a disease or condition that results in abnormal cdk ⁇ activity that contributes to symptoms or manifestations of the disease or condition.
  • an “amount effective to inhibit cdk ⁇ ” as used herein refers to an amount of a compound sufficient to bind to the enzyme cdk ⁇ with the effect of decreasing cdk ⁇ activity.
  • An “amount effective to inhibit cdk2 activity” as used herein refers to an amount of a compound sufficient to bind to the enzyme cdk2 with the effect of decreasing cdk2 activity.
  • reaction inert solvent refers to a solvent system in which the components do not interact with starting materials, reagents, or intermediates of 0 products in a manner which adversely affects the yield of the desired product.
  • any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; and T. W. ⁇ Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, Inc., 1999.
  • a preferred alkyl cyano ⁇ acetate is ethyl cyano acetate.
  • Hydrolysis and decarboxylation of 3a to 3 may be accomplished by exposing 3a to water in a reaction inert solvent, preferably dimethylsulfoxide, at a temperature from about 21 °C to 200 °C, preferably from about 100 °C to 118 °C.
  • Reaction of 3 in a reaction inert solvent, such as a lower alcohol in the presence of a hydrazine at a reaction temperature of from about 0 °C to about 150 °C, where a temperature of from about 70 °C to about 8 ⁇ °C is preferred, affords the corresponding product 4.
  • the ⁇ hydrazine used may be anhydrous hydrazine or a hydrate form of hydrazine, or N-alkyl- hydrazine or N-acyl-hydrazine.
  • Coupling of 4 with an aryl halide or heteroaryl halide to obtain an intermediate of formula 5, wherein R 3 is -(CR 10 R 11 ) 0 - (a bond) can be accomplished by reaction of 4 in a 0 reaction inert solvent, preferably toluene, at a reaction temperature of from about 21 °C to about 1 ⁇ 0 °C, preferably at about 100 °C to about 110 °C, in the presence of a palladium catalyst, a base, preferably cesium carbonate or sodium or potassium tert-butoxide, a ligand, where preferred ligands are 2,2'-bis(diphenylphosphino)-1 ,1 '-binaphythyl, 2- (dicyclohexylphosphino)biphenyl, and 2-(di-tert-butylphosphino)biphenyl, and in the presence ⁇ of the appropriate aryl halide or heteroaryl halide, where
  • the metal catalyst may be a palladium species, for example palladium chloride, palladium acetate, dichlorobis(acetonitrile)palladium, or derivatives thereof, wherein palladium acetate is preferred.
  • Removal of the protecting group from 5 can be accomplished by reaction of 5 in a reaction inert solvent, preferably 0 methylene chloride or no solvent, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6 ⁇ °C to about 7 ⁇ °C, to yield 1a, wherein R 3 represents a bond and R 4 is as defined above for compounds of formula 1.
  • a reaction inert solvent preferably methylene chloride, pyridine, tetrahydrofuran, or die
  • the activated carboxylic acid derivative can be prepared from the carboxylic acid and known activating reagents such as polymer supported coupling agents or coupling agents such as, for instance, dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydride, alkyl chioroformate, bis(2-oxo-3-oxazolidinyl)phosphinic 5 chloride, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or any other such standard literature reagents.
  • activating reagents such as polymer supported coupling agents or coupling agents such as, for instance, dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydride, alkyl chioroformate, bis(2-oxo-3-oxazolidinyl)phosphinic 5 chloride, benzotriazol-1-y
  • Removal of the protecting group on 6 may be accomplished by reaction 6 in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6 ⁇ °C to about 7 ⁇ °C.
  • R 3 is -(CR 10 R 11 ) (1 . 3) -
  • a reaction inert solvent preferably toluene, tetrahydrofuran or methanol
  • reaction temperature from about 0 °C to about 110 °C, preferably about 21 °C
  • preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride, and lithium aluminum hydride to afford an intermediate of formula 6 wherein R 3 is -(CR 10 R 1 ) ⁇ 1 . 3) -.
  • Scheme 2 illustrates an alternative method suitable for preparing compounds of formula 1.
  • the method depicted in Scheme 2 is preferred when R 4 is an electron deficient aryl moiety, such as 4-nitrophenyl, or an electron deficient heteroaryl moiety.
  • hindered amine bases include lithium diisopropyl amide, potassium bis(trimethylsilyl) amide, lithium bis(trimethylsilyl) amide, and other such standard literature reagents.
  • a reaction inert solvent a preferred solvent being a lower alcohol
  • an acid preferably acetic acid
  • a reaction temperature of from about 21 °C to about 100 °C, preferably from about 7 ⁇ °C to about 85 °C, and in the presence of hydrazine, affords a compound of the formula 1a, wherein R 3 is a bond and R 4 is aryl or heteroaryl.
  • Deprotection of the oxo moiety R 5 can be accomplished using well-known conditions, which appear in the literature. For example, treating compound 10a in a reaction inert solvent, preferably a lower ketone for example acetone, in the presence of an acid, preferably hydrogen chloride, p-toluenesulfonic acid monohydrate, or pyridinium p-toluenesulfonate, at a ⁇ temperature of from about room temperature to about 80 °C, preferably about 7 ⁇ °C, affords 10b, wherein R 5 is an oxo (carbonyl) moiety, R 1 is as defined above, R 3 is a bond, and R 4 is aryl or heteroaryl.
  • a reaction inert solvent preferably a lower ketone for example acetone
  • an acid preferably hydrogen chloride, p-toluenesulfonic acid monohydrate, or pyridinium p-toluenesulfonate
  • Reduction of the oxo moiety to obtain an alocohol can be accomplished using well established chemistry.
  • the oxo moiety of 10b can be reacted with an 0 amine, either primary or secondary, wherein the preferred amine is an alkyl amine for example 4-methoxy-benzyl-amine, in a reaction inert solvent, preferably toluene or tetrahydrofuran, at a reaction temperature from about 21 °C to about 1 ⁇ 0 °C, preferably at about 70 °C to about 110 °C.
  • the reaction is cooled to a temperature of about 21 °C to about ⁇ O °C and a reducing reagent is ⁇ added, where preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride and lithium aluminum hydride, to afford 10c, wherein R is as defined above, R 3 is a bond, R 4 is aryl or heteroaryl, and R 5 is -NR 7 R 8 .
  • the activated carboxylic acid derivative is prepared from the carboxylic acid and known activating reagents such as polymer supported coupling agents or alternatively dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydride, alkyl chloroformate, bis(2- ⁇ oxo-3-oxazolidinyl)phosphinic chloride, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or any other such standard literature reagents, in the presence of a trialkyl amine base, such as triethyl amine or diisopropylethyl amine, wherein tripropylphosphonic anhydride and triethylamine are a preferred combination.
  • activating reagents such as polymer supported coupling agents or alternatively dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydr
  • Removal of the protecting group on 10b, 10c, or 10d may be accomplished by reaction in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, preferably trifluoro acetic acid, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6 ⁇ °C to about 75 °C, to yield the corresponding compounds of formula 1 , for example 1c, as depicted in Scheme 2.
  • Scheme 3 illustrates an alternative method suitable for the preparation of compounds of formula 1.
  • a base such as triethylamine, diisopropylethylamine, pyridine, or 2,6-lutidine
  • Intermediate 7c wherein R 3 is -(CR 10 R 11 ) (1 . 3) - can be prepared from intermediate 4a by reaction of 4a with an oxo moiety (aldehyde or ketone) in a reaction inert solvent, preferably toluene, tetrahydrofuran or methanol at a reaction temperature from about 0 °C to about 110 °C, preferably about 21 °C, in the presence of a reducing reagent, where preferred reducing 0 reagents are sodium triacetoxyborohydride, sodium cyanoborohydride, and lithium aluminum hydride to afford an intermediate of formula 6a wherein R 3 is -(CR 10 R 11 ) (1 . 3) -.
  • a reaction inert solvent preferably toluene, tetrahydrofuran or methanol
  • R 5 in 5a and 6a is a protected oxo (carbonyl) moiety (specifically acetal or ketal)
  • removal of the protecting group can first be accomplished using well-known conditions, which appear in the literature.
  • 12 and 15 can be reacted with an amine, primary or secondary, wherein the preferred amines are alkyl amine for example 4-methoxy-benzyl-amine, in a reaction inert solvent, preferably toluene or tetrahydrofuran, at a reaction temperature from about 21 °C to about 1 ⁇ 0 °C, preferably at about 70 °C to about 110 °C.
  • a reaction inert solvent preferably toluene or tetrahydrofuran
  • the reaction can be cooled to a temperature of about 21 °C to about ⁇ O °C, and a reducing reagent is added.
  • Preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride and lithium aluminum hydride.
  • the activated carboxylic acid can be prepared as described above.
  • a base such as triethylamine, diisopropylethylamine, pyridine, or 2,6-lutidine
  • R 7 diisopropylethylamine and chloroformates are a preferred combination
  • Schemes 4 and ⁇ illustrate a preferred method for the preparation of compounds of the formula 1 , wherein R 1 is optionally substituted with OR 7 or R 7 .
  • Preparation of the intermediates 12 and 15 can be accomplished as described in the description of Scheme 3.
  • R 3 in intermediate 12 is a bond
  • R s is an oxo (carbonyl) moiety.
  • R 5 being -OR 7 .
  • R 1 is hydroxylated and substituted with R 7 , for example ( ⁇ -(3-hydroxy, 3-phenyl-cyclobutyl)-2-(Prot)-pyrazol-3-yl)-naphthalen-2-yl-amine.
  • an inert 0 solvent such as methylene chloride, chloroform, or 1 ,2-dichloroethane, or preferably no solvent
  • an acid preferably trifluoroacetic acid
  • silane where tri
  • the metal catalyst may be conveniently suspended on an inert solid support such as charcoal, in a solvent such as ethyl acetate, tetrahydrofuran, dioxane, or a mixture thereof.
  • a base such as triethylamine, 0 diisopropylethylamine, pyridine, or 2,6-lutidine
  • Removal of the protecting group of 22, 27, or a derivative of 19 or 24 can be accomplished by reaction in a reaction inert solvent, preferably methylene chloride, ⁇ chloroform, 1 ,2-dichloroethane, or no solvent, in the presence of an acid, where trifluoroacetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6 ⁇ °C to about 7 ⁇ °C, affording a compound of formula 1i, 1k, or other compound of formula 1.
  • a reaction inert solvent preferably methylene chloride, ⁇ chloroform, 1 ,2-dichloroethane, or no solvent
  • an acid where trifluoroacetic acid is preferred
  • compounds of formula 1 as described herein wherein R 2 is other than hydrogen can be prepared by transformations of the compounds of formula 1 herein wherein R 2 is hydrogen using methods that are well known in the art.
  • compounds of formula 1 wherein R 2 is F can be prepared by treating compounds of formula 17, 6a, or 14 with N-fluorobenzenesulfonimide in a reaction of inert solvent, wherein toluene, dioxane, or xylenes are preferred, from about room temperature to about 150°C, preferably from about 100°C to about 120°C to obtain the corresponding intermediates wherein R 2 is F.
  • Removal of the protecting group from these intermediates may be accomplished by reaction in a reaction of inert solvent, wherein methylene chloride or no solvent are preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20°C to about 100°C, preferably from about 65°C to about 7 ⁇ °C, thus affording compounds of formula 1 wherein R 2 is F.
  • Pharmaceutically acceptable salts of a compound of formula 1 can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base or acid with one chemical equivalent of a pharmaceutically acceptable acid or base. Conventional concentration or crystallization techniques can be employed to isolate the salts.
  • suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids.
  • Illustrative bases are sodium, potassium, and calcium.
  • a compound of this invention may be administered alone or in combination with ⁇ pharmaceutically acceptable carriers, in either single or multiple doses.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed by combining a compound of formula 1 or a pharmaceutically acceptable salt thereof can then be readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These 0 pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, ⁇ gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, ⁇ gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein 0 may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions containing a compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or ⁇ in sterile aqueous solution may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • a compound of formula 1 or a pharmaceutically acceptable salt thereof can be administered orally, transdermally (e.g., through the use of a patch), parenterally (e.g. intravenously), rectally, or topically.
  • the daily dosage for treating a neurodegenerative disease or condition or a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission will generally range from about 0.0001 to about 10.0 mg/kg body weight of the patient to be treated.
  • the daily dosage for treating cancer or disease or condition involving abnormal cell growth of a benign nature will generally range from about 0.0001 to about ⁇ OO mg/kg body weight of the patient to be treated.
  • a compound of the formula 1 or a pharmaceutically acceptable salt thereof can be administered for treatment of a neurodegenerative disorder to an adult human of average weight (about 70kg) in a dose ranging from about 0.01 mg up to about 1000 mg per day, preferably from about 0.1 to about 500 mg per day, in single or divided (i.e., multiple) portions. Variations based on the aforementioned dosage ranges may be made by a physician of ordinary skill taking into account known considerations such as the weight, age, and condition of the person being treated, the severity of the affliction, and the particular route of administration chosen.
  • the compounds of formula 1 and their pharmaceutically acceptable salts can furthermore also be administered or formulated into a pharmaceutical composition with an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents, which amounts are together effective in inhibiting abnormal cell growth.
  • Anti-angiogenesis agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors,
  • MMP-9 matrix-metalloproteinase 9 inhibitors
  • COX-II cyclooxygenase II
  • MMP-9 matrix-metalloproteinase 9 inhibitors
  • COX-II cyclooxygenase II
  • MMP-9 matrix-metalloproteinase 9 inhibitors
  • COX-II cyclooxygenase II inhibitors
  • Examples of useful COX-II inhibitors include CELEBREXTM (celecoxib), valdecoxib, and rofecoxib.
  • Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No.
  • PCT/IB98/01113 (filed July 21 , 1998), European Patent Application No. 99302232.1 (filed March ⁇ 26, 1999), Great Britain patent application number 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 6,861,610 (issued January 19, 1999), and European Patent Publication 780,386 (published June 2 ⁇ , 1997), all of which are incorporated herein in their entireties by reference.
  • Preferred MMP-2 and MMP-9 inhibitors are those that 0 have little or no activity inhibiting MMP-1.
  • MMP- 2 and/or MMP-9 are those that selectively inhibit MMP- 2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1 , MMP-3, MMP-4, MMP- ⁇ , MMP-6, MMP-7, MMP-8, MMP-10, MMP-11 , MMP-12, and MMP-13).
  • MMP-1 , MMP-3, MMP-4, MMP- ⁇ , MMP-6, MMP-7, MMP-8, MMP-10, MMP-11 , MMP-12, and MMP-13 are those that selectively inhibit MMP- 2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1 , MMP-3, MMP-4, MMP- ⁇ , MMP-6, MMP-7, MMP-8, MMP-10, MMP-11 , MMP-12, and MMP-13).
  • MMP inhibitors useful in the present invention are AG-3340, RO 32-3 ⁇ , RS 13-0830, and the compounds recited in the following list: ⁇ 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1 -hydroxycarbamoyl-cyclopentyl)- aminoj-propionic acid;
  • anti-angiogenesis agents including other COX-II inhibitors and other MMP inhibitors, can also be used in the present invention.
  • the effective amount of a COX-II inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed daily effective dose range 0 for a COX-II inhibitor in combination with a cdk5 inhibitor is from about 0.1 to about 2 ⁇ mg/kg body weight.
  • the effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of COX-II inhibitor and/or the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in inhibiting abnormal cell growth.
  • a compound of formula 1 can also be used with signal transduction inhibitors, such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTINTM (Genentech, Inc. of 0 South San Francisco, California, USA).
  • signal transduction inhibitors such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTINTM (Genentech, Inc. of 0 South San Francisco, California, USA).
  • HERCEPTINTM Genetech
  • EGFR inhibitors are described in, for example in WO 96/19970 (published July 27, 1995), WO 98/14451 (published April 9, 1998), WO 98/02434 (published January 22, 1998), and United States Patent 5,747,498 (issued May 5, 1998), and such substances can be used in the ⁇ present invention as described herein.
  • EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C22 ⁇ and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, New York, USA), the compounds ZD-1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc.
  • VEGF inhibitors for example SU-5416 and SU-6668 (Sugen Inc. of South San Francisco).
  • VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT 5 International Application PCT/IB99/00797 (filed May 3, 1999) " ; in WO 95/21613 (published
  • VEGF inhibitors useful in the present invention are IM862 (Cytran Inc. of Kirkland, Washington, USA); anti-VEGF monoclonal antibody of Genentech, Inc. of South San 0 Francisco, California; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California). These and other VEGF inhibitors can be used in the present invention as described herein.
  • ErbB2 receptor inhibitors such as GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) ⁇ and 2B-1 (Chiron), can also be combined with a compound of formula 1 , for example those indicated in WO 98/02434 (published January 22, 1998), WO 99/36146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 1998), WO 97/13760 (published April 17, 1997), WO 96/19970 (published July 27, 1996), United States Patent 5,687,468 (issued December 24, 1996), and United States Patent 6,877,306 (issued 0 March 2, 1999), which are all hereby incorporated herein in their entireties by reference.
  • ErbB2 receptor inhibitors useful in the present invention are also described in United States Provisional Application No. 60/117,341 , filed January 27, 1999, and in United States Provisional Application No. 60/117,346, filed January 27, 1999, both of which are incorporated in their entireties herein by reference.
  • the erbB2 receptor inhibitor compounds and substance described in the 5 aforementioned PCT applications, U.S. patents, and U.S. provisional applications, as well as other compounds and substances that inhibit the erbB2 receptor, can be used with a compound of formula 1 , in accordance with the present invention.
  • a compound of formula 1 can also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing 0 antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as farnesyl protein transferase inhibitors.
  • CTLA4 cytotoxic lymphocite antigen 4
  • anti-proliferative agents such as farnesyl protein transferase inhibitors.
  • Specific CTLA4 antibodies that can be used in the present invention include those described in United States Provisional Application 60/113,647 (filed December 23, 1998) which is incorporated by reference in its entirety, however other CTLA4 antibodies 6 can be used in the present invention.
  • Th e compounds of formula 1 can also be administered in a method for inhibiting abnormal cell growth in a mammal in combination with radiation therapy. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration
  • Compounds of formula 1 can also be administered in combination with a COX-II inhibitor for treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline.
  • COX-II inhibitors useful in this aspect of the invention are provided above, wherein use of a COX-II inhibitor in combination with a compound of formula 1 for treatment of abnormal cell growth is described.
  • the effective amount of a COX-II inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed effective daily dose range for a COX-II inhibitor in combination with a compound of formula 1 is from about 0.1 to about 26 mg/kg body weight.
  • the daily effective amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of COX-II inhibitor and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline.
  • NK-1 receptor antagonists can also be administered in combination with an NK-1 receptor antagonist for treatment of depression or anxiety.
  • An NK-1 receptor antagonist as recited herein, is a substance that is able to antagonize NK-1 receptors, thereby inhibiting tachykinin-mediated responses, such as responses mediated by substance P.
  • Various NK-1 receptor antagonists are known in the art, and any such NK-1 receptor antagonist can be utilized in the present invention as described above in combination with a compound of formula 1.
  • NK-1 receptor antagonists are described in, for example, United States Patent 5,716,965 (issued February 10, 1998); United States Patent 5,852,038 (issued December 22, 1998); WO 90/05729 (International Publication Date May 31 , 1990); United States Patent 5,807,867 (issued September 15, 1998); United States Patent 5,886,009 (issued March 23, 1999); United States Patent 5,939,433 (issued August 17, 1999); United States Patent 5,773,450 (issued June 30, 1998); United States Patent 5,744,480 (issued April 28, 1998); United States Patent 5,232,929 (issued August 3, 1993); United Stated Patent 5,332,817 (issued July 26, 1994); United States Patent 5,122,525 (issued June 16, 1992), United States Patent 5,843,966 (issued December 1 , 1998); United States Patent 5,703,240 (issued December 30, 1997); United States Patent 5,719,147 (issued February 17, 1998); and United States Patent 5,637,699 (issued June 10, 1997).
  • the effective amount of an NK-1 receptor antagonist in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed effective daily dose range for an NK-1 receptor antagonist in combination with a compound of formula 1 is from about 0.07 to about 21 mg/kg body weight.
  • the effective amount of the compound of formula 1 will be between about 0.0001 to about 10 mg/kg body weight.
  • the amount of NK-1 receptor antagonist and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
  • the subject invention also provides combining a compound of formula 1 with a 5HT 1D receptor antagonist for treatment of depression or anxiety.
  • a 5HT 1D receptor antagonist as recited herein, is a substance that antagonizes the 5HT 1D subtype of serotonin receptor. Any such substance can be used in the present invention as described above in combination with a compound of formula 1. Substances having 5HT 1D receptor antagonizing activity can be determined by those of ordinary skill in the art.
  • 5HT 1D receptor antagonists are described in WO 98/14433 (International Publication Date April 9, 1998); WO 97/36867 (International Publication Date October 9, 1997); WO 94/21619 (International Publication Date September 29, 1994); United States Patent 5,610,350 (issued April 23, 1996); United States Patent 5,358,948 (issued October 25, 1994); and GB 2276162 A (published September 21 , 1994).
  • These 5HT 1D receptor antagonists, as well as others, can be used in the present invention.
  • the aforementioned published patent applications and patents are incorporated herein by reference in their entireties.
  • the effective amount of a 5HT1 D receptor antagonist in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed effective daily dose range for a 5HT1 D receptor antagonist in combination with a compound of formula 1 is from about 0.01 to about 40 mg/kg body weight.
  • the effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of 5HT1 D receptor antagonist and/or the amount of compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
  • This invention also provides a pharmaceutical composition and method for treating depression or anxiety in a mammal comprising a compound of formula 1 and a SSRI.
  • SSRIs that can be combined in a method or pharmaceutical composition with compounds of formula 1 and their pharmaceutically acceptable salts include, but are not limited to, fluoxetine, paroxetine, sertraline, and fluvoxamine.
  • Other SSRIs may be combined or administered in combination with a compound of formula 1 or a pharmaceutically acceptable salt thereof.
  • Other antidepressants and/or anxiolytic agents with which a compound of formula 1 may be combined or administered include WELLBUTRIN, SERZONE and EFFEXOR.
  • the effective amount of a SSRI in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed effective daily dose range for a SSRI in combination with a compound of formula 1 is from about 0.01 to about 500 mg/kg body weight.
  • the effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of SSRI and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
  • a compound of formula 1 can also be combined with one or more antipsychotic agents, for example a dopaminergic agent, for the treatment of diseases or conditions the treatment of which can be effected or facilitated by altering dopamine neurotransmission, such as schizophrenia.
  • antipsychotics with which a compound of the invention can be combined include ziprasidone (5-(2-(4-(1 ,2- benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1 ,3-dihydro-2H-indol-2-one; U.S. Patent 4,831 ,031 and U.S.
  • Patent 5,312,925 olanzapine (2-methyl-4-(4-methyl-1-piperazinyl-10H- thieno (2,3b) (1 ,5)benzodiazepine; U.S Patent 4,115,574 and U.S. Patent 5,229,382); risperidone (3-[2-[4-(6-fluoro-1 ,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]6,7,8,9-tetrahydro-2- methyl-4H-pyrido[1 ,2-a]pyrimidin-4-one; U.S.
  • Patent 4,804,663 L-745870 (3-(4-(4- chlorophenyl)piperazin-1-yl)methyl-1 H-pyrrolo(2,3-b)pyridine; U.S. Patent 5,432,177); sonepiprazole (S-4-(4-(2-(isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide; U.S.
  • Patent 5,877,317 discloses RP 62203 (fananserin; 2-(3-(4-(4-fluorophenyl)-1- piperazinyl)propyl)naphtho(1 ,8-c,d)isothiazole-1 ,1 -dioxide; U.S. Patent 5,021 ,420); NGD 941 (U.S. Patent 5,633,376 and U.S.
  • Patent 5,428,165 balaperidone ((1 ⁇ ,5 ⁇ ,6 ⁇ )-3-(2-(6-(4- fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)-2,4(1 H,3H)-quinazolinedione; U.S. Patent 6,475,105); flesinoxan ((+)-4-fluoro-N-[2-[4-5-(2-hydroxymethyl-1 ,4-benzodioxanyl)]-1- piperazinyl]ethyl]benzamide; U.S.
  • Patent 4,833,142 gepirone (4,4-dimethyl-1-(4-(4-(2- pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; U.S. Patent 4,423,049).
  • the patents recited above in this paragraph are each incorporated herein by reference in their entireties.
  • the effective daily amount of the compound of formula 1 will typically be between about 0.0001 to about 10 mg/kg body weight.
  • the amount of any of the aforementioned antipsychotic agents contemplated for use in combination with a compound of formula 1 is generally the amount known in the art to be useful for treating psychotic conditions.
  • the amount of the antipsychotic and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety. It is furthermore to be understood that the present invention also encompasses combining a compound of formula 1 with antipsychotic or dopaminergic other than those in the aforementioned list.
  • a proposed amount for sonepiprazole in the above-described combination with a compound of formula 1, is from about 0.006 to about 60 mg/kg body weight of the patient per day.
  • a proposed amount of RP 62203 in such combination is from about 0.20 to about 6 mg/kg body weight of the patient per day.
  • a proposed amount of NGD 941 in such combination is from about 0.1 to about 140 mg/kg of body weight per day.
  • a proposed amount of balaperidone in such combination is from about 1 to about 100 mg/kg body weight per day.
  • a proposed amount of flesinoxan in such combination is from about 0.02 to about 1.6 mg/kg body weight per day.
  • a proposed amount for gepirone in such combination is from about .01 to about 2 mg/kg body weight per day.
  • a proposed amount of L-746870 in such combination is from about 0.01 to about 250 mg/kg body weight per day, preferably from about 0.05 to about 100 mg/kg body weight per day.
  • a proposed amount of risperidone in such combination is from about O.O ⁇ to about 60 mg/kg body weight per day.
  • a proposed amount of olanzapine in such combination is from about 0.0006 to about 0.6 mg/kg body weight per day.
  • a proposed amount of ziprasidone in such combination is from about O.O ⁇ to about 10 mg/kg body weight per day.
  • the amount of each specific ingredient in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating a psychotic condition.
  • This invention also provides a pharmaceutical composition and method for treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline comprising a compound of formula 1 and an acetylcholinesterase inhibitor.
  • Acetylcholinesterase inhibitors are known in the art, and any such acetylcholinesterase inhibitor can be used in the above- described pharmaceutical composition or method.
  • Examples of acetylcholinesterase inhibitors that can be used in this invention are ARICEPT (donepezil; U.S. Patent 4,895,841 ); EXELON (rivastigmine ((S)-[N-ethyl-3-[1-(dimethylamino)ethyl]phenyl carbamate); U.S.
  • Patent 5,603,176 and U.S. Patent 4,948,807 ; metrifonate ((2,2,2-trichloro-1-hydroxyethyl)phosphonic acid dimethyl ester; U.S. Patent 2,701 ,225 and U.S. Patent 4,950,658); galantamine (U.S. Patent 4,663,318); physostigmine (Forest, USA); tacrine (1 ,2,3,4-tetrahydro-9-acridinamine; U.S.
  • Patent 4,816,456 huperzine A (5R-(5 ,9 ⁇ ,11 E))-5-amino-11-ethylidene- ⁇ ,6,9,10- tetrahydro-7-methyl- ⁇ ,9-methaneocycloocta(b)pyridin-2-(1 H)-one); and icopezil (5,7-dihydro-3- (2-(1-(phenylmethyl)-4-piperidinyl)ethyl)-6H-pyrroio(3,2-f)-1 ,2-benzisoxazol-6-one; U.S. Patent 6,760,642 and WO 92/17475).
  • the patents and patent applications recited above in this paragraph are herein incorporated by reference in their entireties.
  • the effective amount of an acetylcholinesterase inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill.
  • a proposed effective daily dose range for an acetylcholinesterase inhibitor in combination with a compound of formula 1 is from about 0.01 to about 10 mg/kg body weight.
  • the effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight.
  • the amount of acetylcholinesterase inhibitor and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline.
  • the present invention also provides for combining a compound of formula 1 with neuroprotectants, for example NMDA receptor antagonists, for treatment of Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age- related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, or subacute sclerosing panencephalistis.
  • neuroprotectants for example NMDA receptor antagonists
  • NMDA receptor antagonists examples include (1 S,2S)-1 -(4-hydroxyphenyi)-2-(4-hydroxy-4-phenylpiperidin-1 -yl)-1 - propanol (U.S. Patent 5,272,160), eliprodil (U.S. Patent 4,690,931), and gavestenel (U.S. Patent 5,373,018).
  • Other NMDA receptor antagonists which can also be used in the present invention, are described in U.S. Patent 6,373,018; U.S. Patent 4,690,931; U.S. Patent 6,272,160; U.S. Patent 5,186,343; U.S. Patent 5,356,905; U.S.
  • the aforementioned patents and patent applications are each hereby incorporated by reference in their entireties.
  • the effective daily amount of the compound of formula 1 in the combination with an NMDA receptor antagonist generally will be between about 0.0001 to about 10 mg/kg body weight.
  • the amount of the NMDA receptor antagonist contemplated for use in combination with a compound of formula 1 for treatment of any of the aforementioned disorders, for example Alzheimer's disease is generally within the range of from about 0.02 mg/kg/day to about 10 mg/kg/day.
  • the amount of the NMDA antagonist and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating said disorders.
  • the subject invention also provides for combining a compound of formula 1 with certain substances capable of treating a stroke or traumatic brain injury, such as TPA, NIF, or potassium channel modulators, for example BMS-204352.
  • TPA traumatic brain injury
  • NIF neurodegenerative disorders
  • BMS-204352 potassium channel modulators
  • Such combinations are useful for treating neurodegenerative disorders such as stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, for example.
  • the effective amounts of the compound of the invention and of the other agent can generally be determined by those of ordinary skill in the art, based on the effective amounts for the compounds described herein and those known or described for the other agent known in the art, for example the amounts described in the above-recited patents and patent application incorporated herein.
  • the formulations and routes of administration for such therapies and compositions can be based on the information described herein for compositions and therapies comprising a compound of the invention as the sole active agent and on information provided for the other agent in combination therewith.
  • a specific compound of formula 1 can be determined to inhibit cdk2, cdk5, or GSK-3 using biological assays known to those of ordinary skill in the art, for example the assays described below.
  • Enzyme activities can be assayed as the incorporation of [33P] from the gamma phosphate of [33P]ATP (Amersham, cat. no. AH-9968) into biotinylated peptide substrate PKTPKKAKKL
  • reactions are carried out in a buffer containing ⁇ OmM Tris- HCI, pH 8.0; 10mM MgCI2, 0.1 mM Na3V04, and 1mM DTT.
  • the final concentration of ATP is about O. ⁇ uM (final specific radioactivity of 4uCi/nmol), and the final concentration of substrate 0.7 ⁇ uM.
  • Reactions initiated by the addition of either cdk ⁇ and activator protein p25 or cdk2 and activator cyclin E, may be carried out at room temperature for about 60 minutes. Reactions are stopped by addition of 0.6 volume of buffer containing (final concentrations): 2.5mM EDTA, 0.05%Triton-X 100, 100uM ATP, and 1.25 mg/ml streptavidin coated SPA beads (Amersham cat. no. RPNQ0007). Radioactivity associated with the beads is quantified by scintillation counting.
  • a cell-free assay can be carried out in general by incubating GSK-3 with a peptide substrate, radiolabeled ATP (such as, for example, ⁇ 33 P- or ⁇ 32 -P-ATP, both available from Amersham, Arlington Heights, Illinois), magnesium ions, and the compound to be assayed. The mixture is incubated for a period of time to allow incorporation of radiolabeld phosphate into the peptide substrate by GSK-3 activity.
  • radiolabeled ATP such as, for example, ⁇ 33 P- or ⁇ 32 -P-ATP, both available from Amersham, Arlington Heights, Illinois
  • the reaction mixture is washed to remove unreacted radiolabeled ATP, typically after first transferring all or a portion of the enzyme reaction mixture to a well that contains a uniform amount of a ligand that is capable of binding to the peptide substrate.
  • the amount of 33 P or 32 P remaining in each well after washing is then quantified to determine the amount of radiolabeled phosphate incorporated into the peptide substrate. Inhibition is observed as a reduction, relative to a control, in the incorporation of radiolabeled phosphate into the peptide substrate.
  • An example of a suitable GSK-3 peptide substrate for an assay is the SGSG-linked CREB peptide sequence, derived from the CREB DNA binding protein, described in Wang, et al., Anal.
  • Purified GSK-3 for an assay may, for example, be obtained from cells transfected with a human GSK-3 ⁇ expression plasmid as described in, for example Stambolic, et al., Current Biology 6:1664-68 (1996).
  • WO 99/65897; Wang, et al., and Stambolic, et al. are incorporated in their entireties herein by reference.
  • GSK-3 assay Another example of a GSK-3 assay, similar to the one described in the preceding paragraph is as follows: Enzyme activities are assayed as the incorporation of [33P] from gamma phosphate of [33P]ATP (Amersham, cat. No. AH-9968) into biotinylated peptide substrate PKTPKKAKKL. Reactions are carried out in a buffer containing 50mM Tris-HCI, pH 8.0; 10mM MgCI 2 , 0.1 mM Na 3 V0 4 , and 1 mM DTT. The final concentration of ATP is 0.5 ⁇ M (final specific radioactivity of 4 ⁇ Ci/nmol), and the final concentration of substrate is 0.75 ⁇ M.
  • Reactions initiated by the addition of enzyme, are carried out at room temperature for about 60 minutes. Reactions are stopped by addition of 0.6 volume of buffer containing (final concentrations): 2.5mM EDTA, 0.05%Triton-X 100, 100 ⁇ M ATP, and 1.25 mg/ml streptavidin coated SPA beads (Amersham cat. No. RPNQ0007). Radioactivity associated with the beads is quantified by scintillation counting.
  • TFA indicates “trifluoroacetic acid”
  • THF indicates “tetrahydrofuran”
  • MPLC indicates “medium pressure liquid chromatography”
  • TLC indicates
  • the title compound was prepared according to the method for Example 1 , using 5 analogous reactants.
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • the title compound was prepared according to the method for Example 1 , using 0 analogous reactants.
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • Example 7 (3-Bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine The title compound was prepared according to the method for Example 1 , using analogous reactants. HNMR (400MHz, CDCI 3 ), ⁇ 1.82-1.99 (m, 2H), 2.06-2.17 (m, 2H), 2.21-2.29 (m, 2H),
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • Example 9 (2-Chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • Example 10 (3,5-Bis-trifluoromethyl-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)- amine
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • Example 13 (2-Bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine 0
  • the title compound was prepared according to the method for Example 1 , using analogous reactants.
  • Example 14 (5-Cyclobutyl-2H-pyrazol-3-yl)-(3,5-dichloro-phenyl)-amine The title compound was prepared according to the method for Example 1 , using analogous reactants.
  • the reaction was allowed to slowly warm to rt over 20 hr. The reaction was then cooled to 0
  • This material was purified by vacuum distillation (95-106 °C, 2-3 mm) to give the title compound in a quantitative yield and as a colorless oil.
  • the title compound was prepared according to the method for Preparation 1.1 , using analogous reactants.
  • Procedure B Cesium carbonate (296mg, 0.454mmol) was flame dried in a reaction flask and 3.9ml of dry toluene was then transferred followed by 200mg (0.778mmol) of 5- ⁇ Cyclobutyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-ylamine (Preparation 1.3). The resulting mixture was stirred at rt for 10min followed by the additions of 2-chloro-6-methoxy pyridine (93.2mg, 0.648mmol), 2-(dicyclohexylphosphino)-biphenyl (11.7mg, 0.0334mmol) and palladium acetate (3.6mg, 0.0162mmol). Refluxing under nitrogen overnight took the reaction to completion. Filtration through Celite, concentration of the filtrate, and chromatography as in 0 procedure A yielded the title compound of Preparation 1.4 (120mg, 51 % yield) as a solid.
  • Example 17 (5-Cyclobu tyl-2H-pyrazol-3-yl)-(3-trif luoromethyl-phenyl)-amine The title compound was made according to the method for Example 1 ⁇ , using analogous reactants.
  • the title compound was made according to the method for Example 15, using analogous reactants.
  • the title compound was made according to the method for Example 15, using ⁇ analogous reactants.
  • the title compound was made according to the method for Example 15, using analogous reactants.
  • the title compound was made according to the method for Example 15, using ⁇ analogous reactants.
  • Example 25 (5-Cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine 0
  • the title compound was made according to the method for Example 15, using analogous reactants.
  • Example 26 3-7rans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentanone ⁇
  • the title compound was prepared according to the method for Preparation 3.4, using hydrazine instead of 4-methoxy-benzyl-hydrazine (see synthesis of Preparation 3.3, supra).
  • a racemate comprising cis:trans isomers of [5-(3-Benzylamino-cyclopentyl)-1 H- pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine was prepared according to the method for
  • the title compound was prepared according to the method for preparation 3.6, using the title compound of Example 26 instead of the title compound of Preparation 3.4.
  • Analytical separation of the four isomers of the title compound was accomplished using the following conditions: Column: Chiralcel OD, ⁇ cm x 10cm. Mobile phase: 96/5 heptane/EtOH containing 0.025% DEA as a modifier. Flow rate: 76 mL/min. The sample was loaded using 1:1 Methylene chloride/mobile phase. The retention times for the four isomers were 30 min, 37 min, 45min, and 60 min, respectively.
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • Example 32 Pyridine-2-carboxylic acid ⁇ 3-[5-(3-trifluoromethyl-phenylamino)-2H- pyrazol-3-yl]-cyclopentyl ⁇ -amide
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • Example 38 N- ⁇ 3-[5-(3-Trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl ⁇ -propionamide
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • the title compound was prepared according to the method for Example 30, using analogous reactants.
  • the title compound was prepared according to the method for Preparation 3.5, using the title compound of Preparation 4.4 as a reactant instead of the title compound of 0 Preparation 3.4.
  • the title compound was prepared according to the method for Preparation 4.6, using analogous reactants.
  • the title compound was synthesized by the method for Example 30, using analogous reactants.
  • Example 43 N- 3-[5-(2-Naphthalen-1 -yl-acetylamino)-1 H-pyrazol-3-yl]- cyclopentyl ⁇ -benzamide
  • the title compound was synthesized by the method for Example 30, using analogous reactants.
  • Example 54 4-Methoxy-N- ⁇ c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol- 3-yl]-cyclobutyl ⁇ -benzamide ⁇ R f 0.35 (5% MeOH/ CH 2 CI 2 ).
  • 1 HNMR 400MHz, CD 3 OD), ⁇ 2.17-2.26 (m, 2H), 2.68-
  • Example 62 N- ⁇ 5-[(1 R)-(Benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl ⁇ -2- naphthalen-1 -yl-acetamide
  • the title compound was synthesized according to the method for Example 60, using analogous reactants.
  • the title compound was synthesized according to the method for Example 60, using analogous reactants.
  • Example 65-71 The title compounds of the following Examples 65-71 were synthesized as in Example 64, including synthesis of Preparations 7.1 and 7.2, using an analogous starting ketone:

Abstract

The invention provides compounds of formula (1) wherein R?1, R2, R3, and R4¿ are as defined, and their pharmaceutically acceptable salts. Compounds of formula (1) are indicated to have activity inhibiting cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula (1) for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula (1) for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

Description

PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Field of the Invention
The subject invention relates to pyrazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present invention act as inhibitors of cyciin-dependent protein kinase enzymes cdk5 (cyciin-dependent protein kinase 5) and cdk2 (cyciin-dependent protein kinase 2). The compounds of the present invention also are inhibitors of the enzyme GSK-3 (glygocen synthase kinase-3) enzyme.
Background of the Invention The serine/threonine kinase cdk5 along with its cofactor p25 (or the longer cofactor, p35) has been linked to neurodegenerative disorders, and inhibitors of cdk5/p25 (or cdk5/p35) are therefore useful for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, stroke, or Huntington's disease. Treatment of such neurodegenerative disorders using cdk5 inhibitors is supported by the finding that cdk5 is involved in the phosphorylation of tau protein (J. Biochem, 117, 741-749 (1995)). cdk5 also phosphorylates Dopamine and Cyclic AMP-Regulated Phosphorprotein (DARPP-32) at threonine 75 and is thus indicated in having a role in dopaminergic neurotransmission (Nature, 402, 669-671 (1999)).
The serine/threonine kinase cdk2 is essential for normal cell cycling and plays a critical role in disorders arising from abnormal cell cycling, a common characteristic of many oncological disorders. Inhibitors of cdk2 are therefore useful for the treatment of various types of cancer and other diseases or conditions related to abnormal cell growth (Meijer, et al., Properties and Potential-applications of Chemical Inhibitors of Cyciin-dependent Kinsases, Pharmacology & therapeutics, 82 (2-3), 279-284 (1999); Sausville, et al., Cyciin-dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target, Pharmacology & therapeutics 82 (2-3) 285-292 (1999)).
GSK-3 is a serine/threonine protein kinase. It is one of several protein kinases which phosphorylate glycogen synthase (Embi, et al., Eur. J. Biochem. 107:519-527 (1980); Hemmings, et al., Eur. J. Biochem. 119:443-451 (1982)). GSK-3 exists in two isoforms, and β, in vertebrates, reported as having a monomeric structure of 49kD and 47kD respectively. Both isoforms phosphorylate muscle glycogen synthase (Cross, et al., Biochemical Journal 303: 21-26 (1994)). The amino acid identity among GSK-3 species homologs has been indicated to be in excess of 98% within the catalytic domain (Plyte, et al., Biochim. Biophys. Ada 1114:147-162) (1992)). Due to a remarkably high degree of conservation across the phylogenetic spectrum, a fundamental role of GSK-3 in cellular processes is suggested.
GSK-3 has been implicated in numerous different disease states and conditions. For example, Chen, et al, Diabetes 43: 1234-1241 (1994) have suggested that an increase in GSK-3 activity can be important in Type 2 diabetes. Increased GSK-3 expression in diabetic muscle is also though to contribute to the impaired glycogen synthase activity and skeletal muscle insulin resistance present in Type 2 diabetes (Nikoulina, et al., Diabetes 49: 263-271 (2000)). Also, a higher activity of a type 1 protein phosphatase measured in immotile sperm was attributed to higher GSK-3 activity and was indicated as responsible for holding the sperm motility in check (Vijayaraghavan, et al. Biology of Reproduction 54: 709-718 (1996)). Vijayaraghavan et al. indicate that such results suggest a biochemical basis for the development and regulation of sperm motility and a possible physiological role for a protein phosphatase 1 /inhibitor 2/GSK-3 system. GSK-3 activity has also been associated with Alzheimer's disease and mood disorders such as bipolar disorder (WO 97/41854). Among other conditions, GSK-3 has furthermore been implicated in hair loss, schizophrenia, and neurodegeneration, including both chronic neurodegenerative diseases (such as Alzheimer's, supra) and neurotrauma, for example stroke, traumatic brain injury, and spinal cord trauma.
Summary of the Invention This invention provides compounds of the formula
wherein R1 is a straight chain or branched (C.|-C8)alkyl, a straight chain or branched (C2- C8)alkenyl, a straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkeπyl, (3- 8 membered) heterocycloalkyl, (Cs-C^bicycloalkyl, (C7-C.,ι)bicycloalkenyl, or (5-11 membered) heterobicycloalkyl; and wherein R1 is optionally substituted with from one to six substituents R5 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, - NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, -NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, - OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, -OC(=0)NR7R8, -OC(=0)SR7, -SR7, - S(=0)R7, -S(=0)2R7, -S(=0)2NR7R8, and R7;
R2 is H, F, -CH3, -CN, or -C(=0)OR7;
R3 is -C(=0)NR9-, -C(=0)0-, -C(=O)(CR10R11)n-, or -(CR10R11)π-; R4 is a straight chain or a branched (CrC8)alkyl, a straight chain or a branched (C2- C8)alkenyl, a straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C C^bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, or (5-14 membered) heteroaryl; and wherein R4 is optionally substituted with from one to three substitutents R6 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, -NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, -NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, -OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, -OC(=0)NR7R8, -OC(=0)SR7, -SR7, -S(=0)R7, -S(=0)2R7, -S(=0)2NR7Rβ, or R7; each R7, R8, and R9 is independently selected from H, straight chain or branched (C C6)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C^bicycloalkyl, (C7-C.,.|)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl, wherein R7, R8, and R9 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, I, N02, -CN, -CF3, -NR10R11, -NR10C(=O)R1\ -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR10S(=O)2R11, -NR10S(=O)2NR11R12, -OR10, -OC(=0)R1°, -OC(=0)OR1°, -OC(=O)NR 0R11, -OC(=0)SR1°, -SR10, -S(=O)R10 7 -S(=0)2R10, -S(=O)2NR10R11, -C(=0)R10, -C(=0)OR10, -C(=O)NR10R11, and R10; or, when R7 and R8 are as in NR7R8, they may instead optionally be connected to form with the nitrogen of NR7R8 to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further heteroatoms independently selected from N, O, and S; each R10, R11, and R12 is independently selected from H, straight chain or branched (Cr C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C^bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl, wherein R10, R11, and R12 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, l, N02, -CN, -CF3, -NR13R14, -NR 3C(=0)R14, -NR13C(=0)0R14, -NR 3C(=0)NR14R15, -NR13S(=0)2R14, -NR13S(=0)2NR14R15, -OR13, -OC(=0)R13, -OC(=0)OR13, -0C(=0)NR13R14, -OC(=0)SR13, -SR13, -S(=0)R13, -S(=0)2R13, -S(=0)2NR13R14, -C(=0)R13, -C(=0)OR13, -C(=0)NR 3R14, and R13; each R13, R14, and R15 is independently selected from H, straight chain or branched (C,- C8)alkyl, straight chain or branched (C C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C^bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (Ce-C14)aryl, and (5-14 membered) heteroaryl, wherein R13, R14, and R 5 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, I, N02, -CN, -CF3, -NR16R17, -NR16C(=0)R17, -NR16C(=0)OR17, -NR16C(=0)NR17R18, -NR 6S(=0)2R17, -NR16S(=0)2NR17R18 -OR16, -OC(=0)R15, -OC(=0)OR16, -OC(=0)NR16R17, -OC(=0)SR16, -SR16, -S(=0)R16, -S(=0)2R16, -S(=0)2NR16R17, -C(=0)R16, -C(=0)OR16, -C(=0)NR16R17, and R16 each R16, R17, and R18 is independently selected from H, straight chain or branched (C,- C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl),
(C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl,
(C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C3-C14)aryl, and (5-14 membered) heteroaryl; n is O, 1 , 2, or 3; wherein R10 and R11 in -C(=O)(CR10R11)n- and -(CR10R11)n- are for each iteration of n defined independently as recited above; and pharmaceutically acceptable salts thereof.
Amino-substituted pyrazoles can exist as mixtures of tautomeric isomers in equilibrium with one another. The present invention includes all such tautomers of compounds of formula 1, and references herein to compounds of formula 1, unless otherwise indicated, encompass also the tautomers of compounds of formula 1.
Compounds of formula 1 of the invention are inhibitors of serine/threonine kinases, especially cyciin-dependent kinases such as cdkδ and cdk2, and are useful for the treatment of neurodegenerative disorders and other CNS disorders, and of abnormal cell growth, including cancer. The compounds of formula 1 are particularly useful in inhibiting cdk5. The compounds of formula 1 are also useful as inhibitors of GSK-3.
The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl. The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyi.
The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.
The term "cycloalkyl", as used herein, unless otherwise indicated, includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. "Bicycloalkyl" groups are non-aromatic saturated carbocyclic groups consisting of two rings, wherein said rings share one or two carbon atoms. For purposes of the present invention, and unless otherwise indicated, bicycloalkyl groups include spiro groups and fused ring groups. Examples of bicycloalkyl groups include, but are not limited to, bicyclo-[3.1.0]- hexyl, norbornyl, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[4.3]octyl, and spiro[4.2]heptyl. "Cycloalkenyl" and "bicycloalkenyl" refer to non-aromatic carbocyclic cycloalkyl and bicycloalkyl moieties as defined above, except comprising one or more carbon-carbon double bonds connecting carbon ring members (an "endocyclic" double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an "exocyclic" double bond). Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl and cyclobutenyl, and a non-limiting example of a bicycloalkenyl group is norbornenyl. Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups that are substituted with one or more oxo moieties. Examples of such groups with oxo moieties are oxocyclopentyl, oxocyclobutyl, oxocyclopentenyl, and norcamphoryl.
The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, and fluorenyl. The terms "heterocyclic", "heterocycloalkyl", and like terms, as used herein, refer to non-aromatic cyclic groups containing one or more heteroatoms, prefereabiy from one to four heteroatoms, each selected from O, S and N. "Heterobicycloalkyl" groups are non-aromatic two- ringed cyclic groups, wherein said rings share one or two atoms, and wherein at least one of the rings contains a heteroatom (O, S, or N). Heterobicycloalkyl groups for purposes of the present invention, and unless otherwise indicated, include spiro groups and fused ring groups. In one embodiment, each ring in the heterobicycloalkyl contains up to four heteroatoms (i.e. from zero to four heteroatoms, provided that at least one ring contains at least one heteroatom). The heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1 ,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3- dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, quinolizinyl, quinuclidinyl, 1 ,4-dioxaspiro[4.5]decyl, 1 ,4-dioxaspiro[4.4]nonyl, 1,4- dioxaspiro[4.3]octyl, and 1 ,4-dioxaspiro[4.2]heptyl.
"Heteroaryl", as used herein, refers to aromatic groups containing one or more heteroatoms (O, S, or N), preferably from one to four heteroatoms. A multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a "heteroaryl" group. The heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl.
The foregoing groups, as derived from the compounds listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached). The terms referring to the groups also encompass all possible tautomers.
In one embodiment, this invention provides compounds of formula 1, wherein R3 is -C(=0)NR9- or -C(=O)(CR10R11)n-. In another embodiment, R10 and R of -C(=O)(CR10R11)n- are at each iteration of n both hydrogen. In another embodiment, R9 of -C(=0)NR9- is hydrogen. In another embodiment, R3 is -C(=0)NR9- or -C(=O)(CR10R11)n- and R2 is hydrogen. In another embodiment, R3 is -(CR10R11)n-, and n is zero. In a preferred embodiment R3 is -(CR10R 1)n-, n is zero, and R4 is (C6-C14)aryl or (5-14 membered) heteroaryl, each optionally substituted as recited above.
In another embodiment of the invention, a compound of formula 1 is provided wherein R1 is optionally substituted (C3-C8)cycloalkyl or optionally substituted bicycloalkyl. Preferred embodiments are wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, each optionally substituted as recited above (i.e. optionally with from one to six substituents R5 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7RB, -NR7C(=0)R8, -NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, -NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, -OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, -OC(=0)NR7R8, -OC(=0)SR7, -SR7, -S(=0)R7, -S(=0)2R7, -S(=0)2NR7R8, and R7). In a more preferred embodiment, R1 is (C3- C8)cycloalkyl or optionally substituted (Cs-C^) bicycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, and is optionally substituted with from one to three substituents independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, -OR7, -C(=0)OR7, -C(=0)R7, and R7. More preferably, R1 is (C3-C8)cycloalkyl or optionally substituted (Cs-C,,) bicycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, and R is substituted with -NR7C(=0)R8, (C6-C14)aryl, (3-8 membered) heterocycloalkyl, or (5-14 membered) heteroaryl, and wherein said aryl, heterocycloalkyl, and heteroaryl are each optionally substituted with from one to six substituents independently selected from F, CI, Br, I, N02, -CN, -CF3, -NR 0R11, -NR10C(=O)R11, -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR10S(=O)2R11, -NR 0S(=O)3NR11R12, -OR10, -OC(=0)R10, -OC(=0)OR1°, -OC(=O)NR10R11, -OC(=0)SR1°, -SR10, -S(=0)R10, -S(=0)2R10, -S(=O)2NR10R11, -C(=0)R10, -C(=0)OR1°, -C(=O)NR10R11, and R10. In another embodiment of the invention, R1 is bicyclo- [3.1.0]-hexyl and is optionally substituted as recited above (i.e. optionally substituted with from one to six substituents R5 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, -NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R6, -NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, -OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, -OC(=0)NR7R8, -OC(=0)SR7, -SR7, -S(=0)R7, -S(=0)2R7, -S(=0)2NR7R8, and R7.
In another embodiment of the invention, a compound of formula 1 is provided wherein R1 is optionally substituted straight chain or branched (C.,-CB)alkyl or optionally substituted straight chain or branched (C2-C8)alkenyl.
In another embodiment of the invention, compounds of formula 1 are provided, but wherein R2 is hydrogen. In a further embodiment, R2 is hydrogen, and R1 is as subdefined in the preceding paragraphs.
In another embodiment, this invention provides a compound of formula 1 wherein R4 is (C6-C14)aryl or (5-14 membered) heteroaryl, each optionally substituted. In a preferred embodiment, R4 is optionally substituted phenyl or optionally substituted pyridyl. In another preferred embodiment, R4 is naphthyl, quinolyl, or isoquinolyl, each optionally substituted. In another embodiment, R4 is napthyl, quinolyl, or isoquinolyl, and is unsubstituted. In another embodiment, R4 is pyrimidinyl, pyrazinyl, or pyridazyl, and in each case R4 is optionally substituted. In a further embodiment, R4 is pyrimidinyl, pyrazinyl, or pyridazyl, and R4 is unsubstituted.
In another embodiment, compounds of formula 1 are provided, wherein R2 is specifically hydrogen, and R4 is as subdefined in the preceding paragraph.
Examples of preferred compounds of formula 1 are: (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-pyridine-2,6-diamine;
(5-ethy!-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine;
(5-cyc!obutyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine
(5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-2-yl-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-1 -yl-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-naphthalene-1 ,4-diamine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N,,N'-dimethyl-pyridine-2,6-diamine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(6-trifluoromethyl-pyridin-2-yl)-amine;
(3-benzyloxy-phenyi)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethyl-phenyl)-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-benzene-1 ,3-diamine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-methoxy-phenyl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(4-nitro-phenyl)-amine;
(4-chloro-benzyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
(3-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-quinolin-2-yl-amine;
[5-(1 ,4-dioxa-spiro[4.4]non-7-yl)-1 H-pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine;
(6-chloro-pyridin-2-yl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentanone;
(5-cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-4-methyl-quinolin-2-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine;
(2-chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
3-.rans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentanol;
(3,5-bis-trifluoromethyl-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yI)-amine;
[5-(3-c/s-benzylamino-cyclopentyl)-1H-pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine; {5-[3-c/s-(4-methoxy-benzylamino)-cyclopentyl]-1 H-pyrazol-3-yl}-(3-trifluoromethyl- phenyl)-amine;
4-(5-cyclobutyl-2H-pyrazol-3-ylamino)-benzonitrile;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3-fluoro-phenyl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3,5-dichloro-phenyl)-amine; (2-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
N-{c/s-3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-acetamide; pyridin-2-yl-{3-trans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- amine;
(5-cyclobutyl-1 H-pyrazol-3-yl)-(4-methoxy-phenyl)-amine; pyridine-2-carboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
3-trifluoromethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-benzamide; cyclobutanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
2,2-dimethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- propionamide;
4-fluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- benzamide; 2,2,2-trifluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- acetamide; cyclopropanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-propionamide; cyclohexanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
N-[5-(3-acetylamino-cyclopentyl)-2H-pyrazol-3-yI]-2-naphthaien-1 -yl-acetamide; cyclopropanecarboxylic acid {3-[5-(2-naphthalen-1 -yl-acetylamino)-1 H-pyrazol-3-yl]- cyclopentyl}-amide;
2-naphthalen-1-yl-N-{5-[3-(2,2,2-trifluoro-acetylamino)-cyclopentyl3-2H-pyrazol-3-yl}- acetamide;
N-{3-[5-(2-naphthalen-1-yl-acetylamino)-1 H-pyrazol-3-yl]-cyclopentyl}-benzamide;
N-(5-hydroxymethyl- 1 H-pyrazol-3-yl)-2-πaphthalen- 1 -yl-acetamide;
2-naphthalen-1-yl-N-[5-(thiazol-2-ylaminomethyl)-1 H-pyrazol-3-yl]-acetamide;
N-[5-((1S)-hydroxy-ethyl)-2H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide; N-{5-[(1 S)-(benzooxazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[(1 S)-(benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-[5-(3-hydroxy-1-methyl-propyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide; N-[5-(benzothiazol-2-yloxymethyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
N-{5-[3-(benzothiazol-2-yloxy)-1-methyl-propyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-[5-(2-hydroxy-(1S)-methyl-ethyl)-2H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide;
N-{5-[(1 R)-(benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
N-[5-(3-acetylamino-1 -methyl-propyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
3-methoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- benzamide;
N-[5-(c/s-3-acetylamino-cyclobutyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide; N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-benzamide;
2-cyclopropyl-N-{cAs-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-acetamide;
6-chloro-pyridine-2-carboxylic acid (c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; quinoline-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide; pyrazine-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide;
4-methoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- benzamide; N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-3-nitro- benzamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-3- trifluoromethyl-benzamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- isobutyra ide;
2-phenyl-cyclopropanecarboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide;
N-{5-[c/s-3-(benzooxazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide; 4-dimethylamino-N-{c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide;
3,5-dimethoxy-N-{c/s-3-t5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide;
2-naphthalen-1-yl-N-[5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-{5-[c/s-3-(3-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[c/s-3-(4-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
2-naphthalen-1-yl-N-[5-(c/s-3-p-tolyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[c/s-3-(4-chloro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
2-(4-methoxy-phenyl)-N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}- acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-quinoiin-6-yl-acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-pyridin-3-yl-acetamide;
N-{5-[c/s-3-(4-methoxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; 2-quinolin-6-yl-N-[5-(c/s-3-p-tolyl-cyclobutyl)-1 H-pyrazol-3-yl]-acetamide;
N-{5-[c;s-3-(4-fluoro-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinoiin-6-yl-acetamide; N-{5-[c/'s-3-(4-chloro-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
2-quinolin-6-yl-N-[5-(c/s-3-m-tolyl-cyclobutyl)-1 H-pyrazol-3-yl]-acetamide;
4-dimethylamino-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide; 2-naphthalen-1 -yl-N-{5-[c/s-3-(pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
6-methyl-pyridine-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide;
2-phenyl-cyclopropanecarboxylic acid methyl-{c/s-3-[5-(2-naphthalen-1 -yl- acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide; N-{5-[c/s-3-(3-methyl-pyrazin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-(6-methoxy-pyridin-2-yl)- amine;
N-{5-[c/s-3-(3,6-dimethyl-pyrazin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen- 1 -yl-acetamide;
N-{5-[c/s-3-(3-methoxy-pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1- yl-acetamide;
2-methyl-cyclopropanecarboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; 2-naphthalen-1 -yl-N-{5-[c/s-3-(3-trifluoromethyl-pyridin-2-yloxy)-cyclobutyl]-1 H- pyrazol-3-yI}-acetamide;
2-naphthalen-1 -yl-N-{5-[c/s-3-(3-nitro-pyridin-2-yloxy)-cyclobutyl]- 1 H-pyrazol-3-yl}- acetamide;
N-{5-[c/s-3-(benzothiazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
2-naphthalen-1 -yl-N-{5-[c/s-3-(4-trifluoromethyl-pyrimidin-2-yloxy)- cyclobutyl]-1 H- pyrazol-3-yl}-acetamide;
2-naphthalen-1-yl-N-{5-[3-(5-nitro-pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}- acetamide; 2-naphthalen-1 -yl-N-{5-[3-(pyrimidin-2-yloxy)-cyclobutyl]-1 H-pyrazoI-3-yl}-acetamide;
2-naphthalen-1 -yl-N-{5-[3-(5-trifluoromethyl-pyridin-2-yloxy)- cyclobutyl]-1 H-pyrazol-3- yl}-acetamide;
N-{5-[3-(6-methoxy-pyridazin-3-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1 -yl-N-{5-t3-(pyrazin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide; N-{5-[3-(6-methyl-pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[3-(6-chloro-benzothiazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1- yl-acetamide; N-{5-[3-(6-methoxy-benzothiazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-
1 -yl-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other examples of preferred compounds of formula 1 are:
N-{5-[cs-3-(4-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[c/s-3-(3-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
2-Naphthalen-1-yl-N-[5-(c/s-3-pyridin-3-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-[5-(c/s-3-Naphthalen-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-pyridin-3-yl-acetamide;
N-(5-lndan-2-yl-1 H-pyrazol-3-yl)-2-quinolin-6-yl-acetamide;
N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide; N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
2-(4-Methoxy-phenyl)-N-[5-(c/s-3-pyridin-4-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[3-(c/s-2-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
N-(5-{c/s-3-[3-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[2-(2-Dimethylamino-ethoxy)-pheπyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl )-acetamide; 2-(4-Methoxy-phenyl)-N-[5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[c/s-3-(2-Fluoro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[4-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyl)-acetamide; N-(5-{c/s-3-[2-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyiy-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(2-methylsulfanyl-phenyl)-cyclobutyl]-2H-pyrazol-3- yl}-acetamide;
N-{5-[c/s-3-(2-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[c/s-3-(4-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-3-hydroxy-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-[c/s-3-(2-Hydroxy-ethyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[c/s-3-(3-Cyano-phenyl)-cyclobutyl]-2H-pyrazoi-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(3-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
4-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester; N-{5-[c/s-3-(4-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide; Cyclopropanecarboxylic acid {5-[c/s-3-(2-hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3- yl}-amide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-isobutyramide;
N-{5-[c/s-3-(3-Aminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-fc/s-3-(3-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
3-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[c/s-3-(3-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-(5-{c/s-3-[3-(1-Hydroxy-1-methyl-ethyl)-phenyl]-cyciobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
N-{5-[c/s-3-(3-Ethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-[c/s-3-(3-Cyclobutylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-propylaminomethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopentylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; N-(5-{c/s-3-[3-(Benzylamino-methyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[3-(3-methylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol- 3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopropylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-pyrrolidin-1-ylmethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Diethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-[c/s-3-(3-Azetidin-1 -ylmethyl-phenyl)-cycIobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other specific examples of compounds of the invention of formula 1 are:
N-[5-(c/s-3-pyridin-2-yl-cyclobutyl)-1 H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide; N-[5-(c/s-3-pyridin-3-yl-cyclobutyl)-1 H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-[5-(c/s-3-pyridin-4-yl-cyclobutyl)-1H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-[5-(cs-3-pyrazin-2-yl-cyclobutyl)-1 H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-[5-(c/s-3-pyrimidin-4-yl-cyclobutyI)-1 H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(3-methoxy-pyridin-2-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[c/s-3-(4-methoxy-pyridin-3-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[c/s-3-(3-methoxy-pyridin-4-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide; N-{5-[c/5-3-(2-methoxy-pyridin-3-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[c/s-3-(5-methoxy-pyrimidin-4-yl)-cyclobutyl]-1H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[c/s-3-(1-ethyl-1 H-imidazol-2-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide; N-{5-[c/s-3-(1 -ethyl-1 H-pyrro!~2-yl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[c/s-3-(2-aminomethyl-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide; N-{5-[c/s-3-(2-pyrrolidin-1 -ylmethyl-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6- yl-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other specific examples of compounds of formula 1 are:
{4-[(5-cyclobutyl-1 H-pyrazol-3-ylcarbamoyl)-methyl]-phenyl}-acetic acid; N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(1 H-indol-3-yl)-acetamide;
2-(3-chloro-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
2-(3-bromo-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
2-biphenyl-4-yl-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
2-biphenyl-4-yl-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide; N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3,4,5-trimethoxy-phenyl)-acetamide;
{2-[(5-cyclobutyl-1 H-pyrazol-3-ylcarbamoyl)-methyl]-phenyl}-acetic acid;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3,4-dichloro-phenyl)-acetamide;
2-(2-chloro-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2-fluoro-phenyl)-acetamide; 2-(4-butoxy-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2,4-difluoro-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2-iodo-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2,3-dimethoxy-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2,5-dihydroxy-phenyl)-acetamide; N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3-hydroxy-4-methoxy-phenyl)-acetamide;
2-(4-acetylamino-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-trifluoromethyl-phenyl)-acetamide;
2-(4-chloro-3-nitro-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-hydroxy-3,5-dinitro-phenyl)-acetamide; N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3,4-difluoro-phenyl)-acetamide;
2-(2,4-bis-trifluoromethyl-phenyl)-N-(5-cyclobutyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3,5-difluoro-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2-fluoro-3-trifluoromethyl-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-fluoro-3-trifluoromethyl-phenyl)-acetamide; N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(2,4,6-trifluoro-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-methylsulfanyl-phenyl)-acetamide; N-(5-cyclobutyl-1 H-pyrazol-3-yI)-2-(3-hydroxy-phenyl)-acetamide;
N-(5-cyclopentyl-1 H-pyrazol-3-yl)-2-phenyl-acetamide;
2-(4-chloro-phenyl)-N-(5-cyclopentyl-2H-pyrazol-3-yl)-acetamide;
N-(5-cyclopentyl-1 H-pyrazol-3-yl)-2-naphthalen-2-yl-acetamide; N-(5-cyclobutyl-2H-pyrazol-3-yl)-2-(2,4-dichloro-phenyl)-acetamide;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-2-quinolin-6-yl-acetamide;
2-(3-amino-phenyl)-N-(5-cyclobutyl-2H-pyrazol-3-yl)-acetamide;
1 -(5-cyclobutyl-1 H-pyrazol-3-yl)-3-naphthalen-1 -yl-urea;
N-(5-cyclohexyl-1 H-pyrazol-3-yl)-2-naphthalen-2-yl-acetamide; N-(5-cyclohexyl-1 H-pyrazol-3-yl)-2-phenyl-acetamide;
2-(4-chloro-phenyl)-N-(5-cyclohexyl-1 H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-phenoxy-phenyl)-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(4-dimethylamino-phenyl)-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-(2,3,4-trimethoxy-phenyl)-acetamide; N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-(4-isopropyl-phenyl)-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-pyrrolo[2,3-b]pyridin-1 -yl-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-m-tolyl-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-p-tolyl-acetamide;
N-(5-cyclobutyl-1 H-pyrazol-3-yl)-2-(3-trifluoromethoxy-phenyl)-acetamide; N-[5-(3-benzyloxy-propyl)-1 H-pyrazol-3-yl]-2-naphthalen-2-yl-acetamide;
4-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol-3-yl]-piperidine-1 -carboxylic acid benzyl ester;
2-naphthalen-2-yl-N-(5-piperidin-4-yl-2H-pyrazol-3-yl)-acetamide;
N-[5-(1-acetyl-piperidin-4-yl)-2H-pyrazol-3-yl]-2-naphthalen-2-yl-acetamide; N-[5-(1-benzoyl-piperidin-4-yl)-2H-pyrazol-3-yl]-2-naphthalen-2-yl-acetamide;
4-[5-(2-naphthalen-1 -yl-acetylamino)-1 H-pyrazol-3-yl]-piperidine-1 -carboxylic acid benzyl ester;
N-[5-(1-cyclobutanecarbonyl-piperidin-4-yl)-2H-pyrazol-3-yl]-2-naphthalen-2-yl- acetamide; N-{3-[5-(2-naphthalen-2-yl-acetylamino)-4H-pyrazol-3-yl]-propyl}-benzamide;
N-{3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-propyI}-benzamide;
N-{5-[1-(3-methyl-butyl)-piperidin-4-yl]-1H-pyrazol-3-yl}-2-naphthalen-2-yl-acetamide;
N-[3-(5-phenylacetylamino-2H-pyrazol-3-yl)-propyl]-benzamide;
N-{3-[5-(2-m-tolyl-acetylamino)-2H-pyrazol-3-yl]-propyl}-benzamide; N-(3-{5-[2-(3-chloro-phenyl)-acetylamino]-2H-pyrazol-3-yl}-propyl)-benzamide; 6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol- 3-yl]-cyclobutyl}-amide;
6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol- 3-yl]-cyclobutyl}-amide; 6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol-
3-yl]-cyclobutyl}-amide;
N-{5-[3-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-cyclobutyl]-2H-pyrazol-3-yl}-2- naphthalen-2-yl-acetamide;
6-chloro-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetyiamino)-1 H-pyrazol- 3-yl]-cyclobutyl}-amide;
N-{3-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol-3-yl]-cyclobutyl}-benzamide;
2-naphthalen-2-yl-N-[5-(2-pyridin-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-2-yl-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-2-yl-N-[5-(2-pyridin-4-yl-ethyl)-2H-pyrazol-3-yl]-acetamide; 2-naphthalen-1 -yl-N-[5-(2-pyridin-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-1-yl-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-1-yl-N-[5-(2-pyridin-4-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-(3-methoxy-phenyl)-N-[5-(2-pyridin-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-(3-methoxy-phenyl)-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl]-acetamide; 2-(3-methoxy-phenyl)-N-[5-(2-pyridin-4-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-(3-methoxy-phenyl)-N-[5-(2-thiazol-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-1-yl-N-t5-(2-thiazol-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
2-naphthalen-2-yl-N-[5-(2-thiazol-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide;
N-[5-(1-benzyl-piperidin-4-yl)-1 H-pyrazol-3-yl]-2-naphthalen-2-yl-acetamide; 2-naphthalen-1 -yl-N-(5-piperidin-4-yl-1 H-pyrazol-3-yl)-acetamide;
2-(4-chloro-phenyl)-N-{3-[5-(2-naphthalen-2-yl-acetylamino)-1 H-pyrazol-3-yl]- cyclobutyl}-acetamide; pyrazine-2-carboxylic acid {3-[5-(2-naphthalen-2-y!-acetylamino)-1 H-pyrazol-3-yl]- cydobutyl}-amide; 2-(3-methoxy-phenyl)-N-{5-[2-(2-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yl}- acetamide;
2-(3-methoxy-phenyl)-N-{5-[2-(3-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yl}- acetamide;
2-(3-methoxy-phenyl)-N-{5-[2-(4-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yl}- acetamide; 6-methyl-pyridine-2-carboxylic acid (3-{5-[2-(3-methoxy-phenyl)-acetylamino]-2H- pyrazol-3-yl}-cyclobutyl)-amide;
6-methyl-pyridine-2-carboxylic acid (3-{5-[2-(4-methoxy-phenyl)-acetylamino]-2H- pyrazol-3-yl}-cyclobutyl)-annide; 6-methyl-pyridine-2-carboxylic acid (3-{5-[2-(4-chloro-phenyl)-acetylamino]-2H- pyrazol-3-yl}-cyclobutyl)-amide; and pharmaceutically acceptable salts of said compounds.
Salts of compounds of formula 1 can be obtained by forming salts with any acidic or basic group present on a compound of formula 1. Examples of pharmaceutically acceptable salts of the compounds of formula 1 are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid, mandelic acid, sodium, potassium, magnesium, calcium, and lithium. The compounds of formula 1 may have optical centers and therefore may occur in different enantiomeric and other stereoisomeric configurations. The invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of formula 1, as well as racemic and other mixtures thereof.
The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 11C, 14C, 18F, 123l and 125l. Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. 11C and 18F isotopes are particularly useful in PET (positron emission tomography), and 1 5l isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula 1 of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
This invention also includes compounds of the formula
wherein Prot is a protecting group;
R2 is H, F, -CH3, -CN, or -C(=0)OR7; and n is an integer selected from 1 , 2, 3, and 4.
Compounds of formula I are useful as intermediates for synthesizing certain compounds of formula 1 that are described herein.
Preferably, n is 1.
Examples of specific protecting groups include, but are not limited to .-butyl and -CH2- Ar, wherein "Ar" is an aryl or heteroaryl group. An example of the latter type of protecting group is para-methoxybenzyl. This invention also provides a pharmaceutical composition for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective in inhibiting abnormal cell growth, and a pharmaceutically acceptable carrier.
This invention also provides a pharmaceutical composition for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective to inhibit cdk2 activity, and a pharmaceutically acceptable carrier.
This invention also provides a method for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting abnormal cell growth.
This invention also provides a method for treating a diseases or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective to inhibit cdk2 activity.
In a pharmaceutical composition or method of this invention for treating a disease or condition comprising abnormal cell growth, the disease or condition comprising abnormal cell growth is in one embodiment cancer. The cancer may be a carcinoma, for example carcinoma of the bladder, breast, colon, kidney, liver, lung, for example small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin, for example squamous cell carcinoma; a hematopoietic tumor of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumor of myeloid lineage, for example acute and chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia; a tumor of mesenchymal origin, for example fibrosarcoma or rhabdomyosarcoma; a tumor of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xenoderoma pigmentoum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
In another embodiment, the disease or condition comprising abnormal cell growth is benign. Such diseases and conditions include benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, fungal infection, and endotoxic shock.
This invention also provides a pharmaceutical composition for treating a neurodegenerative disease or condition in a mammal, including a human, comprising a compound of formula 1 in an amount effective in treating said disease or condition, and a pharmaceutically acceptable carrier.
This invention also provides a pharmaceutical composition for treating a neurodegenerative disease or condition in a mammal, including a human, comprising a compound of formula 1 in an amount effective in inhibiting cdk5 activity, and a pharmaceutically acceptable carrier. This invention also provides a method for treating a neurodegnerative disease or condition in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdk5 activity.
This invention also provides a method for treating a neurodegenerative disease or condition in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in treating said disease or condition.
In one embodiment of the invention, the neurodegenerative disease or condition which is treated is selected from Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, neurodegeneration associated with bacterial infection, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age- related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotoπic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, and subacute sclerosing panencephalistis. This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising a compound of formula 1 in an amount effective in treating said disease or condition and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising a compound of formula 1 in an amount effective to inhibit cdkδ and a pharmaceutically acceptable carrier.
This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdkδ activity.
This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in treating said disease or condition.
In one embodiment of the invention, the disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission is selected from Parkinson's disease; schizophrenia; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance- induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; personality disorder of the schizoid type; drug addiction, including narcotic (e.g. heroin, opium, and morphine), cocaine and alcohol addiction; drug withdrawal, including narcotic, cocaine and alcohol withdrawal; obsessive compulsive disorder; Tourette's syndrome; depression; a major depressive episode, a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features or with melancholic features or catatonic features, a mood episode with postpartum onset; post-stroke depression, major depressive disorder, dysthymic disorder, minor depressive disorder, premenstrual dysphoric disorder, post-psychotic depressive disorder of schizophrenia, a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia, a bipolar disorder, for example bipolar I disorder, bipolar II disorder, cyclothymic disorder; anxiety; attention deficit and hyperactivity disorder; and attention deficit disorder.
This invention also provides a pharmaceutical composition for treating a disease or condition the treatment of which can be effected or facilitated by decreasing cdk5 activity in a mammal, including a human, which composition comprises a compound of formula 1 in an amount effective in inhibiting cdkδ activity and a pharmaceutically acceptable carrier.
This invention also provides a method for treating a disease or condition the treatment of which can be effected or facilitated by decreasing cdk5 activity in a mammal, including a human, which method comprises administering to the mammal a compound of formula 1 in an amount effective in inhibiting cdkδ activity.
We have also found that the compounds of formula 1 have activity in inhibiting GSK- 3. The compounds of formula 1 therefore can be expected to be useful in treating diseases and conditions the treatment of which can be effected or facilitated by inhibition of GSK-3. Diseases and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include neurodegenerative diseases and conditions. Neurodegenerative diseases and conditions are discussed above and include, but are not limited to, for example Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, cerebral ischemia, AIDS-related dementia, neurodegeneration associated with bacterial infection, multiinfarct dementia, traumatic brain injury, and spinal cord trauma. Therefore, compounds of formula 1 are effective in treating neurodegenerative diseases and conditions based on both cdk5 activity and GSK-3 activity.
Other diseases and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include psychotic disorders and conditions, for example schizophrenia, schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type. The treatment of such diseases and conditions can also be effected or facilitated by altering dopamine mediated neurotransmission. Therefore, compounds of formula 1 are effective in treating such disorders and conditions based on both cdkδ activity and GSK-3 activity.
Other disorders and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 include mood disorders and mood episodes, for example a major depressive episode, a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features or with melancholic features or catatonic features, a mood episode with postpartum onset; post-stroke depression, major depressive disorder, dysthymic disorder, minor depressive disorder, premenstrual dysphoric disorder, post-psychotic depressive disorder of schizophrenia, a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia, a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymic disorder. The treatment of such mood disorders 5 and episodes, for example depression, can also be effected or facilitated by altering dopamine mediated neurotransmission. Therefore, compounds of formula 1 are effective in treating certain mood disorders and mood episodes based on both cdkδ activity and GSK-3 activity.
Other disorders and conditions the treatment of which can be effected or facilitated by inhibiting GSK-3 are male fertility and sperm motility; diabetes mellitus; impaired glucose 0 tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; spinal cord injury; hair loss, hair thinning, and balding; immunodeficiency; and cancer. 5 Accordingly, the present invention also provides a pharmaceutical composition for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example 0 muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which composition comprises a pharmaceutically acceptable carrier and an amount of a compound of formula 1 effective in treating said disease or condition.
The present invention further provides a pharmaceutical composition for treating in a δ mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, 0 abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which composition comprises a pharmaceutically acceptable carrier and an amount of a compound of formula 1 effective in inhibiting GSK-3.
The present invention also provides a method for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes δ mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which method comprises administering to said mammal an amount of a compound of formula 1 δ effective in treating said disease or condition.
The present invention also provides a method for treating in a mammal, including a human, a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline 0 in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency; which method comprises administering to said mammal an amount of a compound of formula 1 effective in inhibiting GSK-3. δ The present invention further provides a method for inhibiting GSK-3 in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula 1 effective in inhibiting GSK-3.
The present invention further provides a pharmaceutical composition for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive 0 impairment, and age-related cognitive decline comprising a compound of formula 1 and a COX-II inhibitor together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention also provides a method for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive impariment, and age-related δ cognitive decline which method comprises administering to said mammal a compound of formula 1 and a COX-II inhibitor, wherein the combined amounts of the compound of formula 1 and the COX-II inhibitor are effective in treating said disorder. The compound of formula 1 and the COX-II inhibitor can be administered to the mammal at the same time and/or separately. Moreover, the compound of formula 1 and the COX-II inhibitor can be administered in a single 0 composition or in separate compositions.
Moreover, a compound of formula 1 of the invention, or a pharmaceutically acceptable salt of a compound of formula 1 , can be administered or formulated into a pharmaceutical composition with one or more anti-depressants or anxiolytic compounds for treatment or prevention of depression and/or anxiety. δ Accordingly, this invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and an NK-1 receptor antagonist together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating depression or anxiety in a mammal, including a human, which method comprises administering to said mammal a 5 compound of formula 1 and an NK-1 receptor antagonist, wherein the combined amounts of the compound of formula 1 and the NK-1 receptor antagonist are effective in treating depression or anxiety. The compound of formula 1 and the NK-1 receptor antagonist can be administered to the mammal at the same time and/or at different times. Moreover, the may be administered together in a single pharmaceutical composition or in separate compositions. 0 This invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and a δHT1D receptor antagonist together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating depression or anxiety in a δ mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and a 5HT1D receptor antagonist, wherein the combined amounts of the compound of formula 1 and the 5HT1D receptor antagonist are effective in treating depression or anxiety. The compound of formula 1 and the 5HT1D receptor antagonist can be administered to the mammal at the same time and/or at different times. Moreover, they may 0 be administered together in a single pharmaceutical composition or in separate compositions. This invention also provides a pharmaceutical composition for treating depression or anxiety in a mammal, including a human, comprising a compound of formula 1 and a SSRI together in an amount effective in treating depression or anxiety, and a pharmaceutically acceptable carrier. δ This invention further provides a method for treating depression or anxiety in a mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and a SSRI, wherein the combined amounts of the compound of formula 1 and the SSRI are effective in treating depression or anxiety. The compound of formula 1 and the SSRI can be administered to the mammal at the same time and/or at 0 different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
This invention also provides a pharmaceutical composition for treating schizophrenia in a mammal, including a human, comprising a compound of formula 1 and an antipsychotic selected from ziprasidone, olanzapine, risperidone, L-74δ870, sonepiprazole, RP 62203, NGD δ 941 , balaperidone, flesinoxan, and gepirone, together in an amount effective in treating schizophrenia, and a pharmaceutically acceptable carrier. This invention further provides a method for treating schizophrenia in a mammal, including a human, which method comprises administering to said mammal a compound of formula 1 and an antipsychotic selected from ziprasidone, olanzapine, risperidone, L-74δ870, sonepiprazole, RP 62203, NGD 941 , balaperidone, flesinoxan, and gepirone, wherein the combined amounts of the compound of formula 1 and the antipsychotic are effective in treating schizophrenia. The compound of formula 1 and the antipsychotic can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions. This invention also provides a pharmaceutical composition for treating a disorder selected from Alzheimer's disease, mild cognitive impairment, and age-related cognitive decline in a mammal, including a human, comprising a compound of formula 1 and an acetylcholinesterase inhibitor together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating in a mammal, including a human, a disorder selected from Alzheimer's disease, mild cognitive impairment, and age-related cognitive decline, which method comprises administering to said mammal a compound of formula 1 and an acetylcholinesterase inhibitor, wherein the combined amounts of the compound of formula 1 and the acetylcholinesterase inhibitor are effective in treating said disorder. The compound of formula 1 and the acetylcholinesterase inhibitor can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia comprising a compound of formula 1 and TPA (tissue plasminogen activator, for example ACTIVASE) together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and TPA, wherein the combined amounts of the compound of formula 1 and the TPA are effective in treating said disease or condition. The compound of formula 1 and the TPA can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions. This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia in a mammal, including a human, comprising a compound of formula 1 and NIF (neutrophil inhibitory factor) together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating in a mammal, including a human, a δ disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and NIF, wherein the combined amounts of the compound of formula 1 and the NIF are effective in treating said disease or condition. The compound of formula 1 and the NIF can be administered to the mammal at the 0 same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
This invention also provides a pharmaceutical composition for treating a disease or condition selected from Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced δ dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age-related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower 0 lateral sclerosis, and subacute sclerosing panencephalistis in a mammal, including a human, comprising a compound of formula 1 and an NMDA receptor antagonist together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from Huntington's disease, stroke, spinal cord trauma, δ traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age-related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, 0 Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, and subacute sclerosing panencephalistis, which method comprises administering to said mammal a compound of formula 1 and an NMDA receptor antagonist, wherein the combined amounts of the compound of formula 1 and the NMDA receptor antagonist are effective in treating said disease or condition. The compound of δ formula 1 and the NMDA receptor antagonist can be administered to the mammal at the same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
This invention also provides a pharmaceutical composition for treating a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, multiinfarct
5 dementia, epilepsy, pain, Alzheimer's disease, and senile dementia in a mammal, including a human, comprising a compound of formula 1 and a potassium channel modulator together in an amount effective in treating said disorder, and a pharmaceutically acceptable carrier.
This invention further provides a method for treating in a mammal, including a human, a disease or condition selected from stroke, spinal cord trauma, traumatic brain injury, 0 multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, which method comprises administering to said mammal a compound of formula 1 and a potassium channel modulator, wherein the combined amounts of the compound of formula 1 and the potassium channel modulator are effective in treating said disease or condition. The compound of formula 1 and the potassium channel modulator can be administered to the mammal at the 5 same time and/or at different times. Moreover, they may be administered together in a single pharmaceutical composition or in separate pharmaceutical compositions.
The terms "treatment", "treating", and the like, refers to reversing, alleviating, or inhibiting the progress of the disease or condition to which such term applies, or one or more symptoms of such disease or condition. As used herein, these terms also encompass, 0 depending on the condition of the patient, preventing the onset of a disease or condition or of symptoms associated with a disease or condition, including reducing the severity of a disease or condition or symptoms associated therewith prior to affliction with said disease or condition. Such prevention or reduction prior to affliction refers to administration of the compound of the invention to a subject that is not at the time of administration afflicted with the disease or δ condition. "Preventing" also encompasses preventing the recurrence of a disease or condition or of symptoms associated therewith.
"Abnormal cell growth", as used herein, refers to cell growth, either malignant (e.g. as in cancer) or benign, that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Examples of benign proliferative diseases are psoriasis, benign prostatic 0 hypertrophy, human papilloma virus (HPV), and restinosis.
"Neurodegenerative diseases and conditions", as used herein and unless otherwise indicated, refers to diseases and conditions having associated therewith degeneration of neurons. Conditions and diseases that are neurodegenerative in nature are generally known to those of ordinary skill in the art. δ References herein to diseases and conditions "the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission" mean a disease or condition that is caused at least in part by dopamine neurotransmission, or a disease or condition that result in abnormal dopamine neurotransmission, thus contributing to symptoms or manifestations of the disease condition.
References herein to diseases and conditions "the treatment of which can be effected or δ facilitated by decreasing cdkδ activity" mean a disease or condition that is caused at least in part by cdkδ activity, or a disease or condition that results in abnormal cdkδ activity that contributes to symptoms or manifestations of the disease or condition.
An "amount effective to inhibit cdkδ" as used herein refers to an amount of a compound sufficient to bind to the enzyme cdkδ with the effect of decreasing cdkδ activity. 0 An "amount effective to inhibit cdk2 activity" as used herein refers to an amount of a compound sufficient to bind to the enzyme cdk2 with the effect of decreasing cdk2 activity.
Detailed Description of the Invention
Compounds of the formula 1, above, and their pharmaceutically acceptable salts, can be prepared according to the following reaction Schemes and discussion. Unless otherwise δ indicated R\ R2, R3, and R4 are as defined above. "Prot" represents a protecting group.
Isolation and purification of the products is accomplished by standard procedures which are known to a chemist of ordinary skill.
As used herein, the expression "reaction inert solvent" refers to a solvent system in which the components do not interact with starting materials, reagents, or intermediates of 0 products in a manner which adversely affects the yield of the desired product.
During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; and T. W. δ Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, Inc., 1999.
Scheme 1 illustrates general methods suitable for preparing compounds of formula 1 wherein R3 is -(CR10R 1)π-, -C(=0)NR9-, -C(=0)0-, or -C(=O)(CR10R11)n-. Treatment of a solution of slurry of magnesium chloride in a reaction inert solvent, preferably acetonitrile, 0 diethyl ether, or tetrahydrofuran, at a reaction temperature from -20 °C to 40 °C, preferably from about -δ °C to 21 °C, with a trialkyl amine base, where triethyl amine or diisopropylethylamine are preferred, in the presence of an alkyl cyano acetate and in the presence of an acid halide of formula 2, wherein acid chlorides are preferred, affords intermediate 3a, a 2-cyano-3-alkyl-3-oxo-propionic acid alkyl ester. A preferred alkyl cyano δ acetate is ethyl cyano acetate. Hydrolysis and decarboxylation of 3a to 3 may be accomplished by exposing 3a to water in a reaction inert solvent, preferably dimethylsulfoxide, at a temperature from about 21 °C to 200 °C, preferably from about 100 °C to 118 °C. Reaction of 3 in a reaction inert solvent, such as a lower alcohol, in the presence of a hydrazine at a reaction temperature of from about 0 °C to about 150 °C, where a temperature of from about 70 °C to about 8δ °C is preferred, affords the corresponding product 4. The δ hydrazine used may be anhydrous hydrazine or a hydrate form of hydrazine, or N-alkyl- hydrazine or N-acyl-hydrazine. Anhydrous hydrazine or an alkyl hydrazine, for example 4- methoxy-benzyl-hydrazine, are preferred.
Coupling of 4 with an aryl halide or heteroaryl halide to obtain an intermediate of formula 5, wherein R3 is -(CR10R11)0- (a bond) can be accomplished by reaction of 4 in a 0 reaction inert solvent, preferably toluene, at a reaction temperature of from about 21 °C to about 1δ0 °C, preferably at about 100 °C to about 110 °C, in the presence of a palladium catalyst, a base, preferably cesium carbonate or sodium or potassium tert-butoxide, a ligand, where preferred ligands are 2,2'-bis(diphenylphosphino)-1 ,1 '-binaphythyl, 2- (dicyclohexylphosphino)biphenyl, and 2-(di-tert-butylphosphino)biphenyl, and in the presence δ of the appropriate aryl halide or heteroaryl halide, where aryl bromides or chlorides and heteroaryl bromides or chlorides are preferred. The metal catalyst may be a palladium species, for example palladium chloride, palladium acetate, dichlorobis(acetonitrile)palladium, or derivatives thereof, wherein palladium acetate is preferred. Removal of the protecting group from 5 can be accomplished by reaction of 5 in a reaction inert solvent, preferably 0 methylene chloride or no solvent, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 7δ °C, to yield 1a, wherein R3 represents a bond and R4 is as defined above for compounds of formula 1.
Coupling of 4 to yield N-acyl derivatives of the nature 6 (wherein R3 is 5 -C(=O)(CR10R11)n-) can be accomplished by reaction of 4 in a reaction inert solvent, preferably methylene chloride, pyridine, tetrahydrofuran, or diethyl ether, in the presence of an acid chloride CIC(=0)(CH2)nR4, acid anhydride R4(CH2)nC(=0))20, or an activated carboxylic acid derivative XC(=0)(CH2)nR4 wherein X represents the activating group, and in the presence of a amine base, such as triethyl amine or diisopropylethyl amine, wherein tripropylphosphonic 0 anhydride and triethylamine are a preferred combination, at a temperature of from about -78 °C to about 40 °C. The activated carboxylic acid derivative can be prepared from the carboxylic acid and known activating reagents such as polymer supported coupling agents or coupling agents such as, for instance, dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydride, alkyl chioroformate, bis(2-oxo-3-oxazolidinyl)phosphinic 5 chloride, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or any other such standard literature reagents. Removal of the protecting group on 6 may be accomplished by reaction 6 in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 7δ °C. A product of formula 1b is obtained, wherein R3 represents -C(=O)(CR10R11)n- and R4 is as defined above for compounds of formula 1.
Alternatively, the amine of 4 can be treated with a base, such as triethylamine, diisopropylethylamine, pyridine, or 2,6-lutidine, and an alkyl, aryl, or heteroaryl chloroformate CIC(=0)OR4 (diisopropylethylamine and aryl or heteroarly chloroformates are a preferred combination) from a temperature about -78 °C to about 40 °C, to afford a compound of an intermediate where R3 -C(=0)0- and R4 is as defined above for compounds of formula 1. Removal of the protecting group from this intermediate can be achieved as described, i.e. in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 65 °C to about 75 °C. This affords a carbamate compound of formula 1 wherein R3 is -C(=0)0- and R4 is as defined above for compounds of formula 1.
Subsequent treatment of the carbamate of the formula 1 formed in the preceding paragraph with a primary or secondary amine in a solvent such as dioxane, dimethylformamide, or acetonitrile, where a 1 :1 mixture of dioxane: dimethylformamide is preferred, at a temperature between about 40 °C and about 90 °C, where about 70 °C is preferred, affords the corresponding urea product of formula 1 where R3 is -C(=0)NR9- and R4 is as defined above for compounds of formula 1.
Compounds of formula 1 wherein R3 is -(CR10R11)(1.3)- can be prepared from intermediates of formula 4 by reaction of 4 with an oxo moiety (aldehyde or ketone) in a reaction inert solvent, preferably toluene, tetrahydrofuran or methanol at a reaction temperature from about 0 °C to about 110 °C, preferably about 21 °C, in the presence of a reducing ragent, where preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride, and lithium aluminum hydride to afford an intermediate of formula 6 wherein R3 is -(CR10R 1){1.3)-. Removal of the protecting group from this intermediate 6 can be achieved as described, i.e. in a reaction inert solvent, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 65 °C to about 75 °C. Scheme 1
Scheme 2 illustrates an alternative method suitable for preparing compounds of formula 1. The method depicted in Scheme 2 is preferred when R4 is an electron deficient aryl moiety, such as 4-nitrophenyl, or an electron deficient heteroaryl moiety. Reaction of a ketone having the general structure of 8, wherein R1 and R2 are as defined above for compounds of formula 1, in a reaction inert solvent, wherein tetrahydrofuran or diethyl ether are preferred as solvents, at a reaction temperature from about -116 °C to about 50 °C, preferably at about -78 °C to about -65 °C, in the presence of a base, a hindered amine base being preferred, and also in the presence of an isothiocyanate of the general formula 9, wherein R3 is a bond (-(CR10R11)0-) and R4 is aryl or heteroaryl, affords 10. Examples of hindered amine bases include lithium diisopropyl amide, potassium bis(trimethylsilyl) amide, lithium bis(trimethylsilyl) amide, and other such standard literature reagents. Treatment of 10 in a reaction inert solvent, a preferred solvent being a lower alcohol, in the presence of an acid, preferably acetic acid, at a reaction temperature of from about 21 °C to about 100 °C, preferably from about 7δ °C to about 85 °C, and in the presence of hydrazine, affords a compound of the formula 1a, wherein R3 is a bond and R4 is aryl or heteroaryl.
Synthesis of compounds of formula 1 wherein R1 is substituted with one or more substituents R5 is also illustrated in Scheme 2. Reaction of a compound of formula 10 in a δ reaction inert solvent, such as lower alcohols, in the presence of an acid, preferably acetic acid, also in the presence of a hydrazine, at a reaction temperature of about 0 °C to about 1δ0 CC, preferably from about 7δ °C to about 8δ °C, affords 10a (wherein R3 is a bond, R4 is aryl or heteroaryl, R1 is as defined above, and R5 is a protected oxo moiety (an acetal or ketal). Preferred hydrazines are alkyl hydrazines, for example 4-methoxy-benzyl hydrazine or t-butyl 0 hydrazine.
Deprotection of the oxo moiety R5 can be accomplished using well-known conditions, which appear in the literature. For example, treating compound 10a in a reaction inert solvent, preferably a lower ketone for example acetone, in the presence of an acid, preferably hydrogen chloride, p-toluenesulfonic acid monohydrate, or pyridinium p-toluenesulfonate, at a δ temperature of from about room temperature to about 80 °C, preferably about 7δ °C, affords 10b, wherein R5 is an oxo (carbonyl) moiety, R1 is as defined above, R3 is a bond, and R4 is aryl or heteroaryl.
Reduction of the oxo moiety to obtain an alocohol (R5 is -OH) can be accomplished using well established chemistry. Alternatively, the oxo moiety of 10b can be reacted with an 0 amine, either primary or secondary, wherein the preferred amine is an alkyl amine for example 4-methoxy-benzyl-amine, in a reaction inert solvent, preferably toluene or tetrahydrofuran, at a reaction temperature from about 21 °C to about 1 δ0 °C, preferably at about 70 °C to about 110 °C. After 10b is consumed, usually within a 12 hour period, the reaction is cooled to a temperature of about 21 °C to about δO °C and a reducing reagent is δ added, where preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride and lithium aluminum hydride, to afford 10c, wherein R is as defined above, R3 is a bond, R4 is aryl or heteroaryl, and R5 is -NR7R8. Coupling of 10c to yield N- acyl derivatives of the formula 10d, wherein R5 is -NR7C(=0)R8, can be accomplished by reaction of 10c in a reaction inert solvent, wherein methylene chloride, pyridine, 0 tetrahydrofuran, diethyl ether are preferred, in the presence of an alkyl chloroformate, acid chloride, acid anhydride, or an activated carboxylic acid derivative, from -78 °C to 40 °C. The activated carboxylic acid derivative is prepared from the carboxylic acid and known activating reagents such as polymer supported coupling agents or alternatively dicyclohexyl carbodiimide, carbonyl diimidazole, tripropylphosphonic anhydride, alkyl chloroformate, bis(2- δ oxo-3-oxazolidinyl)phosphinic chloride, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or any other such standard literature reagents, in the presence of a trialkyl amine base, such as triethyl amine or diisopropylethyl amine, wherein tripropylphosphonic anhydride and triethylamine are a preferred combination.
Removal of the protecting group on 10b, 10c, or 10d may be accomplished by reaction in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, preferably trifluoro acetic acid, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 75 °C, to yield the corresponding compounds of formula 1 , for example 1c, as depicted in Scheme 2.
Scheme 2
Scheme 3 illustrates an alternative method suitable for the preparation of compounds of formula 1. The method illustrated in Scheme 3 is preferred when R1 is substituted with R5 selected from -NR7R8, -NR7C(=0)R8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, -NR7S(=0)2NR8R9, - C(=0)R7, -C(=0)OR7, and -C(=0)NR7R8. Referring to Scheme 3, reacting an organolithium δ base, preferably n-butyl lithium, sec-butyl lithium, phenyl lithium, or tert-butyl lithium, at a reaction temperature from about -116 °C to about 60 °C, preferably at about -78 °C to about - 4δ °C, in a reaction inert solvent, especially tetrahydrofuran or diethyl ether, in the presence of alkylnitrile, preferably acetonitrile, and in the presence of an ester of the formula 11, wherein R1 is as defined above and R5 is a protected oxo moiety (specifically a ketal or acetal) or R5 is 0 as defined above, gives 3b, wherein R5 is the same as in the compound of formula 11. Processing of a compound with the formula 3b to a compound with the formula 1d or formula 1e where R3 is, respectively, -C(=O)(R10R11)n- or a bond and R5 is as in the compound of formula 11 can be accomplished as described in the description of Scheme 1. If R5 is a protected oxo moiety, conversion of such group to carbonyl, can be accomplished at the same δ time as removal of the protecting group from the pyrazole nitrogen.
Alternatively, the amine of 4a can be treated with a base, such as triethylamine, diisopropylethylamine, pyridine, or 2,6-lutidine, and a chloroformate CIC(=0)OR4 (diisopropylethylamine and aryl or heteroarly chloroformates are a preferred combination) as described above for scheme 1 to afford a carbamate intermediate 7a where R3-C(=0)0- and 0 R4 is as defined above for compounds of formula 1.
Subsequent treatment of 7a formed in the preceding paragraph with a primary or secondary amine in a solvent such as dioxane, dimethylformamide, or acetonitrile, where a 1 :1 mixture of dioxane: dimethylformamide is preferred, at a temperature between about 40 °C and about 90 °C, where about 70 °C is preferred, affords the corresponding urea intermediate δ 7b where R3 is -C(=0)NR9- and R4 is as defined above for compounds of formula 1.
Intermediate 7c wherein R3 is -(CR10R11)(1.3)- can be prepared from intermediate 4a by reaction of 4a with an oxo moiety (aldehyde or ketone) in a reaction inert solvent, preferably toluene, tetrahydrofuran or methanol at a reaction temperature from about 0 °C to about 110 °C, preferably about 21 °C, in the presence of a reducing reagent, where preferred reducing 0 reagents are sodium triacetoxyborohydride, sodium cyanoborohydride, and lithium aluminum hydride to afford an intermediate of formula 6a wherein R3 is -(CR10R11)(1.3)-. Removal of the protecting group from this intermediate 6a can be achieved as described, i.e. in a reaction inert solvent, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 7δ °C. Intermediates of formula 5a, 6a, 7a, 7b, or 7c can also be converted to form further compounds of the invention, as illustrated in Scheme 3. Scheme 3 depicts use of 5a (wherein R3 is a bond) and 6a (wherein R3 is -C(=O)(R10R 1)n-) as reactants, however the same chemistry can be applied to intermediates of formulae 7a, 7b, or 7c to obtain analogous δ products. Referring to Scheme 3, if R5 in 5a and 6a is a protected oxo (carbonyl) moiety (specifically acetal or ketal), removal of the protecting group can first be accomplished using well-known conditions, which appear in the literature. Treating a compound 5a or 6a (or 7a, 7b, or 7c), in a reaction inert solvent, preferably a lower ketone, for example acetone, in the presence of an acid, where preferred acids are hydrogen chloride, p-toluenesulfonic acid 0 monohydrate, pyridinium p-toluenesulfonate, at a temperature varying from about room temperature to about 80 °C, preferable at about 7δ °C, affords 12, where R3 is a bond, or 15, where R3 is -C(=O)(CR10R11)n-, or, if 7a, 7b, or 7c were used as reactants, compounds analogous to 12 and 15 but wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-, respectively, in each case R5 being an oxo (carbonyl) moiety. δ The oxo moiety of the intermediates produced in the preceding paragraph, such as in
12 and 15, can be reacted with an amine, primary or secondary, wherein the preferred amines are alkyl amine for example 4-methoxy-benzyl-amine, in a reaction inert solvent, preferably toluene or tetrahydrofuran, at a reaction temperature from about 21 °C to about 1 δ0 °C, preferably at about 70 °C to about 110 °C. After 12 or 15 is consumed, usually within a 12 0 hour period, the reaction can be cooled to a temperature of about 21 °C to about δO °C, and a reducing reagent is added. Preferred reducing reagents are sodium triacetoxyborohydride, sodium cyanoborohydride and lithium aluminum hydride. Such reaction of fer example 12 or 15 affords 13, wherein R3 is a bond, or 16, wherein R3 is -C(=O)(CR10R 1)n-, respectively, in each case R5 being -NR7R8. Analogous compounds to 13 and 16, wherein R5 is -NR7R8 and δ R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)- can also be prepared, using the intermediates analogous to 12 and 15 described above. Coupling of 13 or 16 or the analogous intermediates to yield an N-acyl derivative 14 or 17 or N-acyl derivatives analogous thereto but having R3 as -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-, can be accomplished by reaction of 13 or 16 or the analogous intermediates in a reaction inert solvent, wherein methylene 0 chloride, pyridine, tetrahydrofuran, diethyl ether are preferred, in the presence of an acid chloride, acid anhydride, or an activated carboxylic acid derivative, from about -78 °C to about 40 °C. The activated carboxylic acid can be prepared as described above.
Alternatively, the amine of 16 or 13 or the intermediates analogous thereto can be treated with a base, such as triethylamine, diisopropylethylamine, pyridine, or 2,6-lutidine, and 5 an alkyl, aryl or heteroaryl chloroformate CIC(=0)2R7 (diisopropylethylamine and chloroformates are a preferred combination) from a temperature of about -78 °C to about 40 °C, where from about -78 °C to about -40 °C are preferred, to afford a compounds of formula 1 where R5 -NR7C(=0)OR8. Subsequent treatment of the carbamate of the formula 1 with a primary or secondary amine in a solvent such as dioxane, dimethylformamide, or acetonitrile, where a 1 :1 mixture of dioxane: dimethylformamide is preferred, at a temperature between 40 °C and 90 °C, where 70 °C is preferred, affords the corresponding urea intermediate where R5 is -NR C(=0)NR8R9.
Removal of the protecting group on 12, 13, 14, 15, 16, or 17 or any of the analogous compounds described above wherein R3 and/or R5 is instead -C(=0)0-, -C(=0)NR9-, or - (CR10R11)(1.3)- may be accomplished by reaction in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 75 °C, affording respective compounds of formula 1 , for example a compound formula 1c, wherein R3 is a bond and R5 is -NR7C(=0)R8 or a compound of formula 1f, wherein R3 is -C(=O)(CR10R11)n- and R5 is -NR7C(=0)R8.
Schemes 4 and δ illustrate a preferred method for the preparation of compounds of the formula 1 , wherein R1 is optionally substituted with OR7 or R7. Preparation of the intermediates 12 and 15 can be accomplished as described in the description of Scheme 3. R3 in intermediate 12 is a bond, and R3 in intermediate 15 is -C(=O)(CR10R11)n-. Also, intermediates analogous to 12 and 15, but wherein R3 is -C(=0)0-, -C(=0)NR9-, or - (CR10R11)(1.3)-, can be used in Schemes 4 and 5. In each case (12, 15, or analogous intermediate), Rsis an oxo (carbonyl) moiety. Conversion of the oxo (=0) moiety to a hydroxyl moiety (-OH), as in 18 and 23, can be accomplished using well-established chemistry. The preferred method is by reaction of 12 or 15 or intermediate analogous thereto in a reaction inert solvent, preferably a tetrahydrofuran/water mixture, at a reaction temperature from about -78 °C to about 50 °C, 5 preferable at about 20 °C, in the presence of a reducing agent, preferably NaBH4 or lithium aluminum hydride, to afford 18 or 23 or compound analogous thereto wherein R3 is -C(=0)0-, -C(=O)NR9-, or -(CR10R11)(1.3)-.
Reaction of 18 or 23 or compound analogous thereto wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R1 )(1.3)- in a reaction inert solvent, preferably tetrahydrofuran, at a 0 reaction temperature from about -20 °C to about δO °C, preferably at about 20 °C, in the presence of R7-halide, where the preferred R7-halide is R7-CI, affords 19 or 24 or compound analogous thereto wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-, in each case R5 being -OR7. Removal of the protecting group can be accomplished by reaction in a reaction inert solvent, wherein methylene chloride or no solvent is preferred, in the presents of an acid, δ wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to 100 °C, preferably from about 6δ °C to about 75 °C, to obtain a compound of formula 1g, wherein R3 is a bond and where R5 = OR7, a compound of formula 1 h, wherein R3 is -C(=O)(CR10R11)(0. 3)-, or an analogous compound wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-.
Alternatively, treatment of a solution of compound 12 or 15 or analogous intermediate 0 wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)- (in each case R5 being an oxo moiety, specifically carbonyl) in a reaction inert solvent, where tetrahydrofuran is preferred, with an organometallic reagent, such as an organomagnesium halide, organolithium, organocerium, organotitanium, organozinc, organocopper, or organoaluminum, where the organomagnesium halide (Grignard reagent) or organolithium reagents are preferred, at a temperature from 5 about -78 °C to about 40 °C, where -78 °C to about 0 °C is preferred, affords the alcohol product 21 or 26 or analogous compound wherein R3 is -C(=0)0-, -C(=0)NR9-, or - (CR10R11)(1.3)-, wherein in each case R1 is hydroxylated and substituted with R7, for example (δ-(3-hydroxy, 3-phenyl-cyclobutyl)-2-(Prot)-pyrazol-3-yl)-naphthalen-2-yl-amine. Removal of the alcohol is accomplished by reaction of 21 or 26 or analogous compound in an inert 0 solvent, such as methylene chloride, chloroform, or 1 ,2-dichloroethane, or preferably no solvent, in the presence of an acid, preferably trifluoroacetic acid, and in the presence of a silane, where triethylsilane and triphenylsilane are preferred, at a temperature from about -10 °C to about δO °C, where about 20 °C to about 40 °C is preferred, obtaining a compound of formula 22 or 27 or compound analogous thereto but wherein R3 is -C(=0)0-, -C(=0)NR9-, or δ -(CR10R11)(1.3)-, the intermediate in each case comprising R7 bonded directly to R1. Alternatively, treatment of the alcohol products such as 21 or 26 and about one to ten equivalents of a base, where about five equivalents of pyridine or 2,6-lutidine are preferred, in a reaction inert solvent, preferably methylene chloride, with a strongly acidic reagant, preferably thionyl chloride, at a temperature from about -110 °C to about 0 °C, where about - δ 78 °C to about -4δ °C is preferred, results in replacement of the alcohol (-OH group) with chloride. Reductive removal of the chloride may be accomplished by exposing a mixture of said chloride of 21 or 26 and a noble metal catalyst, palladium being preferred, to an atmosphere of hydrogen gas at a pressure of about 1 to about 100 atmospheres, where a preferred pressure of hydrogen gas is about one to about ten atmospheres, to obtain 22 or 27 0 or a compound analogous thereto wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R1 )(1.3)-. The metal catalyst may be conveniently suspended on an inert solid support such as charcoal, in a solvent such as ethyl acetate, tetrahydrofuran, dioxane, or a mixture thereof.
In Schemes 4 and δ, the R5 hydroxy moiety of a compound of formula 18 or 23, or of the analogous compounds wherein R3 is -C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-, can be δ derivatized using chemistry known in the art to obtain corresponding compounds wherein R5 is -OC(=0)R7, -OC(=0)OR7, -0C(=0)NR7R8, and -OC(=0)SR7, -SR7, -S(=0)R7, -S(=0)2R7, or -S(=0)2NR7R8.
For example, the amine of 18 or 23 or a compound analogous thereto wherein R3 is - C(=0)0-, -C(=0)NR9-, or -(CR10R11)(1.3)-, can be treated with a base, such as triethylamine, 0 diisopropylethylamine, pyridine, or 2,6-lutidine, and an alkyl, aryl or heteroaryl chloroformate CIC(=0)2R7 (diisopropylethylamine and chloroformates are a preferred combination) from a temperature of about -78 °C to about 40 °C, where from about -78 °C to -40 °C are preferred, to afford a carbonate intermediate where R5 is -OC(=0)OR8. Subsequent treatment of the carbonate with a primary or secondary amine in a solvent such as dioxane, δ dimethylformamide, or acetonitrile, where a 1 :1 mixture of dioxane: dimethylformamide is preferred, at a temperature between about 40 °C and about 90 °C, where about 70 °C is preferred, affords the corresponding urea intermediate where R5 is -OC(=0)NR8R9. Removal of the protecting group of either intermediate may be accomplished by reaction in a reaction of inert solvent, wherein methylene chloride or no solvent is preferred, in the presence of an 0 acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 65 °C to about 7δ °C, affording a compound of formula 1, where R5 -OC(=0)OR7 or -OC(=0)NR8R9.
Removal of the protecting group of 22, 27, or a derivative of 19 or 24 can be accomplished by reaction in a reaction inert solvent, preferably methylene chloride, δ chloroform, 1 ,2-dichloroethane, or no solvent, in the presence of an acid, where trifluoroacetic acid is preferred, at a reaction temperature from about 20 °C to about 100 °C, preferably from about 6δ °C to about 7δ °C, affording a compound of formula 1i, 1k, or other compound of formula 1.
Compounds of formula 1 as described herein wherein R2 is other than hydrogen can be prepared by transformations of the compounds of formula 1 herein wherein R2 is hydrogen using methods that are well known in the art. For example, referring to Scheme 3, supra, compounds of formula 1 wherein R2 is F can be prepared by treating compounds of formula 17, 6a, or 14 with N-fluorobenzenesulfonimide in a reaction of inert solvent, wherein toluene, dioxane, or xylenes are preferred, from about room temperature to about 150°C, preferably from about 100°C to about 120°C to obtain the corresponding intermediates wherein R2 is F. Removal of the protecting group from these intermediates may be accomplished by reaction in a reaction of inert solvent, wherein methylene chloride or no solvent are preferred, in the presence of an acid, wherein trifluoro acetic acid is preferred, at a reaction temperature from about 20°C to about 100°C, preferably from about 65°C to about 7δ°C, thus affording compounds of formula 1 wherein R2 is F.
Scheme 5
Some of the compounds of formula 1 prepared according to the above processes are obtained as a mixture of isomers or enantiomers. Such mixtures of isomers or enantiomers are within the scope of the present invention. The separation of such mixtures into the single isomers or enantiomers according to conventional techniques is also within the scope of the δ present invention, as are the separated isomers and enantiomers themselves.
Pharmaceutically acceptable salts of a compound of formula 1 can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base or acid with one chemical equivalent of a pharmaceutically acceptable acid or base. Conventional concentration or crystallization techniques can be employed to isolate the salts. 0 Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids. Illustrative bases are sodium, potassium, and calcium.
A compound of this invention may be administered alone or in combination with δ pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining a compound of formula 1 or a pharmaceutically acceptable salt thereof can then be readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These 0 pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, δ gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein 0 may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
For parenteral administration, solutions containing a compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or δ in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
A compound of formula 1 or a pharmaceutically acceptable salt thereof can be administered orally, transdermally (e.g., through the use of a patch), parenterally (e.g. intravenously), rectally, or topically. In general, the daily dosage for treating a neurodegenerative disease or condition or a disease or condition the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission will generally range from about 0.0001 to about 10.0 mg/kg body weight of the patient to be treated. The daily dosage for treating cancer or disease or condition involving abnormal cell growth of a benign nature will generally range from about 0.0001 to about δOO mg/kg body weight of the patient to be treated. As an example, a compound of the formula 1 or a pharmaceutically acceptable salt thereof can be administered for treatment of a neurodegenerative disorder to an adult human of average weight (about 70kg) in a dose ranging from about 0.01 mg up to about 1000 mg per day, preferably from about 0.1 to about 500 mg per day, in single or divided (i.e., multiple) portions. Variations based on the aforementioned dosage ranges may be made by a physician of ordinary skill taking into account known considerations such as the weight, age, and condition of the person being treated, the severity of the affliction, and the particular route of administration chosen. The compounds of formula 1 and their pharmaceutically acceptable salts can furthermore also be administered or formulated into a pharmaceutical composition with an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents, which amounts are together effective in inhibiting abnormal cell growth. Anti-angiogenesis agents, such as MMP-2 (matrix-metalloproteinase 2) inhibitors,
MMP-9 (matrix-metalloproteinase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound of formula 1 in the methods and pharmaceutical compositions described herein for treatment of abnormal cell growth, including cancer. Examples of useful COX-II inhibitors include CELEBREX™ (celecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931 ,788 (published July 28, 1999), WO 90/06719 (published May 331 , 1990), WO 99/52910 (published October 21 , 1999), WO 99/62889 (published October 21 , 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21 , 1998), European Patent Application No. 99302232.1 (filed March δ 26, 1999), Great Britain patent application number 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 6,861,610 (issued January 19, 1999), and European Patent Publication 780,386 (published June 2δ, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that 0 have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP- 2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1 , MMP-3, MMP-4, MMP-δ, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11 , MMP-12, and MMP-13).
Some specific examples of MMP inhibitors useful in the present invention are AG-3340, RO 32-3δδδ, RS 13-0830, and the compounds recited in the following list: δ 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1 -hydroxycarbamoyl-cyclopentyl)- aminoj-propionic acid;
3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane- 3-carboxylic acid hydroxyamide;
(2R, 3R) 1 -[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl- 0 piperidine-2-carboxylic acid hydroxyamide;
4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclobutyl)- aminoj-propionic acid; 6 4-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide;
(R) 3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-3-carboxylic acid hydroxyamide;
(2R, 3R) 1 -[4-(4-fluoro-2-methyi-benzyloxy)-benzenesulfonyl]-3-hydroxy-3- 0 methyl-piperidine-2-carboxylic acid hydroxyamide;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-1-methyl-ethyl)- aminoj-propionic acid;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4-hydroxycarbamoyl-tetrahydro-pyran- 4-yl)-amino]-propionic acid; δ 3-exo-3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-
3-carboxylic acid hydroxyamide; 3-endo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3- carboxylic acid hydroxyamide; and
(R) 3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxylic acid hydroxyamide; δ and pharmaceutically acceptable salts and solvates of said compounds.
Other anti-angiogenesis agents, including other COX-II inhibitors and other MMP inhibitors, can also be used in the present invention.
The effective amount of a COX-II inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed daily effective dose range 0 for a COX-II inhibitor in combination with a cdk5 inhibitor is from about 0.1 to about 2δ mg/kg body weight. The effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of COX-II inhibitor and/or the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in inhibiting abnormal cell growth. δ A compound of formula 1 can also be used with signal transduction inhibitors, such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN™ (Genentech, Inc. of 0 South San Francisco, California, USA). Such combinations are useful for treating and preventing abnormal cell growth, including cancer, as described herein.
EGFR inhibitors are described in, for example in WO 96/19970 (published July 27, 1995), WO 98/14451 (published April 9, 1998), WO 98/02434 (published January 22, 1998), and United States Patent 5,747,498 (issued May 5, 1998), and such substances can be used in the δ present invention as described herein. EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C22δ and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, New York, USA), the compounds ZD-1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, New Jersey, USA), and OLX-103 (Merck & Co. of Whitehouse Station, New Jersey, USA), VRCTC-310 (Ventech Research) and EGF 0 fusion toxin (Seragen Inc. of Hopkinton, Massachusettes). These and other EGFR-inhibiting agents can be used in the present invention.
VEGF inhibitors, for example SU-5416 and SU-6668 (Sugen Inc. of South San
Francisco, California, USA), can also be combined with a compound of formula 1. VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT 5 International Application PCT/IB99/00797 (filed May 3, 1999)"; in WO 95/21613 (published
August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent 5,834,504 (issued November 10, 1998), WO 98/50356 (published November 12, 1998), United States Patent 5,883,113 (issued March 16, 1999), United States Patent 5,886,020 (issued March 23, 1999), United States Patent 5,792,783 (issued August 11 , 1998), WO 99/10349 (published March 4, 1999), WO 97/32866 (published September 12, 1997), WO 97/22596 (published June δ 26, 1997), WO 98/64093 (published December 3, 1998), WO 98/02438 (published January 22, 1998), WO 99/16755 (published April 8, 1999), and WO 98/02437 (published January 22, 1998), all of which are incorporated herein in their entireties by reference. Other examples of some specific VEGF inhibitors useful in the present invention are IM862 (Cytran Inc. of Kirkland, Washington, USA); anti-VEGF monoclonal antibody of Genentech, Inc. of South San 0 Francisco, California; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California). These and other VEGF inhibitors can be used in the present invention as described herein.
ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) δ and 2B-1 (Chiron), can also be combined with a compound of formula 1 , for example those indicated in WO 98/02434 (published January 22, 1998), WO 99/36146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 1998), WO 97/13760 (published April 17, 1997), WO 96/19970 (published July 27, 1996), United States Patent 5,687,468 (issued December 24, 1996), and United States Patent 6,877,306 (issued 0 March 2, 1999), which are all hereby incorporated herein in their entireties by reference. ErbB2 receptor inhibitors useful in the present invention are also described in United States Provisional Application No. 60/117,341 , filed January 27, 1999, and in United States Provisional Application No. 60/117,346, filed January 27, 1999, both of which are incorporated in their entireties herein by reference. The erbB2 receptor inhibitor compounds and substance described in the 5 aforementioned PCT applications, U.S. patents, and U.S. provisional applications, as well as other compounds and substances that inhibit the erbB2 receptor, can be used with a compound of formula 1 , in accordance with the present invention.
A compound of formula 1, can also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing 0 antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as farnesyl protein transferase inhibitors. Specific CTLA4 antibodies that can be used in the present invention include those described in United States Provisional Application 60/113,647 (filed December 23, 1998) which is incorporated by reference in its entirety, however other CTLA4 antibodies 6 can be used in the present invention. Th e compounds of formula 1 can also be administered in a method for inhibiting abnormal cell growth in a mammal in combination with radiation therapy. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of the invention in this combination therapy can be determined as described herein.
Compounds of formula 1 can also be administered in combination with a COX-II inhibitor for treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline. Specific examples of COX-II inhibitors useful in this aspect of the invention are provided above, wherein use of a COX-II inhibitor in combination with a compound of formula 1 for treatment of abnormal cell growth is described. The effective amount of a COX-II inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed effective daily dose range for a COX-II inhibitor in combination with a compound of formula 1 is from about 0.1 to about 26 mg/kg body weight. The daily effective amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of COX-II inhibitor and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline.
Compounds of formula 1 can also be administered in combination with an NK-1 receptor antagonist for treatment of depression or anxiety. An NK-1 receptor antagonist, as recited herein, is a substance that is able to antagonize NK-1 receptors, thereby inhibiting tachykinin-mediated responses, such as responses mediated by substance P. Various NK-1 receptor antagonists are known in the art, and any such NK-1 receptor antagonist can be utilized in the present invention as described above in combination with a compound of formula 1. NK-1 receptor antagonists are described in, for example, United States Patent 5,716,965 (issued February 10, 1998); United States Patent 5,852,038 (issued December 22, 1998); WO 90/05729 (International Publication Date May 31 , 1990); United States Patent 5,807,867 (issued September 15, 1998); United States Patent 5,886,009 (issued March 23, 1999); United States Patent 5,939,433 (issued August 17, 1999); United States Patent 5,773,450 (issued June 30, 1998); United States Patent 5,744,480 (issued April 28, 1998); United States Patent 5,232,929 (issued August 3, 1993); United Stated Patent 5,332,817 (issued July 26, 1994); United States Patent 5,122,525 (issued June 16, 1992), United States Patent 5,843,966 (issued December 1 , 1998); United States Patent 5,703,240 (issued December 30, 1997); United States Patent 5,719,147 (issued February 17, 1998); and United States Patent 5,637,699 (issued June 10, 1997). Each of the foregoing U.S. patents and the foregoing published PCT International Application are incorporated in their entireties herein by reference. The compounds described in said references having NK-1 receptor antagonizing activity can be used in the present invention. However, other NK-1 receptor antagonists can also be used in this invention.
The effective amount of an NK-1 receptor antagonist in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed effective daily dose range for an NK-1 receptor antagonist in combination with a compound of formula 1 is from about 0.07 to about 21 mg/kg body weight. The effective amount of the compound of formula 1 will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of NK-1 receptor antagonist and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
The subject invention also provides combining a compound of formula 1 with a 5HT1D receptor antagonist for treatment of depression or anxiety. A 5HT1D receptor antagonist, as recited herein, is a substance that antagonizes the 5HT1D subtype of serotonin receptor. Any such substance can be used in the present invention as described above in combination with a compound of formula 1. Substances having 5HT1D receptor antagonizing activity can be determined by those of ordinary skill in the art. For example, 5HT1D receptor antagonists are described in WO 98/14433 (International Publication Date April 9, 1998); WO 97/36867 (International Publication Date October 9, 1997); WO 94/21619 (International Publication Date September 29, 1994); United States Patent 5,610,350 (issued April 23, 1996); United States Patent 5,358,948 (issued October 25, 1994); and GB 2276162 A (published September 21 , 1994). These 5HT1D receptor antagonists, as well as others, can be used in the present invention. The aforementioned published patent applications and patents are incorporated herein by reference in their entireties. The effective amount of a 5HT1 D receptor antagonist in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed effective daily dose range for a 5HT1D receptor antagonist in combination with a compound of formula 1 is from about 0.01 to about 40 mg/kg body weight. The effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of 5HT1 D receptor antagonist and/or the amount of compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
This invention also provides a pharmaceutical composition and method for treating depression or anxiety in a mammal comprising a compound of formula 1 and a SSRI. Examples of SSRIs that can be combined in a method or pharmaceutical composition with compounds of formula 1 and their pharmaceutically acceptable salts include, but are not limited to, fluoxetine, paroxetine, sertraline, and fluvoxamine. Other SSRIs may be combined or administered in combination with a compound of formula 1 or a pharmaceutically acceptable salt thereof. Other antidepressants and/or anxiolytic agents with which a compound of formula 1 may be combined or administered include WELLBUTRIN, SERZONE and EFFEXOR.
The effective amount of a SSRI in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed effective daily dose range for a SSRI in combination with a compound of formula 1 is from about 0.01 to about 500 mg/kg body weight. The effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of SSRI and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety.
A compound of formula 1 , or a pharmaceutically acceptable salt thereof, can also be combined with one or more antipsychotic agents, for example a dopaminergic agent, for the treatment of diseases or conditions the treatment of which can be effected or facilitated by altering dopamine neurotransmission, such as schizophrenia. Examples of antipsychotics with which a compound of the invention can be combined include ziprasidone (5-(2-(4-(1 ,2- benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1 ,3-dihydro-2H-indol-2-one; U.S. Patent 4,831 ,031 and U.S. Patent 5,312,925); olanzapine (2-methyl-4-(4-methyl-1-piperazinyl-10H- thieno (2,3b) (1 ,5)benzodiazepine; U.S Patent 4,115,574 and U.S. Patent 5,229,382); risperidone (3-[2-[4-(6-fluoro-1 ,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]6,7,8,9-tetrahydro-2- methyl-4H-pyrido[1 ,2-a]pyrimidin-4-one; U.S. Patent 4,804,663); L-745870 (3-(4-(4- chlorophenyl)piperazin-1-yl)methyl-1 H-pyrrolo(2,3-b)pyridine; U.S. Patent 5,432,177); sonepiprazole (S-4-(4-(2-(isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide; U.S. Patent 5,877,317); RP 62203 (fananserin; 2-(3-(4-(4-fluorophenyl)-1- piperazinyl)propyl)naphtho(1 ,8-c,d)isothiazole-1 ,1 -dioxide; U.S. Patent 5,021 ,420); NGD 941 (U.S. Patent 5,633,376 and U.S. Patent 5,428,165); balaperidone ((1α,5α,6α)-3-(2-(6-(4- fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)-2,4(1 H,3H)-quinazolinedione; U.S. Patent 6,475,105); flesinoxan ((+)-4-fluoro-N-[2-[4-5-(2-hydroxymethyl-1 ,4-benzodioxanyl)]-1- piperazinyl]ethyl]benzamide; U.S. Patent 4,833,142); and gepirone (4,4-dimethyl-1-(4-(4-(2- pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; U.S. Patent 4,423,049). The patents recited above in this paragraph are each incorporated herein by reference in their entireties. The effective daily amount of the compound of formula 1 will typically be between about 0.0001 to about 10 mg/kg body weight. The amount of any of the aforementioned antipsychotic agents contemplated for use in combination with a compound of formula 1 is generally the amount known in the art to be useful for treating psychotic conditions. However, in some instances, the amount of the antipsychotic and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating depression or anxiety. It is furthermore to be understood that the present invention also encompasses combining a compound of formula 1 with antipsychotic or dopaminergic other than those in the aforementioned list.
A proposed amount for sonepiprazole in the above-described combination with a compound of formula 1, is from about 0.006 to about 60 mg/kg body weight of the patient per day. A proposed amount of RP 62203 in such combination is from about 0.20 to about 6 mg/kg body weight of the patient per day. A proposed amount of NGD 941 in such combination is from about 0.1 to about 140 mg/kg of body weight per day. A proposed amount of balaperidone in such combination is from about 1 to about 100 mg/kg body weight per day. A proposed amount of flesinoxan in such combination is from about 0.02 to about 1.6 mg/kg body weight per day. A proposed amount for gepirone in such combination is from about .01 to about 2 mg/kg body weight per day. A proposed amount of L-746870 in such combination is from about 0.01 to about 250 mg/kg body weight per day, preferably from about 0.05 to about 100 mg/kg body weight per day. A proposed amount of risperidone in such combination is from about O.Oδ to about 60 mg/kg body weight per day. A proposed amount of olanzapine in such combination is from about 0.0006 to about 0.6 mg/kg body weight per day. A proposed amount of ziprasidone in such combination is from about O.Oδ to about 10 mg/kg body weight per day. In some instances for each of the aforementioned combinations, however, the amount of each specific ingredient in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating a psychotic condition.
This invention also provides a pharmaceutical composition and method for treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline comprising a compound of formula 1 and an acetylcholinesterase inhibitor. Acetylcholinesterase inhibitors are known in the art, and any such acetylcholinesterase inhibitor can be used in the above- described pharmaceutical composition or method. Examples of acetylcholinesterase inhibitors that can be used in this invention are ARICEPT (donepezil; U.S. Patent 4,895,841 ); EXELON (rivastigmine ((S)-[N-ethyl-3-[1-(dimethylamino)ethyl]phenyl carbamate); U.S. Patent 5,603,176 and U.S. Patent 4,948,807); metrifonate ((2,2,2-trichloro-1-hydroxyethyl)phosphonic acid dimethyl ester; U.S. Patent 2,701 ,225 and U.S. Patent 4,950,658); galantamine (U.S. Patent 4,663,318); physostigmine (Forest, USA); tacrine (1 ,2,3,4-tetrahydro-9-acridinamine; U.S. Patent 4,816,456); huperzine A (5R-(5 ,9β,11 E))-5-amino-11-ethylidene-δ,6,9,10- tetrahydro-7-methyl-δ,9-methaneocycloocta(b)pyridin-2-(1 H)-one); and icopezil (5,7-dihydro-3- (2-(1-(phenylmethyl)-4-piperidinyl)ethyl)-6H-pyrroio(3,2-f)-1 ,2-benzisoxazol-6-one; U.S. Patent 6,760,642 and WO 92/17475). The patents and patent applications recited above in this paragraph are herein incorporated by reference in their entireties.
The effective amount of an acetylcholinesterase inhibitor in combination with a compound of formula 1 can generally be determined by a person of ordinary skill. A proposed effective daily dose range for an acetylcholinesterase inhibitor in combination with a compound of formula 1 is from about 0.01 to about 10 mg/kg body weight. The effective daily amount of the compound of formula 1 generally will be between about 0.0001 to about 10 mg/kg body weight. In some instances the amount of acetylcholinesterase inhibitor and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating Alzheimer's disease, mild cognitive impairment, or age-related cognitive decline.
The present invention also provides for combining a compound of formula 1 with neuroprotectants, for example NMDA receptor antagonists, for treatment of Huntington's disease, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, amyotrophic lateral sclerosis, pain, viral induced dementia for example AIDS induced dementia, migraine, hypoglycemia, urinary incontinece, brain ischemia, multiple sclerosis, Alzheimer's disease, senile dementia of the Alzheimer's type, mild cognitive impairment, age- related cognitive decline, emesis, corticobasal degeneration, dementia pugilistica, Down's syndrome, myotonic dystrophy, Niemann-Pick disease, Pick's disease, prion disease with tangles, progessive supranuclear palsy, lower lateral sclerosis, or subacute sclerosing panencephalistis. Examples of NMDA receptor antagonists that can be used in the present invention include (1 S,2S)-1 -(4-hydroxyphenyi)-2-(4-hydroxy-4-phenylpiperidin-1 -yl)-1 - propanol (U.S. Patent 5,272,160), eliprodil (U.S. Patent 4,690,931), and gavestenel (U.S. Patent 5,373,018). Other NMDA receptor antagonists, which can also be used in the present invention, are described in U.S. Patent 6,373,018; U.S. Patent 4,690,931; U.S. Patent 6,272,160; U.S. Patent 5,186,343; U.S. Patent 5,356,905; U.S. Patent 5,744,483; WO 97/23216; WO 97/23215; WO 97/23214; WO 96/37222; WO 96/06081; WO 97/23458; WO 97/32581 ; WO 98/18793; WO 97/23202; and U.S. Serial No. 08/292,651 (filed August 18, 1994). The aforementioned patents and patent applications are each hereby incorporated by reference in their entireties.
The effective daily amount of the compound of formula 1 in the combination with an NMDA receptor antagonist generally will be between about 0.0001 to about 10 mg/kg body weight. The amount of the NMDA receptor antagonist contemplated for use in combination with a compound of formula 1 for treatment of any of the aforementioned disorders, for example Alzheimer's disease, is generally within the range of from about 0.02 mg/kg/day to about 10 mg/kg/day. However, in some instances, the amount of the NMDA antagonist and/or the amount of the compound of formula 1 in the combination may be less than would be required on an individual basis to achieve the same desired effect in treating said disorders.
The subject invention also provides for combining a compound of formula 1 with certain substances capable of treating a stroke or traumatic brain injury, such as TPA, NIF, or potassium channel modulators, for example BMS-204352. Such combinations are useful for treating neurodegenerative disorders such as stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, pain, Alzheimer's disease, and senile dementia, for example.
For the above-described combination therapies and pharmaceutical compositions, the effective amounts of the compound of the invention and of the other agent can generally be determined by those of ordinary skill in the art, based on the effective amounts for the compounds described herein and those known or described for the other agent known in the art, for example the amounts described in the above-recited patents and patent application incorporated herein. The formulations and routes of administration for such therapies and compositions can be based on the information described herein for compositions and therapies comprising a compound of the invention as the sole active agent and on information provided for the other agent in combination therewith.
A specific compound of formula 1 can be determined to inhibit cdk2, cdk5, or GSK-3 using biological assays known to those of ordinary skill in the art, for example the assays described below.
The specific activity of a compound of formula 1 for inhibition of cdk5 or cdk2 can, for example, be ascertained by means of the following assays using materials available to those of ordinary skill in the art:
Enzyme activities can be assayed as the incorporation of [33P] from the gamma phosphate of [33P]ATP (Amersham, cat. no. AH-9968) into biotinylated peptide substrate PKTPKKAKKL In such an assay, reactions are carried out in a buffer containing δOmM Tris- HCI, pH 8.0; 10mM MgCI2, 0.1 mM Na3V04, and 1mM DTT. The final concentration of ATP is about O.δuM (final specific radioactivity of 4uCi/nmol), and the final concentration of substrate 0.7δuM. Reactions, initiated by the addition of either cdkδ and activator protein p25 or cdk2 and activator cyclin E, may be carried out at room temperature for about 60 minutes. Reactions are stopped by addition of 0.6 volume of buffer containing (final concentrations): 2.5mM EDTA, 0.05%Triton-X 100, 100uM ATP, and 1.25 mg/ml streptavidin coated SPA beads (Amersham cat. no. RPNQ0007). Radioactivity associated with the beads is quantified by scintillation counting. The specific activity of a compound of formula 1 for inhibition of GSK-3 can be determined in both cell-fee and cell-based assays, both of which are described in the art (see, for example, WO 99/65897). A cell-free assay can be carried out in general by incubating GSK-3 with a peptide substrate, radiolabeled ATP (such as, for example, γ33P- or γ32-P-ATP, both available from Amersham, Arlington Heights, Illinois), magnesium ions, and the compound to be assayed. The mixture is incubated for a period of time to allow incorporation of radiolabeld phosphate into the peptide substrate by GSK-3 activity. The reaction mixture is washed to remove unreacted radiolabeled ATP, typically after first transferring all or a portion of the enzyme reaction mixture to a well that contains a uniform amount of a ligand that is capable of binding to the peptide substrate. The amount of 33P or 32P remaining in each well after washing is then quantified to determine the amount of radiolabeled phosphate incorporated into the peptide substrate. Inhibition is observed as a reduction, relative to a control, in the incorporation of radiolabeled phosphate into the peptide substrate. An example of a suitable GSK-3 peptide substrate for an assay is the SGSG-linked CREB peptide sequence, derived from the CREB DNA binding protein, described in Wang, et al., Anal. Biochem., 220:397-402 (1994). Purified GSK-3 for an assay may, for example, be obtained from cells transfected with a human GSK-3β expression plasmid as described in, for example Stambolic, et al., Current Biology 6:1664-68 (1996). WO 99/65897; Wang, et al., and Stambolic, et al. are incorporated in their entireties herein by reference.
Another example of a GSK-3 assay, similar to the one described in the preceding paragraph is as follows: Enzyme activities are assayed as the incorporation of [33P] from gamma phosphate of [33P]ATP (Amersham, cat. No. AH-9968) into biotinylated peptide substrate PKTPKKAKKL. Reactions are carried out in a buffer containing 50mM Tris-HCI, pH 8.0; 10mM MgCI2, 0.1 mM Na3V04, and 1 mM DTT. The final concentration of ATP is 0.5μM (final specific radioactivity of 4μCi/nmol), and the final concentration of substrate is 0.75μM. Reactions, initiated by the addition of enzyme, are carried out at room temperature for about 60 minutes. Reactions are stopped by addition of 0.6 volume of buffer containing (final concentrations): 2.5mM EDTA, 0.05%Triton-X 100, 100μM ATP, and 1.25 mg/ml streptavidin coated SPA beads (Amersham cat. No. RPNQ0007). Radioactivity associated with the beads is quantified by scintillation counting.
All of the title compounds of the following Examples had an IC50 inhibiting peptide substrate phosphorylation of less than about 50 μM when assayed for cdk5 inhibition according to the preceding assay.
Several of the title compounds of the following Examples were assayed for GSK-3 inhibition using an assay such as that described above, and all tested had an IC50 for inhibition of GSK-3β of less than about 60 μM . The following Examples illustrate the present invention. It is to be understood, however, that the invention, as fully described herein and as recited in the claims, is not intended to be limited by the details of the following Examples.
In the following Examples "TFA" indicates "trifluoroacetic acid", "THF" indicates "tetrahydrofuran", "MPLC" indicates "medium pressure liquid chromatography", "TLC" indicates
"thin layer chromatography", "KOBu1" indicates "potassium-t-butoxide", "DMSO" is "dimethyl sulfoxide", and "EtOAc" is "ethyl acetate". "MS", as in, for example, "Powdered 4 A MS" is
"molecular sieve".
EXAMPLES Example 1. (5-Cyclobutyl-1 H-pyrazol-3-yl)-(4-nitro-phenyl)-amine
Step 1. 3-Cyclobutyl-N-(4-nitro-phenyl)-3-oxo-thiopropionamide To a stirring solution of lithium bis(trimethylsilyl)amide (3.6 mL, 3.6 mmol, 1.0 M in tetrahydrofuran) in tetrahydrofuran at -78 °C (acetone/C02 bath) was added a solution of methyl cyclobutyl ketone (400 uL, 360 mg, 3.6 mmol) in 10 mL of tetrahydrofuran. After 1 hr 4-nitro-phenyl isothiocyanate (328 mg, 1.8 mmol) was added in one portion. The reactant was allowed to slowly warm to rt overnight. After 16 hr the reaction was quenched with NH4CI, diluted with CH2CI2. The layers were separated and the aqueous layer was extracted with CH2CI2, dried over MgS04 and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash system eluting with a gradient of hexanes through 50 % EtOAc/ hexanes. The product-containing fractions were collected and concentrated to give 3-cyclobutyl-N-(4-nitro-phenyl)-3-oxo-thiopropionamide (266 mg, 53 % yield) as a yellow oil. Rf = 0.54 (30% acetone/hexanes); 1H NMR (400 MHz, CDCI3) δ 2.35- 1.80 (m, 6H), 3.41 (dddd, J=8.2, 8.2, 7.9, 7.9 Hz, 1 H), 4.04 (s, 2H), 7.70 (d, 8.7 Hz, 1 H), 8.11 (d, 9.1 Hz. 2H), 8.23 (d, 9.2 Hz, 2H); LRMS m/z (APCI+) 279 (M+1 ). Step 2
To a stirring solution of 3-Cyclobutyl-N-(4-nitro-phenyl)-3-oxo-thiopropionamide from Step 1 (266 mg, 0.95 mmol) in 2 mL of EtOH was added 150 uL of acetic acid follow by anhydrous hydrazine (283 uL, 306 mg, 9.6 mmol). The reaction was heated to 71 °C for 2 hr and then cooled to rt. The reaction was then quenched with aqueous NaHC03 diluted with EtOAc and then the layers were separated. The organic layer was washed with water and the aqueous layer was back extracted with CH2CI2. The combined organic layers were dried over MgS04, filtered and concentrated under reduced pressure. Purification of this material was accomplished by MP LC using the Biotage Flash system eluting with a gradient of hexanes through 50 % acetone/ hexanes. The product containing fractions were collected and concentrated to give (5-cyclobutyl-1 H-pyrazol-3-yl)-(4-nitro-phenyl)-amine (216 mg, 88%) as a tan solid. Rf 0.36 (30% acetone/hexanes); 1H NMR (400 MHz, CDCI3) δ 1.84-2.22 (m, 4H), 2.38-2.42 (m, 2H), 3,50 (dddd, J=8.7, 8.7, 8.2, 8.2Hz, 1 H), 5.91 (s, 1 H), 7.16 (d, J=7.1 Hz, 2H), 8.12 (d, J=7.1 Hz, 2H). LRMS m/z (APCI+) 259.3 (M+1 ).
Example 2. (5-Cyclobutyl-2H-pyrazol-3-yl)-naphthalen-2-yl-amine
The title compound was prepared according to the method for Example 1 , using 5 analogous reactants.
1HNMR (400MHz, CDCI3), δ 1.76-1.98 (m, 2H), 2.04-2.19 (m, 2H), 2.20-2.28 (m, 2H), 3.26 (dddd, J=8.7, 8.7, 8.3, 8.3Hz, 1 H), 5.96 (s, 1 H), 7.18 (dd, J=9.1 , 8.7Hz, 1 H), 7.31 (d, J=7.8Hz, 1 H), 7.37 (d, J=7.9Hz, 1 H), 7.53 (s, 1 H), 7.61-7.71 (m, 3H). LRMS m/z (APCI+) 264 (M+1). 0 Example 3. (5-Cyclobutyl-2H-pyrazol-3-yl)-naphthalen-1-yl-amine
The title compound was prepared according to the method for Example 1 , using analogous reactants.
Rf 0.35 (50% EtOAc/Hexane), 1H NMR (400MHz, CDCI3) δ 1.75-1.98 (m, 2H), 2.04- 2.19 (m, 2H), 2.20-2.28 (m, 2H), 3.36-3.44 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 5.92 (s, 1 H), 5 7.31-7.44 (m, 5H), 7.80 (d, J=8.31 Hz, 1 H), 8.98 (d, J=8.72 Hz, 1 H). LRMS m/z (APCI+) 264 (M+1 ).
Example 4. N-(5-Cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-naphthalene-1 ,4- diamine
The title compound was prepared according to the method for Example 1 , using 0 analogous reactants.
!HNMR (400MHz, CDCI3), δ 1.73-1.90 (m, 2H), 2.09-2.28 (m, 4H), 2.85 (s, 6H), 3,37
(dddd, J=8.7, 8.7, 8.3, 8.3Hz, 1 H), 5.81 (s, 1 H), 7.02 (d, J=8.3Hz, 1 H), 7.36 (d, J=7.8Hz, 1 H),
7.40 (dd, J=6.6, 6.6Hz, 1 H), 7.51 (dd, J=4.8, 4.8Hz, 1 H), 8.04 (d, J=8.3Hz, 1 H), 8.30 (d,
J=8.3Hz, 1 H). 13C NMR (100MHz, CDCI3), δ 153.4,150.2, 145.6, 135.1 , 129.9, 127.7, 128.6, 5 124.7, 122.1, 114.7, 113.4, 91.5, 45.8, 32.3, 29.5, 18.9. LRMS m/z (APCI+) 307.3 (M+1).
Example 5. (3-Benzyloxy-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine
The title compound was prepared according to the method for Example 1 , using analogous reactants.
1HNMR (400MHz, CDCI3), δ 1.82-2.00 (m, 2H), 2.09-2.20 (m, 2H), 2.24-2.32 (m, 2H), 0 3.41 (dddd, J=8.7, 8.7, 8.3, 8.3Hz, 1 H), 5.01 (s, 2H), 5.88 (s, 1 H), 6.47 (bs, 1H), 6.50 (dd, J=7.5, 1.6Hz, 1 H), 6.67 (dd, J=9.5, 1.6Hz, 1 H), 6.81 (dd, J=2.0, 2.0Hz, 1 H), 7.14 (dd, J=7.9, 8.3Hz, 1H), 7.31-7.43 (m, 5H). LRMS m/z (APCI+) 320.4 (M+1).
Example 6. (4-Chloro-benzyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine
The title compound was prepared according to the method for Example 1 , using δ analogous reactants. 1HNMR (400MHz, CDCI3), δ 1.85-2.16 (m, 4H), 2.26-2.32 (m, 2H), 3.39 (dddd, J=8.7, 8.7, 8.3, 8.3Hz, 1 H), 4.29 (s, 2H), 5.41 (s, 1 H), 5.80 (bs, 2H), 7.26 (7.31 (m, 4H). LRMS m/z
Example 7. (3-Bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine The title compound was prepared according to the method for Example 1 , using analogous reactants. HNMR (400MHz, CDCI3), δ 1.82-1.99 (m, 2H), 2.06-2.17 (m, 2H), 2.21-2.29 (m, 2H),
3.39 (dddd, J=8.8, 8.8, 8.8, 8.8Hz, 1 H), 5.86 (s, 1 H), 6.78 (bs, 1 H), 6.98-6.92 (m, 2H), 7.04 (dd, J=7.9, 7.8Hz, 1 H), 7.24 (s, 1 H), 9.80 (bs, 1 H). LRMS m/z (APCI+) 292.3, 294.2 (M+1 ). Example 8. [5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-1 H-pyrazol-3-yl]-(3-trifluoromethyl- pheπyQ-amiπe
The title compound was prepared according to the method for Example 1 , using analogous reactants.
1HNMR (400MHz, CDCI3), δ 1.72-2.16 (m, 5H), 2.26 (ddd, J=13.7, 8.7, 0 Hz, 1 H), 3.26 (dddd, J=8.3, 8.2, 8.2, 7.8Hz, 1 H), 3.91-3.97 (m, 4H), 5.83 (s, 1 H), 6.71 (bs, 1 H), 7.06-7.32 (m, 4H), 9.0 (bs, 1 H). LRMS m/z (APCI+) 354.1 (M+1).
Example 9. (2-Chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine The title compound was prepared according to the method for Example 1 , using analogous reactants. Rf 0.35 (30% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.90-2.23 (m, 4H), 2.36-
2.44 (m, 2H), 3.48-3.67 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 5.96 (s, 1 H), 7.72-7.76 (d, 1 H), 8.05-8.08 (d, 1 H), 8.26 (s, 1 H). LRMS m/z (APCI+) 293 (M+1 ).
Example 10. (3,5-Bis-trifluoromethyl-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)- amine The title compound was prepared according to the method for Example 1 , using analogous reactants.
Rf 0.35 (30% EtOAc/Hexane), H NMR (400MHz, CDCI3), δ 1.80-2.21 (m, 4H), 2.31-
2.40 (m, 2H), 3.47-3.51 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 5.83 (s, 1 H), 7.26 (s, 1 H), 7.56 (s, 1 H), 7.56 (s, 1 H). LRMS m/z (APCI+) 350 (M+1 ). Example 11. 4-(5-Cyclobutyl-2H-pyrazol-3-ylamino)-benzonitrile
The title compound was prepared according to the method for Example 1 , using analogous reactants.
Rf 0.38 (50% EtOAc/ Hexane), 1H NMR (400 MHz, CD3OD), δ 1.88-2.11 (m, 2H),
2.15-2.25 (m, 2H), 2.32-2.40 (m, 2H), 3.49-3.57 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 5.85 (s, 1 H), 7.22-7.25 (dd, J=2.5 Hz, 2H), 7.46-7.49 (dd, J=2.5 Hz, 2H). LRMS m/z (APCI+) 239 (M+1 ).
Example 12. (5-Cyclobutyl-2H-pyrazol-3-yl)-(3-fluoro-phenyl)-amine
The title compound was prepared according to the method for Example 1 , using analogous reactants. 5 Rf 0.30 (50% EtOAc/ Hexane), 1H NMR (500 MHz, CDCI3), δ 1.86-2.04 (m, 2H), 2.12-
2.19 (m, 2H), 2.30-2.36 (m, 2H), 3.43-3.49 (dddd, J=8.8, 8.8, 8.8, 8.8Hz, 1 H), 5.89 (s, 1 H), 6.53-6.57 (m, 1 H), 6.80-6.82 (m, 1 H), 6.91-6.94 (m, 1 H), 7.14-7.19 (m, 1 H). LRMS m/z (APCI+) 232 (M+1 ).
Example 13. (2-Bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine 0 The title compound was prepared according to the method for Example 1 , using analogous reactants.
Rf 0.33 (30% EtOAc/ Hexane). 1HNMR (400 MHz, CDCI3), δ 1.90-2.12 (m, 2H), 2.13- 2.22 (m, 2H), 2.33-2.41 (m, 2H), 3.44-3.51 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 6.90 (s, 1 H), 6.69-6.73 (dd, J=6.6, 6.6Hz, 1 H), 7.18-7.22 (dd, J=5.8, 5.8Hz, 1 H), 7.47-7.49 (d, 1 H), 7.698- δ 7.69 (d, 1 H). LRMS m/z (APCI+) 292 (M+1 ).
Example 14. (5-Cyclobutyl-2H-pyrazol-3-yl)-(3,5-dichloro-phenyl)-amine The title compound was prepared according to the method for Example 1 , using analogous reactants.
Rf 0.60 (60% EtOAc/ Hexane), 1H NMR (CDCI3), δ 1.86-2.07 (m, 2H), 2.09-2.19 (m, 0 2H), 2.29-2.38 (m, 2H), 3.42-3.50 (dddd, J=8.δ, 8.5, 8.5, 8.5Hz, 1 H), 5.84 (s, 1 H), 6.80 (s, 1 H), 6.98 (s, 1 H), 6.98 (s, 1H). LRMS m/z (APCI+) 282 (M+1).
Preparation 1.1. 2-Cyano-3-cyclobutyl-3-oxo-propionic acid ethyl ester
To anhydrous MgCI2 (22.3 g, 0.19 mmol) in 320 mL of CH3CN at 0 °C was added ethyl cyanoacetate (21.5 g, 0.19 mmol). After 15 min Et3N (62.0 mL, 38.0 g, 0.37 mmol) was 6 added via syringe. The reaction was allowed to stir an additional 15 min and then cyclobutane carbonyl chloride (21.0 mL 22.3 g, 0.19 mmol) was added over a five min period.
The reaction was allowed to slowly warm to rt over 20 hr. The reaction was then cooled to 0
°C, quenched with aqueous 0.5 M HCl, and then diluted with 150 mL of Et20. The aqueous layer was extracted with Et20 (3x150 mL) and then the combined organic layers were washed 0 with 150 mL of brine, dried over MgS04, filtered and concentrated to give a yellow-orange oil.
This material was purified by vacuum distillation (95-106 °C, 2-3 mm) to give the title compound in a quantitative yield and as a colorless oil.
1H NMR (400MHz, CDCI3), δ 1.32-1.36 (t, 3H), 1.88-2.09 (m, 2H), 2.21-2.28 (m, 2H), 2.32-2.43 (m, 2H), 3.64-3.69 (dddd, J=8.5, 8.5, 8.5, 8.5Hz, 1 H), 4.28-4.34 (q, 2H), 13.81 (s, 6 1H). Preparation 2.1. 2-Cyano-3-oxo-pentanoic acid ethyl ester
The title compound was prepared according to the method for Preparation 1.1 , using analogous reactants.
1H NMR (400MHz, CDCI3), δ 1.23-1.27 (t, 3H), 1.34-1.37 (t, 3H), 2.61-2.66 (q, 2H), 4.30-4.35 (q, 2H), 13.70 (s, 1 H). LRMS m/z (APCI") 168 (M-1 ). Preparation 1.2. 3-Cyclobutyl-3-oxo-propionitrile
To 2-cyano-3-cyclobutyl-3-oxo-propionic acid ethyl ester (Preparation 1.1) in 40 mL of DMSO was added 2 mL of H20 and then the reaction was heated to 118 °C. After 35 min the reaction was cooled in an ice water bath and then quenched with a saturated solution of NaCl. This reaction mixture was further diluted with HzO and CH2CI2 and the layers were separated. The aqueous layer was extracted with CH2CI2. The combined organic layers were dried over MgS04, filtered and concentrated under reduced pressure to give the title compound of Preparation 1.2 as a yellow oil. This material was used without further purification.
1H NMR (400MHz, CDCI3), δ 1.83-2.17 (m, 2H), 2.19-2.30 (m, 2H), 2.31-2.55 (m, 2H), 3.39 (s, 2H), 3.39-3.43 (dddd, J=8.δ, 8.δ, 8.5, 8.5Hz, 1 H). LRMS m/z (APCI") 122 (M-1). Preparation 1.3. 5-Cyclobutyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-ylamine To crude 3-cyclobutyI-3-oxo-propionitrile prepared above in 515 mL of EtOH was added 4-methoxy-benzyl-hydrazine (12.6 g, 82.9 mmol) and the reaction was heated to reflux (oil bath at 85 ° C). After 2 hr the reaction was cooled to rt and concentrated under reduced pressure to give a viscous oil. Purified of this material was accomplished by MPLC using the Biotage Flash 45S system eluting with a gradient of 10% and 20% EtOAc/ hexanes. The product containing fractions were collected and concentrated to give the title compound (10.2 g, 77% yield over 2 steps) as a colorless solid.
Rf 0.3 (40% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.86-2.00 (m, 2H), 2.12- 2.20 (m, 2H), 2.25-2.31 (m, 2H), 3.41-3.46 (dddd, J=8.1 , 8.1 , 8.1 , 8.1 Hz, 1 H), 3.76 (s, 3H), 5.07 (s, 2H), 5.46 (s, 1 H), 6.82-6.84 (d, J=6.64 Hz, 2H), 7.07-7.09 (d, J=6.64 Hz, 2H). LRMS /77/z (APCI+) 258 (M+1).
Preparation 2.3. 5-Ethyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-ylamine The title compound was prepared according to the method for Preparation 1.3, using Preparation 2.1 instead of Preparation 1.1.
R, 0.4 (50% EtOAc/Hexane, 1H NMR (400MHz, CDCI3), δ 1.16-1.20 (t, 3H), 2.49-2.55 (q, 2H), 3.74 (s, 3H), 5.06 (s, 2H), 5.36 (s, 1H), 6.80-6.82 (d, 2H), 7.06-7.08 (d, 2H). LRMS 77/z (APCI+) 232 (M+1 ).
Preparation 1.4. [5-Cyclobutyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-(6- methoxy-pyridin-2-yl)-amine Procedure A: A dry toluene solution of δ-Cyclobutyl-2-(4-methoxy-benzyl)-2H- pyrazol-3-ylamine (Preparation 1.3, 2.27g, 8.83mmol), 2-chloro-6-methoxy pyridine (1.06g, 7.36mmol), sodium tert-butoxide (1.09g, 10.3mmol), 2-(dicyclohexylphosphino)-biphenyl (258mg, 0.736mmol), and palladium acetate (165mg, 0.736mmol), was heated to 120 °C for δ an hour and then cooled to rt. The reaction was then filtered through Celite pad and the filtrate was concentrated down and chromatographed using the Biotage Flash 46S system eluting with 20% EtOAc/hexanes to give the title compound of Preparation 1.4 as a peach colored solid (2g, 74% yield).
Rf 0.2δ (20% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.82-2.00 (m, 2H), 2.11- 0 2.34 (m, 4H), 3.46-3.66 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 3.71 (s, 3H), 3.80 (s, 3H), 5.10 (s, 2H), 6.01-6.03 (d, 1 H), 6.07 (s, 1 H), 6.14-6.16 (d, 1 H), 6.75-6.78 (d, J=6.65 Hz, 2H), 7.03-7.06 (d, J=8.72 Hz, 2H), 7.29-7.33 (apt, 1 H). LRMS m/z (APCI+) 365 (M+1 ).
Procedure B. Cesium carbonate (296mg, 0.454mmol) was flame dried in a reaction flask and 3.9ml of dry toluene was then transferred followed by 200mg (0.778mmol) of 5- δ Cyclobutyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-ylamine (Preparation 1.3). The resulting mixture was stirred at rt for 10min followed by the additions of 2-chloro-6-methoxy pyridine (93.2mg, 0.648mmol), 2-(dicyclohexylphosphino)-biphenyl (11.7mg, 0.0334mmol) and palladium acetate (3.6mg, 0.0162mmol). Refluxing under nitrogen overnight took the reaction to completion. Filtration through Celite, concentration of the filtrate, and chromatography as in 0 procedure A yielded the title compound of Preparation 1.4 (120mg, 51 % yield) as a solid.
Procedure C. To a dry toluene (1.95ml) solution of 5-Cyclobutyl-2-(4-methoxy- benzyl)-2H-pyrazol-3-ylamine (Preparation 1.3, 100mg, 0.389mmol) was added 1.0M potassium t-butoxide (628μl, 0.628mmol) at rt. After 5min stirring, 3-bromo-anisole (60mg, 0.324mmol), 2-(dicyclohexylphosphino)-biphenyl (23mg, 0.065mmol), and palladium acetate 6 (7.δmg, 0.032mmol) were added and the reaction was heated to 106 °C for 6 hours when the reaction went to completion. The reaction was cooled to rt, filtered through Celite, and chromatographed as in the procedure A to give the title compound of Preparation 1.4 (72mg, 61% yield) as a viscous gum.
Rf 0.30 (30% EtOAc/hexanes), 1HNMR (400MHz, CDCI3), δ 1.86-2.04 (m, 2H), 2.12- 0 2.19 (m, 2H), 2.30-2.36 (m, 2H), 3.64 (dddd, J=8.8, 8.8, 8.8, 8.8Hz, 1 H), 3.73 (s, 3H), 3.77 (s, 3H), 5.12 (s, 2H), 5.98 (s, 1 H), 6.29 (d, J=10.7Hz, 1 H), 6.32-6.35 (m, 1 H), 6.40-6.43 (m, 1 H), 6.82 (d, J-6.6HZ, 2H), 7.10 (d, J=8.3Hz, 2H), 7.25 (s, 1 H). LRMS m/z (APCI+) 364.2 (M+1 ).
Preparation 2.4. [5-Ethyl-2- (4-methoxy-benzyl)-2H-pyrazol-3-yl]-(6-methoxy- pyridin-2-yl)-amine δ The title compound was prepared according to the method for Preparation 1.4, using
Preparation 2.3 instead of Preparation 1.3. R, 0.28 (25% EtOAc/Hexane), H NMR (400MHz, CDCI3), δ 1.22-1.26 (t, 3H), 2.60- 2.66 (q, 2H), 3.74 (s, 3H), 3.82 (s, 3H), 5.12 (s, 2H), 6.01-6.02 (d, 1 H), 6.04 (s, 1H), 6.16-6.18 (d, 1 H), 6.79-6.81 (d, J=6.64 Hz, 2H), 7.07-7.09 (d, J=6.64 Hz, 2H), 7.32-7.36 (apt, 1 H). LRMS /z (APCI+) 339 (M+1 ). Example 15. (5-Cyclobu tyl-2H-pyrazol-3-yl)-(3-methoxy-phenyl)-amine
To [δ-Cyclobutyl-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-(3-methoxy-phenyl)-amine (Preparation 1.4, 120 mg, 0.331 mmol) was added neat trifluoro acetic acid (2.0 mL) and the reaction was heated to 70 °C. After 48 hr the reaction was cooled to rt and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash system eluting with 40% EtOAc/hexanes. The product-containing fractions were collected and concentrated to give the title compound (30 mg, 37 % yield).
Rf 0.35 (75% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.80-2.03 (m, 2H), 2.12- 2.17 (m, 2H), 2.29-2.33 (m, 2H), 3.40-3.48 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 3.77 (s, 3H), 5.88 (s, 1 H), 6.41-6.43 (d, J=10.4 Hz, 1 H), 6.65-6.68 (m, 1 H), 6.71-6.72 (m, 1 H), 7.11-7.15 (apt, 1 H). LRMS m/z (APCI+) 244 (M+1 ).
Example 16. (5-Cyclobutyl-2H-pyrazol-3-yl)-(6-trifluoromethyl-pyridin-2-yl)- amine
The title compound was made according to the method for Example 1 δ, using analogous reactants. R, 0.50 (10% MeOH/CH2CI2), 1H NMR (400MHz, CD3OD), δ 1.86-2.19 (m, 2H), 2.21-
2.32 (m, 2H), 2.32-2.39 (m, 2H), 3.61-3.67 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 6.15 (s, 1 H), 7.10 (d, J=9.13 Hz, 1 H), 7.73-7.76 (d, J=8.72 Hz, 1 H), 8.38 (s, 1 H). LRMS m/z (APCI+) 283 (M+1 ).
Example 17. (5-Cyclobu tyl-2H-pyrazol-3-yl)-(3-trif luoromethyl-phenyl)-amine The title compound was made according to the method for Example 1δ, using analogous reactants.
R, 0.30 (40% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.92-2.26 (m, 4H), 2.38- 2.46 (m, 2H), 3.50-3.58 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 6.01 (s, 1 H), 7.31-7.47 (m, 4H). LRMS m/z (APCI-) 282 (M+1 ). Example 18. N-(5-Cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-benzene-1 ,3- diamine
The title compound was made according to the method for Example 15, using analogous reactants.
Rf 0.50 (5% MeOH/CH2CI2), 1H NMR (400Mz, CDCI3), δ 1.91-2.18 (m, 2H), 2.20-2.30 (m, 2H), 2.35-2.43 (m, 2H). 3.11 (s, 6H), 3.48-3.56 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 6.13 (bs, 1 H), 6.84-6.95 (m, 2H), 7.13-7.28 (m, 2H), 7.31-7.35 (apt, 1H). LRMS m/z (APCI+) 257 (M+1 ).
Example 19. (5-Cyclobutyl-2H-pyrazol-3-yl)-quinolin-2-yl-amine
The title compound was made according to the method for Example 15, using δ analogous reactants.
Rf 0.36 (70% EtOAc/Hexane), 1H NMR (400MHz, CD3OD), δ 1.92-2.20 (m, 2H), 2.22- 2.28 (m, 2H), 2.41-2.45 (m, 2H), 3.60-3.66 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 6.08 (s, 1 H), 7.26-7.28 (d, J=9.54 Hz, 1 H), 7.60-7.64 (m, 1 H), 7.87-7.88 (m, 2H), 7.89-8.00 (d, J=7.46 Hz, 1 H), 8.49-8.51 (d, 1 H). LRMS m/z (APCI+) 26δ (M+1 ). 0 Example 20. (6-Chloro-pyridin-2-yl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine
The title compound was made according to the method for Example 1δ, using analogous reactants.
Rf 0.40 (75% EtOAc/Hexane), 1H NMR (400MHz, CD3OD), δ 1.98-2.21 (m, 2H), 2.24- 2.34 (m, 2H), 2.42-2.49 (m, 2H), 3.62-3.68 (dddd, J=8.8, 8.8, 8.8, 8.8Hz, 1 H), 6.18 (s, 1 H), 5 6.87-6.89 (d, J=8.29 Hz, 1 H), 7.05-7.07 (d, J=7.47 Hz, 1 H), 7.72-7.76 (apt, 1 H). LRMS m/z (APCI+) 249 (M+1 ).
Example 21. (5-Cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-4-methyl-quinolin-2-yl)- amine
The title compound was made according to the method for Example 15, using 0 analogous reactants.
R, 0.35 (75% EtOAc/Hexane), 1H NMR (400MHz, CD3OD), δ 1.90-2.18 (m, 2H), 2.19- 2.30 (m, 2H), 2.37-2.47 (m, 2H), 2.78 (s, 3H), 3.60-3.68 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 3.97 (s, 3H), 6.02 (s, 1 H), 7.10 (s, 1 H), 7.45 (s, 1 H), 7.46 (d, 1H), 7.78-7.80 (d, 1H). LRMS m/z (APCI+) 309 (M+1). 5 Example 22. (5-Cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine
The title compound was made according to the method for Example 15, using analogous reactants.
R, 0.15 (30% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.88-2.07 (m, 2H), 2.10-
2.20 (m, 2H), 2.30-2.38 (m, 2H), 3.42-3.51 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 5.84 (s, 1 H), 0 6.68-6.70 (d, 1 H), 6.99-7.19 (m, 2H), 7.21 -7.24 (apt, 1 H). LRMS m/z (APCI+) 298 (M+1 ).
Example 23. N-(5-Cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-pyridine-2,6- diamine
The title compound was made according to the method for Example 15, using analogous reactants. 5 R, 0.50 (5% MeOH/CH2CI2), 1H NMR (400MHz, CDCI3), δ 1.82-2.01 (m, 2H), 2.11-
2.21 (m, 2H), 2.26-2.33 (m, 2H), 3.06 (s, 6H), 3.42-3.48 (dddd, J=8.7, 8.7, 8.7, 8.7Hz, 1 H), 5.83 (s, 1 H), δ.93 (d, J=8.31 Hz, 1 H), 6.09 (d, J=7.89 Hz, 1 H), 7.29-7.33 (1 H, apt). LRMS m/z (APCI+) 258 (M+1 ).
Example 24. (5-Ethyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine
The title compound was made according to the method for Example 15, using δ analogous reactants.
Rf 0.20 (60% EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.20-1.28 (m, 3H), 2.60- 2.68 (m, 2H), 3.90- (s, 3H), 6.25-6.27 (d, 1 H), 6.45-6.47 (d, 1 H), 6.54 (s, 1 H), 7.42-7.46 (apt, 1 H). LRMS m/z (APCI+) 219 (M+1 ).
Example 25. (5-Cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine 0 The title compound was made according to the method for Example 15, using analogous reactants.
R, 0.30 (50%EtOAc/Hexane), 1H NMR (400MHz, CDCI3), δ 1.87-2.23 (m, 4H), 2.33- 2.41 (m, 2H), 3.46-3.66 (dddd, J=8.3, 8.3, 8.3, 8.3Hz, 1 H), 3.93 (s, 3H), 6.26-6.28 (d, 1 H), 6.46-6.47 (d, 1 H), 6.57 (s, 1 H), 7.43-7.47 (apt, 1 H). LRMS m/z (APCI+) 245 (M+1 ). 5 Preparation 3.1. 1,4-Dioxa-spiro[4.4]non-7-yl)-ethanone
To a stirring solution of known nitrile (1.25 g, 8.17g)((Aust. J. Chem. 1994, 47, 1833) in tetrahydrofuran at rt was added a solution of methyl magnesium bromide (6.4 mL, 16.3 mmol, 3.0M in THF) followed by copper (I) bromide (23 mg, 0,16 mmol). The reaction was then heated to 66 °C. After 20 hr the reaction cooled to rt and then to 0 °C (ice/water bath) 0 and quenched with a saturated solution of NH4CI. This mixture was diluted with methylene chloride (100 mL) and the layers separated. The aqueous layer was extracted with methylene chloride (100 mL) and the combined organic layers were dried over MgS04, filtered and concentrated under reduced pressure. Purification was accomplished by vacuum distillation (120 °C, 2 mm) to give the title compound (1.39 g, 51% yield) as a clear colorless oil. 5 1HNMR (400MHz, CDCI3), δ 1.79-2.08 (m, 6H), 2.15 (s, 3H), 2.99 (dddd, J=8.3Hz,
1 H), 3.87-3.94 (m, 4H). LRMS m/z (APCI+) 171 (M+1 ).
Preparation 3.2. 3-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-3-oxo-N-(3-trifluoromethyl- phenyl)-thiopropionamide
To a stirring solution of LiHMDS( 3.2 mL, 3.2 mmol 1 M in THF) in 20 mL of THF at 0 -78 °C (acetone/C02) was a precooled solution (-78 °C) of 1-(1 ,4-Dioxa-spiro[4.4]non-7-yl)- ethanone (Preparation 3.1 , 500 mg, 2.94 mmol in 5 mL of THF) via cannula down the side of the flask. After 30 minutes, 1-isothiocyanato-3-trifluoromethyl-benzene (988 uL, 1.3 g, 6.5 mmol) was added dropwise via syringe. The resulting reaction was slowly allowed to warm to rt overnight. The reaction was then quenched with NaHC03, diluted with EtOAc and the 6 layers were separated. Purification of this material was accomplished by MPLC using the Biotage Flash 45S system eluting with 20% EtOAc/toluene, followed by a second MPLC using the Biotage Flash 45S system eluting with 20% acetone/hexanes. The product-containing fractions were collected and concentrated to give the title compound (598 mg, δδ% yield) as a yellow viscous gum. δ Rf 0.3 (25% Acetone/ Hexanes). 1HNMR (400MHz, CDCI3), δ 1.84-1.87 (m, 2H), 1.95-
2.20 (m, 2H), 2.64-2.70 (m, 1 H), 3.28-3.32 (m, 1 H), 3.89-4.05 (m, 4H), 3.92 (s, 2H), 7.60-7.64 (m, 2H), 7.93-7.97 (m, 1 H), 8.13-8.15 (m, 1 H). LRMS m/z (APCI+) 374 (M+1 ).
Preparation 3.3. [5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-2-(4-methoxy-benzyl)-2H- pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine 0 To a stirring solution of 3-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-3-oxo-N-(3-trifluoromethyl- phenyl)-thiopropionamide (Preparation 3.1 , 785 mg, 2.1 mmol) in 21 mL of EtOH was added acetic acid (2.1 mL) followed by 4-methoxy-benzyl-hydrazine (480 mg, 3.2 mmol) and the resulting mixture was heated to 7δ °C. After 1 hr the reaction was cooled to rt quenched with H20, diluted with EtOAc and the layers were separated. To the aqueous layer was added a 5 few drops of concentrated ammonium hydroxide and then extracted with EtOAc. The combined organic layers were dried over MgS04, filtered and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash 45S system eluting with 40% EtOAc/hexanes. The product-containing fractions were collected and concentrated under reduced pressure to give the title compound (788 mg, 79% 0 yield) as a yellow viscous gum.
Rf 0.3 (60% EtOAc/Hexanes). 1HNMR (400MHz, CDCI3), δ 1.78-2.08 (m, 4H), 2.16- 2.20 (m, 1 H), 2.31-2.38 (m, 1 H), 3.30 (dddd, J=7.9, 9.6, 8.3, 8.7Hz, 1 H), 3.77 (s, 3H), 3.85- 4.00 (m, 4H), 5.14 (s, 2H), 5.96 (s, 1 H), 6.81-6.90 (m, 3H), 7.07-7.11 (m, 3H), 7.26-7.29 (m, 2H). LRMS m/z (APCI+) 474 (M+1 ). 5 Preparation 3.4. 3-[1 -(4-Methoxy-benzyl)-5-(3-trif luoromethyl-phenylamino)-1 H- pyrazol-3-yl]-cyclopentanone
To a stirring solution of [5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-2-(4-methoxy-benzyl)-2H- pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine (Preparation 3.3, 679 mg, 1.4 mmol) in 14 mL of acetone was added 700 uL H20 followed by a catalytic amount of p-toluenesulfonic acid 0 monohydrate (27.3 mg, 0.14 mmol). The reaction mixture was then heated to 65 °C. After 1 hr the reaction was cooled to rt and quenched with H20, diluted with EtOAc and the layers were separated. The organic layer was dried over MgS04, filtered and concentrated under reduced pressure to give the title compound (617 mg, quantitative yield) as a yellow viscous oil. This material was used without further purification. 5 Rf 0.28 (50% EtOAc/Hexanes). 1HNMR (400MHz, CDCI3), δ 2.02-2.14 (m, 1 H), 2.20-
2.30 (m, 1 H), 2.36-2.50 (m, 3H), 2.58-2.63 (m, 1 H), 3.45 (dddd, J=6.2, 6.2, 6.2, 6.2Hz, 1 H), 3.76 (s, 3H), δ.11 (s, 2H), δ.94 (s, 1 H), 6.79-6.88 (m, 4H), 7.04-7.10 (m, 3H), 7.26-7.29 (m, 1 H). LRMS m/z (APCI+) 430 (M+1 ).
Example 26. 3-7rans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentanone δ The title compound was prepared according to the method for Preparation 3.4, using hydrazine instead of 4-methoxy-benzyl-hydrazine (see synthesis of Preparation 3.3, supra).
1HNMR (400MHz, CDCI3), δ 1.94-1.99 (m, 1 H), 2.20-2.48 (m, 4H). 2.62 (ddd, J=18.2, 7.9, 0Hz, 1 H), 3.38 (dddd, J=9.5, 9.6, 7.6, 6.6Hz, 1 H), 5.86 (s, 1 H), 7.09 (d, J=7.4Hz, 1 H), 7.20 (d, J=8.3Hz, 1 H), 7.26-7.33 (m, 2H). LRMS m/z (APCI+) 310.3 (M+1 ). 0 Preparation 3.5. {2-(4-Methoxy-benzyl)-5-[3-(4-methoxy-benzylamino)- cyclopentyl]-2H-pyrazol-3-yl}-(3-trifluoromethyl-phenyl)-amine
To a stirring slurry of 3-[1-(4-Methoxy-benzyl)-5-(3-trifluoromethyl-phenylamino)-1 H- pyrazol-3-yl]-cyclopentanone (Preparation 3.4, 3.3 g, 7.6 mmol) in 76 mL of toluene was added, powdered 4 A MS (16.1 g), followed by 4-methoxybenzyl amine (2.0 g, 16.3 mmol). 6 The resulting mixture was heated to 110 °C overnight. After 12 hr the reaction was cooled to rt and Na(OAc)3BH (3.2g, 16.3 mmol) was added and stirred for an additional hr before 4 A MS were filtered off and the resulting solution was concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash 7δS system eluting with a gradient of 5% through 8% MeOH/CH2CI2 containing 0.1% NH4OH. The 0 product-containing fraction was collected and concentrated under reduced pressure to give the title compound (3.9 g, 92% yield) as a yellow viscous oil and a 3:1 mixture of diastereomers.
Rf 0.28 (8% MeOH/CH2CI2), 3:2 ratio of cis, trans isomers seen in the 1HNMR obtained in CD3OD. LRMS m/z (APCI+) δδ1 (M+1 ). 6 Examples 27 and 28. Isomers of [5-(3-Benzylamino-cyclopentyl)-1H-pyrazol-3- yl]-(3-trifluoromethyl-phenyl)-amine
A racemate comprising cis:trans isomers of [5-(3-Benzylamino-cyclopentyl)-1 H- pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine was prepared according to the method for
Preparation 3.5, using Example 26 instead of Preparation 3.4. Cis:trans isomers (Examples 0 27 and 28) were isolated from the mixture by MPLC using the Biotage flash 756 system eluting with a gradient of 5% through 8% MeOH/CH2CI2 containing 0.1% NH4OH.
Example 27.
1HNMR (400MHz, CD3COCD3), δ 1.65-1.79 (m, 1 H), 1.81-2.07 (m, 4H), 2.25 (m, 1 H), 2.50 (dddd, J=7.1 , 7.1 , 7.1 , 7.1 Hz, 1 H), 3.24 (dddd, J=2.1 , 2.1 , 2.1 , 2.1 Hz, 1 H), 3.80 (s, 2H), 5 5.70 (s, 1 H), 7.01 (d, J=4.3Hz, 1 H), 7.22-7.55 (m, 5H), 7.66 (d, J=2.1 Hz, 1 H), 7.98 (s, 1 H), 8.01 (s, 1 H). LRMS m/z (APCI+) 401.3 (M+1 ). Example 28.
1HNMR (400MHz, CD3COCD3), δ 1.67-1.84 (m, 2H), 1.86-1.99 (m, 1 H), 2.04-2.23 (m, 3H), 3.34-3.42 (m, 2H), 3.80 (s, 2H), δ.70 (s, 1 H), 7.00 (d, J=7.9Hz, 1 H), 7.20-7.55 (m, 5H), 7.66 (d, J=2.0Hz, 1 H), 7.98 (s, 1 H), 8.00 (s, 1 H). LRMS m/z (APCI+) 401.3 (M+1 ). Example 29. {5-[c/s-3-(4-Methoxy-benzylamino)-cyclopentyl]-1 H-pyrazol-3-yl}-(3- trifluoromethyl-phenyl)-amine
The title compound was prepared according to the method for preparation 3.6, using the title compound of Example 26 instead of the title compound of Preparation 3.4.
1HNMR (400MHz, CD3OD), δ 1.47-1.66 (m, 1 H), 1.60-1.69 (m, 1 H), 1.90-1.97 (m, 2H), 2.10-2.18 (m, 2H), 3.28-3.31 (m, 2H), 3.67 (s, 2H), 3.75 (s, 3H), 5.72 (s, 1 H), 6.86 (d, J=6.6Hz, 2H), 6.97 (d, J=7.0Hz, 1 H), 7.25 (d, J=8.7Hz, 2H), 7.31-7.35 (m, 2H), 7.48 (s, 1 H). LRMS m/z (APCI+) 431.3 (M+1 ).
Preparation 3.6. N-(4-Methoxy-benzyl)-N-{3-[1-(4-methoxy-benzyl)-5-(3- trifluoromethyl-phenylamino)-1H-pyrazol-3-yl]-cyclopentyl}-acetamide To a stirring solution of {2-(4-Methoxy-benzyl)-5-[3-(4-methoxy-benzylamino)- cyclopentyl]-2H-pyrazol-3-yl}-(3-trifiuoromethyl-phenyl)-amine (Preparation 3.5, 109 mg, 0.198 mmol) in 0.5 mL of pyridine was added acetic anhydride (94 uL, 0.99 mmol). After 30 min the reaction was determined to be complete by TLC analysis. This reaction mixture was concentrated under reduced pressure to give N-(4-Methoxy-benzyl)-N-{3-[1-(4-methoxy- benzyl)-5-(3-trifluoromethyl-phenylamino)-1 H-pyrazol-3-yl]-cyclopentyl}-acetamide as a 1 :1 ratio of cis, trans isomers determined by HNMR and as a foam. This material was used without further purification.
Rf 0.76 (5% MeOH/ CH2CI2); LRMS m/z (APCI+) 593 (M+1).
Analytical separation of the four isomers of the title compound was accomplished using the following conditions: Column: Chiralcel OD, δcm x 10cm. Mobile phase: 96/5 heptane/EtOH containing 0.025% DEA as a modifier. Flow rate: 76 mL/min. The sample was loaded using 1:1 Methylene chloride/mobile phase. The retention times for the four isomers were 30 min, 37 min, 45min, and 60 min, respectively.
Example 30. N-{c/s-3-[5-(3-Trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-acetamide
To N-(4-Methoxy-benzyl)-N-{3-[1-(4-methoxy-benzyl)-5-(3-trifluoromethyl- phenylamino)-1 H-pyrazol-3-yl]-cyclopentyl}-acetamide (Preparation 3.6, 0.20 mmol 140 mg) was added 2 mL of TFA and reaction was heated to 76 °C. After 72 h the reaction cooled to rt and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using a 10 g ISCO™ column eluting with 5% MeOH/CH2CI2. The product-containing fractions were collected and concentrated to give the title compound (60 mg, 86% yield over two steps).
Rf0.30 (56 MeOH/CH2CI2); 1HNMR (400MHz, CD3COCD3), δ 1.56-1.69 (m, 1 H), 1.66-
1.74 (m, 1 H), 1.83 (s, 3H), 1.97-2.03 (m, 2H), 2.09-2.20 (m, 2H), 3.32 (dddd, J=8.3, 8.3, 8.3,
8.3Hz, 1 H), 4.33 (dddd, J=12.9, 7.0, 7.0, 7.0Hz, 1 H), 5.71 (s, 1 H), 7.01 (d, J=7.9Hz, 1 H), 7.16 (bs, 1 H), 7.36 (dd, J=7.9, 7.9Hz, 1 H), 7.55 (d, J=8.3Hz, 1 H), 7.99 (bs, 1 H), 8.01 (bs, 1 H).
LRMS m/z (APCI+) 353.2 (M+1 ).
Example 31. Pyridine-2-carboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)- 2H-pyrazol-3-yl]-cyclopentyl}-amide
The title compound was prepared according to the method for Example 30, using analogous reactants.
Rf 0.33 (5% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 416 (M+1), mp 180.1 °C (HCl salt)
Example 32. Pyridine-2-carboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H- pyrazol-3-yl]-cyclopentyl}-amide The title compound was prepared according to the method for Example 30, using analogous reactants.
Rf 0.28 (5% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 483 (M+1 ), mp 162.5 °C (HCl salt)
Example 33. Cyclobutanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylarniπo)- 2H-pyrazol-3-yl]-cyclopentyl}-amide
The title compound was prepared according to the method for Example 30, using analogous reactants.
Rf 0.25 (5% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 393 (M+1), mp 232.4 °C (HCl salt) Example 34. 2,2-Dimethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3- yl]-cyclopentyl}-propionamide
The title compound was prepared according to the method for Example 30, using analogous reactants.
Rf 0.23 (5% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 395 (M+1 ), mp 249.2 °C (HCl salt)
Example 35. 4-Fluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yt]- cyclopentyl}-benzamide
The title compound was prepared according to the method for Example 30, using analogous reactants. R, 0.30 (δ% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in ΗNMR obtained in
CD3OD. LRMS m/z (APCI+) 433 (M+1 ); mp (dec)' no distinct melting point. Example 36. 2,2,2-Trifluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol- 3-yl]-cyclopentyl}-acetamide
The title compound was prepared according to the method for Example 30, using analogous reactants. Rf 0.30 (5% MeOH/ CH2CI2), 3:2 ratio of cis, trans isomers seen in 1HNMR obtained in
CDCI3. LRMS m/z (APCI+) 407 (M+1 ).
Example 37. Cyclopropanecarboxylic acid {3-[5-(3-trifluoromethyl- phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-amide
The title compound was prepared according to the method for Example 30, using analogous reactants.
R, 0.28 (8% MeOH/ CH2CI2), 3:2 ratio of cis, trans isomers seen in 1HNMR obtained in CDCI3. LRMS m/z (APCI+) 379 (M+1).
Example 38. N-{3-[5-(3-Trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-propionamide The title compound was prepared according to the method for Example 30, using analogous reactants.
Rf 0.30 (8% MeOH/ CH2CI2), 3:2 ratio of cis, trans isomers seen in 1HNMR obtained in CDCI3. LRMS m/z (APCI+) 367 (M+1).
Example 39. Cyclohexanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)- 2H-pyrazol-3-yl]-cyclopentyl}-amide
The title compound was prepared according to the method for Example 30, using analogous reactants.
R, 026 (8% MeOH/ CH2CI2), 3:2 ratio of cis, trans isomers seen in 1HNMR obtained in CDCI3. LRMS m/z (APCI+) 421 (M+1 ). Preparation 4.1. (1 ,4-Dioxa-spiro[4.4]non-7-yl)-oxo-acetonitrile
To 9 mL of THF at -78 °C was added nBuLi (3.4 mL, 8.6 mmol, 2.5 M in hexanes). After reaction temperature equilibrated (-15 min), acetonitrile (449 uL, 359 mg, 8.6 mmol) was added dropwise. Reaction was allowed to stir 1 hr before a solution of 1 ,4-Dioxa- spiro[4.4]nonane-7-carboxylic acid methyl ester (723 mg, 4.3 mmol) was added down the side of the flask. After 1 hr the reaction was warmed to -45 °C (acetonitrile/C02) and allowed to stir for 2 hr. Reaction was quenched cold by the dropwise addition of 2 N HCl (-4.3 mL), pH=7 and then diluted with Et20. The layers were separated and the organic layer was dried over MgS04, filtered and concentrated under reduced pressure to yield the title compound as a brown oil that was used without further purification. Rf 0.19 (50 % EtOAc/hexanes); LRMS m/z (APCI+) 196 (M+1 ).
Preparation 4.2. 5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-2-(4-methoxy-benzyl)-2H- pyrazol-3-ylamine
To crude (1 ,4-Dioxa-spiro[4.4]non-7-yl)-oxo-acetonitrile (Preparation 4.1 ) in EtOH (6.8 mL) was added 4-methoxy-benzyl-hydrazine (0.60 g, 4.0 mmol), and then the reaction was heated to 65 °C. After 2 1/2 hr the reaction was cooled to rt and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash 40L system eluting with a gradient of 50% through 100% EtOAc/hexanes, collecting 18 mm fractions. The product containing-fraction was collected and concentrated under reduced pressure to give the title compound (0.83 g, 75% yield over 2 steps).
R, 0.13 (50% EtOAc/hexanes); 1HNMR (400MHz, CDCI3), δ 2.10-1.72 (m, 5H), 2.23 (dd, J = 13.3, 7.9 Hz, 1 H), 3.15 (dddd, J = 7.9, 7.9, 2.5, 2.6 Hz, 1H), 3.39 (br s, 2H), 3.73 (s, 3H), 3.91-3.84 (m, 4H), 5.03 (s, 2H), 5.34 (s, 1 H), 6.80 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.6 Hz, 2H); 13C NMR (100 Mz, CDCI3) δ 31.4, 36.4, 37.2, 43.1 , 51.2, 55.5, 64.3, 64.5, 89.0, 114.4, 117.9, 128.3, 129.1 , 145.2, 155.0, 159.3; LRMS m/z (APCI+) 330 (M+1 ).
Preparation 4.3. N-[5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-2-(4-methoxy-benzyl)-2H- pyrazol-3-yl]-2-naphthalen-1-yl-acetamide
To a stirring solution of 5-(1 ,4-Dioxa-spiro[4.4]non-7-yl)-2-(4-methoxy-benzyl)-2H- pyrazol-3-ylamine (Preparation 4.2, 0.83 g, 2.δ mmol) in CH2CI2 (5 mL) was added a freshly prepared solution of naphthalen-1-yl-acetyl chloride (1.03 g, δ.O mmol in CH2CI2) followed by the addition of 1 mL of pyridine. After 2 hr, the reaction was quenched with H20, and 2 mL of a solution of NH4OH (15%) was added. This mixture was diluted with CH2CI2 and the layers were separated. The organic layer was dried over MgS04, filtered and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using the Biotage Flash 40L system eluting with a gradient of 25% through 50% acetone/hexanes, collecting 18 mm fractions. The product-containing fraction was collected and concentrated under reduced pressure to give the title compound (1.2 g, 97% yield) as a light yellow solid. mp 162.8 °C; 1HNMR (400MHz, CDCI3), δ 2.09-173 (m, 5H), 2.21 (dd, J = 13.3, 7.9 Hz, 1H), 3.18 (dddd, J =7.5, 5.0 Hz, 1H), 3.68 (s, 3H), 3.89-3.81 (m, 4H), 3.98 (s, 2H), 4.60 (s, 2H), 6.22 (s, 1 H), 6.36 (d, J = 8.7 Hz, 2H), 6.51 (d, J = 8.7 Hz, 2H), 7.03 (br s, 1 H), 7.23 (d, J = 6.7 Hz, 1H), 7.39 (dd, J = 7.1, 7.1 Hz, 1H), 7.53-7.45 (m, 2H), 7.88-7.83 (m, 2H), 7.89 (d, J = 1.7 Hz, 1 H); 13C NMR (100 Mz, CDCI3) δ 31.2, 36.4, 37.2, 42.0, 42.9, 51.9, 55.4, 64.3, 64.5, 97.2, 114.2, 117.8, 123.7, 125.9, 126.7, 127.4, 127.7, 127.9, 128.7, 129.1 , 129.32, 130.2, 132.1 , 134.2, 135.3, 154.9, 159.2, 168.6; LRMS m/z (APCI+) 498 (M+1).
Preparation 4.4. N-[2-(4-Methoxy-benzyl)-5-(3-oxo-cyclopentyl)-2H-pyrazol-3-yl]- 2-naphthalen-1 -yl-acetamide The title compound was synthesized according to the method for Preparation 3.4, using the title compound of Preparation 4.3 instead of the title compound of Preparation 3.3 as a reactant.
1HNMR (400MHz, CDCI3), δ 1.99-2.18 (m, 1 H), 2.21-2.28 (m, 1 H), 2.35-2.46 (m, 3H), 2.63-2.62 (m, 1 H), 3.43 (dddd, J=9.5, 6.2, 7.9, 9.δHz, 1 H), 3.75 (s, 3H), 4.12 (s, 2H), 4.62 (s, 2H), 6.30 (s, 1 H), 6.33 (d, J=9.5Hz, 1 H), 6.5δ (d, J=8.7Hz, 1 H), 7.31-7.33 (m, 1 H), 7.46-7.48 δ (m, 1 H), 7.66-7.60 (m, 2H), 7.89-7.97 (m, 3H). LRMS /z (APCI+) 454 (M+1 ).
Preparation 4.5. N-{2-(4-Methoxy-benzyl)-5-[3-(4-methoxy-benzylamino)- cyclopentyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl-acetamide
The title compound was prepared according to the method for Preparation 3.5, using the title compound of Preparation 4.4 as a reactant instead of the title compound of 0 Preparation 3.4.
Rf 0.25 (8% MeOH/ CH2CI2) (minor), Rf 0.20 (8% MeOH/ CH2CI2) (major), 3:2 ratio of cis, trans isomers seen in 1HNMR obtained in CDCl3. LRMS m/z (APCI+) 575 (M+1 ).
Preparation 4.6. N-[5-{3-[Acetyl-(4-methoxy-benzyl)-amino]-cyclopentyl}-2-(4- methoxy-benzyl)-2H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide 5 The title compound was synthesized according to the method for Preparation 3.6, using the title compound of Preparation 4.6 instead of the title compound of Preparation 3.5 as a reactant.
Rf 0.30 (80% EtOAc/ Toluene), Rf 0.25 (80% EtOAc/ Toluene), 1 :1 ratio of cis, trans isomers seen in 1HNMR obtained in CDCI3. 0 Enantiomeric separation of the isomer with the R, 0.25 was accomplished using the following conditions: Column: Chiralcel OD, 5cm x 50cm. Mobile phase: 60/40 Heptane/EtOH containing 0.025% DEA as a modifier. Flow rate: 60 mL/min. The sample was loaded using methanol. The retention times for the two enantiomers were 36 min and 45 min. LRMS m/z (APCI+) 617 (M+1 ). 5 Preparation 5.1. Cyclobutanecarboxylic acid (4-methoxy-benzyl)-{3-[5-(3- trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-arnide
The title compound was prepared according to the method for Preparation 4.6, using analogous reactants.
Rf 0.45 (5% MeOH/ CH2CI2), 1 :1 ratio of cis, trans isomers seen in HNMR obtained in 0 CDCI3. LRMS m/z (APCI+) 633 (M+1 ).
Example 40. N-[5-(3-Acetylamino-cyclopentyl)-2H-pyrazol-3-yl]-2-naphthalen-1 - yl-acetamide
The title compound was synthesized by the method for Example 30, using Preparation 4.6 as a reactant instead of Preparation 3.6. 5 Rf 0.30 (8% MeOH/ CH2CI2). 1 :1 ratio of cis, trans isomers was seen in the 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 377 (M+1 ). Example 41. Cyclopropanecarboxylic acid {3-[5-(2-naphthalen-1-yl- acetylamino)-1H-pyrazol-3-yl]-cyclopentyl}-amide
The title compound was synthesized by the method for Example 30, using analogous reactants. Rf 0.30 (5% MeOH/ CH2CI2). 1 :1 ratio of cis, trans isomers was seen in the 1HNMR obtained in CDCI3. LRMS m/z (APCI+) 403 (M+1 ).
Example 42. 2-Naphthalen-1-yl-N-{5-[3-(2,2,2-trifluoro-acetylamino)- cyclopentyl]-2H-pyrazol-3-yl}-acetamide
The title compound was synthesized by the method for Example 30, using analogous reactants.
Rf 0.30 (5% MeOH/ CH2CI2). 1 :1 ratio of cis, trans isomers was seen in the 1HNMR obtained in CD3OD. LRMS m/z (APCI+) 431 (M+1).
Example 43. N- 3-[5-(2-Naphthalen-1 -yl-acetylamino)-1 H-pyrazol-3-yl]- cyclopentyl}-benzamide The title compound was synthesized by the method for Example 30, using analogous reactants.
Rf 0.30 (5% MeOH/ CH2CI2). 1 :1 ratio of cis, trans isomers was seen in the 1HNMR obtained in CDCI3. LRMS m/z (APCI+) 439 (M+1 ).
The following title compounds of Examples 44-57 were synthesized by preparing an intermediate analogous to the title compound of Preparation 4.6, using the steps described in "Preparation 4.2" through "Preparation 4.5". In each case, a reactant analogous to naphthalen-1-yl acetal chloride used in synthesis of the title compound of Preparation 4.3 was used. This intermediate was than treated according to the method described for synthesis of the title compound of Example 30: Example 44. 3-Methoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-
3-yl]-cyclobutyl}-benzamide
Rf 0.33 (10% MeOH/CH2Cl2); mp 124.8 °C (mono HCl salt); 1HNMR (400MHz, CD3OD), δ 2.20 (dd, J = 10.2 Hz, 2H), 2.72-2.66 (m, 2H), 3.14 (apt quint, J= 8.8 Hz, 1 H); 3.75 (s, 3H), 4.12 (s, 2H), 4.40 (apt quint, 8.4 Hz, 1H), 6.31 (s, 1H), 7.03-7.00 (m, 1 H), 7.28 (dd, J = 7.8 Hz, 1 H), 7.46-7.35 (m, 6H), 7.74 (d, J = 7.9 Hz, 1 H), 7.81 (d, J=7.0 Hz, 1 H), 8.01 (d, J= 7.4 Hz, 1 H); 13C NMR (100 Mz, CD3OD) δ 170.6, 168.1 , 160.0, 149.0, 146.0, 135.5, 134.2, 132.4, 131.3, 129.4, 128.6, 128.1 , 127.9, 126.2, 125.7, 125.4, 123.7, 119.3, 117.3, 112.5, 93.8, 64.7, 41.5, 40.2, 36.9, 24.8; LRMS m/z (APCI+) 455.1 (M+1 ).
Example 45. N-{c/s-3-[5-(2-Naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobu.yl}-3-trifluoromethyl-benzamide
R, 0.56 (10% MeOH/CH2CI2); mp 142.8 °C (mono HCl salt); HNMR (400MHz, CD3OD), δ 2.22 (dd, J = 9.5, 9.5 Hz, 2H), 2.73 (dd, J = 7.4, 7.4 Hz, 2H), 3.18 (apt quint, J = 7.9 Hz, 1 H), 4.14 (s, 2H), 4.46 (apt quint, J=7.5 Hz, 1 H), 6.40 (s, 1 H), 7.48-4.37 (m , 4H), 7.83 (d, J = 4.9Hz, 1 H), 8.03 (s, 1 H), 8.05 (s, 1 H), 8.13 (s, 1 H); 13C NMR (100 Mz, CD3OD) δ 170.5, 166.4, 148.7, 146.5, 135.2, 134.2, 132.5, 131.5, 130.9, 130.5, 129.3, 128.5, 128.0, 127.8, 126.2, 126.6, 125.4, 124.1 , 124.0, 123.7, 94.0, 41.6, 40.3, 36.9, 24.9; LRMS m/z (APCI+) 493.0 (M+1).
Example 46. N-{c/s-3-[5-(2-Naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-isobutyramide
Rf 0.43 (10% MeOH/CH2CI2 with 0.1 % NH4OH aq); mp 130.6 °C (mono HCl salt); 1HNMR (400MHz, d6 DMSO), δ 0.93 (s, 3H), 0.95 (s, 3H), 1.92 (dd, J = 9.9, 9.9 Hz, 2H), 2.24 (apt quint, J = 6.8 Hz, 1 H), 2.54,-2.48 (m, 2H), 3.01 (apt quint, J = 8.3 Hz, 1 H), 4.08 (s, 2H), 4.15-4.08 (m, 1 H), 6.32 (s, 1 H), 7.54-7.43 (m, 4H), 7.81 (d, J = 7.4 Hz, 1 H), 7.94-7.89 (m , 2H), 8.13 (d, J= 7.9 Hz, 1 H); ); 13C NMR (100 Mz, d6 DMSO) δ 175.7, 168.7, 147.7, 134.0, 132.6, 129.0, 128.5, 127.8, 126.7, 126.3, 126.2, 125.0, 94.0, 39.6, 38.2, 34.6, 24.5, 20.2; LRMS m/z (APCI+) 391 (M+1 ).
Example 47. 2-Phenyl-cyclopropanecarboxylic acid {c/s-3-[5-(2-naphthalen-1-yl- acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide
Rf 0.56 (10% MeOH/CH2CI2 with 0.1 % NH4OH aq); mp 139.8 °C (mono HCl salt);
1HNMR (400MHz, d6 DMSO), δ 1.17-1.14 (m, 1 H), 1.32-1.28 (m, 1 H), 1.75-1.70 (m, 1 H), 1.97-1.89 (dd, J = 10.4, 10.4, 2H), 2.20-2.16 (m, 1 H), 2.55-2.49 (m, 2H), 3.02 (apt quint, J =
8.2 Hz, 1 H), 4.07 (s, 2H), 4.17 (m, 1 H), 6.30 (s, 1 H), 7.23-7.07 (m, 5H), 7.64-7.42 (m," 4H), 7.80 (d, J = 7.9, 1 H), 7.90 (d, J= 7.9 Hz, 1 H), 8.12 (d, J = 7.8 Hz, 1 H), 8.37 (d, J = 7.8 Hz, 1 H); 13C NMR (100 MHz, d6 DMSO) δ 172.9, 170.8, 152.5, 142.8, 140.8, 134.2, 132.4, 130.3, 129.0, 128.6, 128.3, 126.3, 126.1 , 125.9, 125.8, 125.4, 123.6, 92.9, 41.1 , 36.5, 25.5, 24.8, 24.2, 15.1 ; LRMS m/z (APCI+) 465.0 (M+1 ).
Example 48. N-[5-(c/s-3-Acetylamino-cyclobutyl)-1 H-pyrazol-3-yl]-2-naphthalen- 1 -yl-acetamide
Rf 0.50 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 1.86 (s, 3H), 1.97-2.05
(m, 2H), 2.59-2.66 (m, 2H), 3.07 (apt quint, J=8.0Hz, 1 H), 4.13 (s, 2H), 4.20 (apt quint, J=7.8Hz, 1 H), 6.25 (s, 1 H), 7.37-7.48 (m, 4H), 7.77 (d, J=7.9Hz, 1 H), 7.81-7.85 (m, 1H), 8.01-
8.03 (m, 1 H). 13C-NMR: 21.37, 24.64, 37.09, 40.20, 40.78, 93.59, 93.65, 123.71 , 125.41 , 125.70, 126.22, 127.88, 128.04, 128.68, 131.36, 132.45, 134.18, 146.36, 148.68, 170.53, 171.31. ). MS LRMS m/z (APCI+) 363 (M+1 ), mp 209.4 °C (HCl salt).
Example 49. N-{c/s-3-[5-(2-Naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide Rf 0.50 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.20-2.30 (m, 2H), 2.70- 2.80 (m, 2H), 3.20 (apt quint, J=8.0Hz, 1 H), 4.18 (s, 2H), 4.48 (apt quint, J=7.8Hz, 1 H), 6.24 (bs, 1 H), 7.38-7.50 (m, 7H), 7.75-7.88 (m, 4H), 8.00-8.06 (m, 1 H). 13C-NMR: 24.68, 36.92, 40.12, 41.47, 93.64, 123.68, 126.39, 126.72, 126.25, 127.20, 127.96, 128.12, 128.35, 128.59, 5 131.17, 131.66, 132.44, 134.20, 145.86, 149.19, 168.39, 170.60. MS LRMS m/z (APCI+) 425 (M+1 ), mp 194.0 °C(HCI salt).
Example 50. 2-Cyclopropyl-N-(c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-acetamide
Rf 0.60 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 0.93 (t, J=7.5Hz, 2H), 0 1.34 (d, J=6.2Hz, 1 H), 1.65 (d, J=5.0Hz, 1 H), 1.70-1.78 (m, 2H), 2.01-2.15 (m, 2H), 2.55-2.58 (m, 1 H), 2.62-2.68 (m, 2H), 3.20 (apt quint, J=7.8Hz, 1 H), 4.20 (s, 2H), 5.40 (apt quint, J=6.2Hz, 1 H), 6.22 (bs, 1 H), 7.40-7.56 (m, 4H), 7.78-7.88 (m, 2H), 8.02-8.08 (m, 1 H). 13C- NMR: 8.27, 24.52, 26.64, 36.63, 36,85, 36.96, 39.47, 40.12, 40.77, 77.66, 93.27, 112.50, 123.67, 125.38, 125.73, 126.24, 127.95, 128.14, 128.59, 132.45, 134.21 , 146.71 , 169.62, 5 170.63. MS LRMS m/z (APCI+) 403 (M+1 ), mp 93.2 °C (HCl salt).
Example 51. 6-Chloro-pyridine-2 -carboxylic acid {c/s-3-[5-(2-naphthalen-1-yl- acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide
Rf 0.50 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.25-2.42 (m, 2H), 2.76- 2.82 (m, 2H), 3.30 (apt quint, J=7.9Hz, 1 H), 4.22 (s, 2H), 4.54 (apt quint, J=7.δHz, 1 H), 6.35 0 (s, 1 H), 7.42-7.64 (m, 5H), 7.81-7.89 (m, 2H), 7.93-8.11 (m, 3H). 13C-NMR: 24.58, 36.65, 40.17, 41.06, 77.50, 93.77, 121.03, 122.58, 123.67, 123.82, 124.50, 125.40, 125.72, 126.24, 127.37, 128.01 , 128.11 , 128.59, 134.20, 140.63, 140.70, 144.41 , 150.36, 170.70, 182.15. MS LRMS m/z (APCI+) 460 (M+1 ), mp (dec) (HCl salt).
Example 52. Quinoline-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1-yl- 5 acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide
R, 0.30 (5% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.25-2.38 (m, 2H), 2.76- 2.78 (m, 2H), 3.25 (apt quint, J=8.3Hz, 1H), 4.16 (s, 2H), 4.56 (apt quint, 8.7Hz, 1 H), 6.36 (bs, 1 H), 7.38-7.49 (m, 4H), 7.60-7.64 (m, 1 H), 7.71-7.99 (m, 4H), 8.02-8.13 (m, 3H), 8.36 (d, J=8.7Hz, 1 H). 13C-NMR: 24.80, 37.08, 40.22, 41.08, 63.60, 94.03, 118.41 , 123.70, 124.50, 0 125.39, 125.70, 126.22, 127.25, 127.82, 128.15, 128.57, 129.42, 129.64, 130.34, 132.43, 134.18, 137.70, 137.80, 146.02, 146.73, 148.93, 149.60, 164.89, 170.57. MS LRMS m/z (APCI+) 476 (M+1), mp 200.3 °C (HCl salt).
Example 53. Pyrazine-2 -carboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl- acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide δ Rf 0.30 (6% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.26-2.38 (m, 2H), 2.75-
2.84 (m, 2H), 3.26 (apt quint, J=8.7Hz, 1 H), 4.21 (s, 2H), 4.55 (apt quint, J=8.7Hz, 1 H), 6.28 (s, 1 H), 7.42-7.54 (m, 4H), 7.81-7.89 (m, 2H), 8.03-8.07 (m, 1 H), 8.66 (d, J=2.δHz, 1 H), 8.76 (d, J=2.δHz, 1 H), 9.20 (s, 1 H). MS LRMS m/z (APCI+) 427 (M+1 ).
Example 54. 4-Methoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol- 3-yl]-cyclobutyl}-benzamide δ Rf 0.35 (5% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.17-2.26 (m, 2H), 2.68-
2.75 (m, 2H), 3.18 (apt quint, J=8.3Hz, 1 H), 3.79 (s, 3H), 4.15 (s, 2H), 4.44 (apt quint, J=7.8Hz, 1 H), 6.33 (s, 1 H), 6.91 (d, J=δ.0Hz, 2H), 7.37-7.49 (m, 4H), 7.77 (d, J=δ.0Hz, 2H), 7.82-7.84 (m, 1 H), 7.96-8.04 (m, 2H). 13C-NMR: 24.80, 37.02, 40.22, 41.46, 54.71 , 54.76, 93.90, 113.50, 123.72, 126.41 , 125.70, 126.22, 127.24, 127.88, 128.08, 128.58, 129.09, 0 131.36, 132.44, 134.17, 142.17, 146.03, 146.21 , 149.14, 162.76, 167.93, 170.56. MS LRMS m/z (APCI*) 455 (M+1), mp 175.6 °C (HCl salt).
Example 55. N-(c/s-3-[5-(2-Naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-3-nitro-benzamide
Rf 0.35 (5% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.26-2.34 (m, 2H), 2.74- 6 2.79 (m, 2H), 3.25 (apt quint, J=8.7Hz, 1 H), 4.19 (bs, 2H), 4.50 (apt quint, J=8.3Hz, 1 H), 6.31 (bs, 1 H), 7.37-7.49 (m, 4H), 7.63-7.80 (m, 3H), 8.19-8.33 (m, 2H), 8.58-8.65 (m, 2H). 13C- NMR: 24.82, 36.80, 40.10, 41.73, 93.87, 115.43, 118.34, 122.22, 122.28, 123.81 , 125.87, 126.27, 127.38, 127.87, 128.56, 129.81 , 131.39, 132.40, 133.22, 134.06, 135.89, 141.96, 142.04, 146.50, 161.89, 165.60. MS LRMS m/z (APCI+) 470 (M+1), mp 123.5 °C (HCl salt). 0 Example 56. 3,5-Dimethoxy-N-{c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-benzamide
Rf 0.50 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.23-2.30 (, 2H), 2.73-
2.79 (m, 2H), 3.23 (apt quint, J=8.3Hz, 1 H), 3.78 (s, 6H), 4.19 (bs, 2H), 4.47 (apt quint, J=8.3Hz, 1H), 6.30 (bs, 1 H), 6.62 (s, 1H), 6.97 (s, 2H), 7.41-7.52 (m, 4H), 7.85 (m, 2H), 8.03- 5 8.08 (m, 1 H). MS LRMS m/z (APCI+) 485 (M+1 )
Example 57. 4-Dimethylamino-N-{c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-benzamide
Rf 0.45 (10% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 2.18-2.28 (m, 2H), 2.70-
2.80 (m, 2H), 2.99 (s, 6H), 3.20 (apt quint, J=8.2Hz, 1 H), 4.18 (bs, 2H), 4.46 (apt quint, 0 J=8.3Hz, 1 H), 6.31 (bs, 1 H), 6.69 (d, J=8.7Hz, 2H), 7.42-7.53 (m, 4H), 7.71 (d, J=9. Hz, 2H),
7.80-7.88 (m, 2H), 8.06 (d, J=8.3Hz, 1 H). MS LRMS m/z (APCI+) 485 (M+1 ).
Example 58. N-[5-((1S)-Hydroxy-ethyl)-2H-pyrazol-3-yl]-2-naphthalen-1 -yl- acetamide
Synthesis of the title compound was accomplished by the method for the title 5 compound of Preparation 4.3, using a reactant analogous to naphthalen-1-yl-acetyl chloride.
This was followed by deprotection. The resulting intermediate was treated according to the method for Example 30.
Rf 0.50 (10%MeOH/ CH2CI2). 1HNMR (400MHz, CDCI3), δ 1.64 (d, J=6.6Hz, 3H), 4.12 (s, 2H), 5.97 (dd, J=6.6, 6.6Hz, 1 H), 6.47 (s, 1 H), 7.34-7.40 (m, 2H), 7.42-7.50 (m, 2H), 7.74- 7.87 (m, 3H). LRMS m/z (APCI+) 296 (M+1 ); mp 101.3 °C (HCl salt). Example 59. N-[5-(2-Hydroxy-(1S)-methyl-ethyl)-2H-pyrazol-3-yl]-2-naphthalen-
1 -yl-acetamide
Synthesis of the title compound was accomplished by the method for Preparation 4.3, using a reactant analogous to naphthalen-1 -yl-acetyl chloride. This was followed by deprotection. The resulting intermediate was treated according to the method for Example 30. HNMR (400MHz, CD3OD), δ 1.25 (d, J=7.1Hz, 3H), 2.92-3.01 (m, 1 H), 3.58-3.62 (m,
2H), 4.20 (bs, 2H), 6.22 (bs, 1 H), 7.40-7.58 (m, 4H), 7.80 (d, J=7.0Hz, 1 H), 7.88 (d, J=7.1 Hz, 1 H), 8.06 (d, J=7.0Hz, 1 H). LRMS m/z (APCI+) 310 (M+1 ), mp 117.6 °C (HCl salt).
Preparation 6.1. N-[5-[1 -(Benzothiazol-2-yloxy)-ethyl]-2-(4-methoxy-benzyl)-2H- pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide To a stirring solution of N-[5-(1-Hydroxy-ethyl)-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-
2-naphthalen-1 -yl-acetamide (300 mg, 0.72 mmol) in 7.2 mL of THF was added 2- chlorobenzthiozole (104 uL, 0.79 mmol, 135 mg) followed by a solution of KOBu' (1.4 mL, 1.4 mmol, 1.0 M in THF) dropwise. After 2 hrs the reaction was quenched with NH4CI and then diluted with EtOAc. The layers were separated and the organic layer was dried of MgS04, filtered and concentrated under reduced pressure. Purification of this material was accomplished by MPLC using a 10 g ISCO cartridge on a Biotage system eluting with 30% EtOAc/hexanes, collecting 8 mm fractions. The product-containing fraction was collected and concentrated under reduced pressure to give the title compound (100 mg, 25% yield) as a yellow viscous oil. R, 0.50 (50% EtOAc/Hexanes). 1HNMR (400MHz, CDCI3), δ 1.82 (d, J=7.5Hz, 3H),
3.74 (s, 3H), 4.06 (d, J=4.6Hz, 2H), 4.65 (dd, J=15.8, 15.8Hz, 2H), 6.02 (dd, J=7.1 , 7.1 Hz, 1 H), 6.27 (s, 1 H), 6.29 (d, J=8.7Hz, 2H), 6.51 (d, J=8.7Hz, 2H), 6.99-7.06 (m, 3H), 7.27-7.29 (m, 1 H), 7.30-7.38 (m, 1 H), 7.40-7.43 (m, 1 H), 7.50-7.60 (m, 2H), 7.87-7.95 (m, 3H). LRMS m/z (APCI+) 549 (M+1). Example 60. N-{5-[(1S)-(Benzothiazol-2-yloxy)-ethyl]-1H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide
The title compound was synthesized using Preparation 6.1 according to the method for Example 15.
Rf 0.41 (5% MeOH/ CH2CI2). HNMR (400MHz, CDCI3), δ 1.81 (d, J=7.1 Hz, 3H), 4.17 (s, 2H), 5.84 (dd, 6.7, 6.7Hz, 1 H), 6.68 (s, 1 H), 6.85 (d,J=7.9 Hz, 1 H), 7.10-7.20 (m, 2H), 7.32- 7.57 (m, 5H), 7.79-7.86 (m, 2H), 7.97-7.99 (m, 1H). LRMS m/z (APCI+) 429 (M+1). Example 61. N-[5-(Beπzothiazol-2-yloxymethyl)-1 H-pyrazol-3-ylj-2-naphthalen- 1 -yl-acetamide
The title compound was synthesized according to the method for Example 60, using analogous reactants. Rf 0.50 (5% MeOH/ CH2CI2). 1HNMR (400MHz, CD3OD), δ 4.20 (s, 2H), 5.38 (s, 2H),
6.46 (s, 1 H), 7.40-7.58 (m, 5H), 7.80-7.90 (m, 4H), 8.06-8.08 (m, 2H). LRMS m/z (APCI") 412 (M-1).
Example 62. N-{5-[(1 R)-(Benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide The title compound was synthesized according to the method for Example 60, using analogous reactants.
Rf O.41 (5% MeOH/ CH2CI2). 1HNMR (400MHz, CDCI3), δ 1.85 (d, J=7.1 Hz, 3H), 4.20 (s, 2H), 5.88 (dd, J=7.1 , 7.1 Hz, 1 H), 6.68 (s, 1 H), 6.91 (d, J=7.9Hz, 1H), 7.15-7.26 (m, 2H), 7.38-7.60 (m, 5H), 7.78-7.95 (m, 3H). LRMS m/z (APCI+) 429 (M+1 ). Example 63. N-{5-[c/s-3-(Benzooxazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide
The title compound was synthesized according to the method for Example 60, using analogous reactants.
R, 0.24 (10% MeOH/CH2CI2); mp 142.0 °C (mono HCl salt); 1HNMR (400MHz, CDCI3) δ 2.43-2.17 (m, 2H), 3.01-2.94 (m, 2H), 3.18 (apt quint, J = 8.3 Hz, 1 H), 4.12 (s, 2H), 5.21 (apt quint, J = 7.3Hz, 1 H), 6.59 (s, 1 H), 7.54-7.31 (m, 8H), 7.72 (dd, J = 7.9 Hz, 1 H), 7.77 (dd, 7.5 Hz, 1 H), 7.94 (d, J = 8.3 Hz, 1 H); 13C NMR (100 MHz, CDCI3 ) δ 170.3, 162.0, 151.5, 148.4, 143.2, 140.5, 134.0, 132.2, 129.7, 129.0, 128.8, 126.9, 125.8, 125.7, 124.7, 123.8, 123.5, 123.4, 118.1 , 110.1 , 94.9, 71.3, 41.5, 36.7, 22.8(m, 3H). LRMS m/z (APCI+) 439.1 (M+1 ). Preparation 7.1. N-[5-(c/s-3-hydroχy-3-phenyl-cyclobutyl)-2-(4-methoxy-benzyl)-
2H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide
Preparation of the starting ketone N-[2-(4-methoxy-benzyl)-5-(3-oxo-cyclobutyl)-2H- pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide was accomplished using a method analogous to that described for Preparation 4.4 (including synthesis of Preparations 4.1-4.3). A solution of the ketone (50 mg, 0.11 mmol) in tetrahydrofuran (5 mL) cooled to -30
°C was treated dropwise with phenyl magnesium bromide (500 uL, 0.5 mmol, 1 M solution in THF). Upon completion of addition, the reaction mixture was stirred for 40 min at -30 °C, then saturated aqueous ammonium chloride solution was added and the mixture was warmed to room temperature. THF was removed in vacuo, and the residue was diluted with methylene chloride which was washed with water and brine. The diluted residue was then dried and filtered. The crude material was purified by silica gel chromatography (50:1 chloroform- methanol) to afford 54 mg (80% yield) of the title comopund.
1 H NMR (400 MHz, CDCI3) δ 7.9 (m, 3H), 7.55 (m, 4H), 7.46 (m, 1 H), 7.35 (m, 3H), 7.21 (m, 1 H), 6.90 (m, 1 H), 6.80 (dd, J = 0.8, 8.7 Hz, 1 H), 6.54 (d, J = 8.7 Hz, 2H), 6.37 (d, J = 8.7 Hz, 2H), 6.34 (s, 1 H), 4.65 (s, 2H), 4.12 (s, 2H), 3.74 (s, 3H), 3.20 (m, 1 H), 3.01 (m, 2H), 2.55 (m, 2H); MS (AP/CI): 518.2 (M+H)+.
Preparation 7.2 N-[2-(4-methoxy-benzyl)-5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol- 3-yl]-2-naphthalen-1 -yl-acetamide
A solution of N-[5-(3-hydroxy-3-phenyl-cyclobutyl)-2-(4-methoxy-benzyl)-2H-pyrazol- 3-yl]-2-naphthalen-1-yl-acetamide (Preparation 7.1 , 54 mg, 0.10 mmol) in 1:1 methylene chloride-trifluoroacetic acid (4 mL) was treated with triethylsilane (1.2 mL) at 23 °C. After stirring for 16 h, the solvent was removed in vacuo and the residue was purified by silica gel chromatography (100:1 chloroform-methanol) to afford 39 mg (78% yield) of the title compound as a 10:1 mixture of cis - trans isomers.
1 H NMR (400 MHz, CDCI3): δ 7.90 (m, 3H), 7.56 (m, 2H), 7.45 (dd, J = 7.1, 8.3 Hz, 1 H), 7.30 (m, 3H), 7.25 (m, 1 H), 7.18 (m, 1 H), 6.78 (s, 1 H), 6.55 (d, J = 8.7 Hz, 2H), 6.36 (m,
3H), 4.63 (s, 2H), 4.10 (s, 2H), 3.74 (s, 3H), 3.44 (m, 2H), 2.73 (m, 2H), 2.30 (m, 2H); MS
(AP/CI): 502.2 (M+H)+; minor isomer, characteristic 1 H NMR signals: δ 4.66 (s), 4.12 (s),
2.60 (m).
Example 64. 2-naphthalen-1-yl-N-[5-(c/s-3-phenyl-cyclobutyl)-1H-pyrazol-3-yl]- acetamide
A solution of N-[2-(4-methoxy-benzyl)-5-(3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-2- naphthalen-1 -yl-acetamide (Preparation 7.2, 38 mg, 0.076 mmol) in trifluoroacetic acid (5 mL) at room temperature was treated with anisole (165 uL, 1.5 mmol). The solution was heated at 70 °C for 5 h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (40:1 chloroform-methanol) to afford 27 mg (89% yield) of the title compound as a 94:6 mixture of cis - trans isomers. The product was dissolved in ethyl acetate and treated with hydrogen chloride in diethyl ether to afford the HCl salt.
1 H NMR (400 MHz, CD30D): δ 8.04 (d, J = 8.3 Hz, 1 H), 7.88 (d, J = 7.5 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1 H), 7.50 (m, 4H), 7.28 (m, 4H), 7.17 (m, 1 H), 6.26 (s, 1 H), 4.27 (s, 2H), 3.59 (m, 2H), 2.82 (m, 2H), 2.30 (m, 2H); MS (AP/CI): 382.3 (M+H)+.
The title compounds of the following Examples 65-71 were synthesized as in Example 64, including synthesis of Preparations 7.1 and 7.2, using an analogous starting ketone:
Example 65. N-{5-[c/s-3-(2-Methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2- quinolin-6-yl-acetamide 1 H NMR (400 MHz, CDCI3): δ 9.23 (s, 1 H), 8.80 (dd, J = 1.7, 4.1 Hz, 1 H), 7.93 (m,
2H), 7.54 (d, J = 1.7 Hz, 1 H), 7.47 (dd, J = 2.1 , 8.7 Hz, 1 H), 7.27 (q, J = 4.1 Hz, 1 H), 7.15 (m, 1 H), 7.08 (d, J = 7.5 Hz, 1 H), 6.87 (td, J = 0.8, 7.5 Hz, 1 H), 6.78 (d, J = 7.9 Hz, 1 H), 6.57 (s, 1 H), 3.76 (s, 3H), 3.73 (s, 2H), 3.61 (m, 1 H), 3.38 (m, 1 H), 2.68 (m, 2H), 2.22 (m, 2H); MS (AP/CI): 413.2 (M+H)+.
Example 66. N-{5-[c/s-3-(2-Methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2- pyridin-3-yl-acetamide
1 H NMR (400 MHz, CD30D): δ 8.95 (s, 1 H), 8.82 (d, J = 5.8 Hz, 1 H), 8.67 (d, J = 8.3 Hz, 1 H), 8.11 (m, 1 H), 7.17 (m, 2H), 6.89 (m, 2H), 6.32 (s, 1 H), 4.21 (s, 2H), 3.81 (s, 3H), 3.76 (m, 1 H), 3.62 (m, 1 H), 2.82 (m, 2H), 2.34 (m, 2H); MS (AP/CI): 363.2.
Example 67. N- 5-[c/s-3-(2-Methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide hydrochloride
1 H NMR (400 MHz, CD30D): δ 8.03 (d, J = 7.9 Hz, 1 H), 7.89 (d, J = 7.5 Hz, 1 H), 7.83 (d, J = 7.5 Hz, 1 H), 7.5 (m, 4H), 7.17 (m, 2H), 6.91 (m, 2H), 6.22 (s, 1 H), 4.27 (s, 2H), 3.80 (s, 3H), 3.75 (m, 1 H), 3.60 (m, 1 H), 2.81 (m, 2H), 2.32 (m, 2H); MS (AP/CI): 412.2.
Example 68. N-{5-[c/s-3-(4- ethoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide
1 H NMR (400 MHz, CDCI3): δ 7.97 (m, 2H), 7.83 (d, J = 7.5 Hz, 1 H), 7.77 (m, 1 H), 7.49 (m, 2H), 7.40 (m, 2H), 7.11 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 6.51 (s, 1H), 4.08 (s, 2H), 3.78 (s, 3H), 3.4 (m, 2H), 2.69 (m, 2H), 2.18 (m, 2H); MS (AP/CI): 412.2; minor isomer, characteristic 1 H NMR signals: 6.65 (s), 2.51 (m). Example 69. N-{5-[c/s-3-(4-Chloro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2- naphthalen-1 -yl-acetamide
1 H NMR (400 MHz, CDCI3): d 7.96 (d, J = 7.5 Hz, 1 H), 7.85 (m, 2H), 7.74 (s, 1 H), 7.51 (m, 2H), 7.42 (m, 2H), 7.26 (m, 1 H), 7.12 (d, J = 8.3 Hz, 2H), 6.49 (s, 1 H), 4.12 (s, 2H), 3.40 (m, 2H), 2.72 (m, 2H), 2.20 (m, 2H); MS (AP/CI): 416.1 , 418.1 (M+H)+; minor isomer, characteristic 1 H NMR signals: δ 6.65 (s), 2.55 (m).
Example 70. 2-Naphthalen-1 -yl-N-[5-(c/s-3-p-tolyl-cyclobutyl)-2H-pyrazol-3-yl]- acetamide
1 H NMR (400 MHz, CDCI3): d 8.04 (s, 1 H), 7.95 (d, J = 7.9 Hz, 1 H), 7.81 (d, J = 8.3 Hz, 1 H), 7.75 (m, 1 H), 7.47 (m, 2H), 7.36 (m, 2H), 7.10 (m, 3H), 6.52 (s, 1 H), 4.06 (s, 2H), 3.38 (m, 2H), 2.70 (m, 2H), 2.32 (s, 3H), 2.20 (m, 2H); MS (AP/CI): 396.2; minor isomer, characteristic 1 H NMR signals: δ 6.65 (s), 3.65 (m), 2.51 (m).
Example 71. 2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]- 2H-pyrazol-3-yl}-acetamide
1 H NMR (400 MHz, CD30D): δ 7.23 (d, J = 8.7 Hz, 2H), 7.16 (d, J = 7.5 Hz, 2H), 6.89 (m, 4H), 6.21 (s, 1 H), 3.80 (s, 3H), 3.76 (s, 3H), 3.7 (m, 1 H), 3.67 (s, 2H), 3.59 (m, 1 H), 2.79 (m, 2H), 2.29 (m, 2H); MS (AP/CI): 392.2 (M+H)+.
The following additional Examples of compounds of the invention were synthesized as described herein:
N-{5-[c/s-3-(4-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[c/s-3-(3-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yi-acetamide;
2-Naphthalen-1-yl-N-[5-(c/s-3-pyridin-3-yl-cyclobutyl)-2H-pyrazol-3-yI]-acetamide;
N-[5-(c/s-3-Naphthalen-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-pyridin-3-yl-acetamide;
N-(5-lndan-2-yl-1 H-pyrazoI-3-yl)-2-quinolin-6-yl-acetamide;
N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide; N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
2-(4-Methoxy-phenyl)-N-[5-(c/s-3-pyridin-4-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[3-(c/s-2-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
N-(5-{cs-3-[3-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-pheny -acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[2-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-[5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol-3-yI]-acetamide;
N-{5-[c/s-3-(2-Fluoro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[4-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyl)-acetamide; N-(5-{c/s-3-[2-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(2-methylsulfanyl-phenyl)-cyclobutyl]-2H-pyrazol-3- yl}-acetamide;
N-{5-[c/s-3-(2-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(4-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-3-hydroxy-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-[c/s-3-(2-Hydroxy-ethyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide; N-{5-[c/s-3-(3-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[c/s-3-(3-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
4-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[c/s-3-(4-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazo)-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
Cyclopropanecarboxylic acid {5-[c/s-3-(2-hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3- yl}-amide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1H-pyrazol-3-yl}-isobutyramide;
N-{5-[c/s-3-(3-Aminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(3-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
3-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1 H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[c/s-3-(3-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-(5-{c/s-3-[3-(1 -Hydroxy- 1 -methyl-ethyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
N-{5-[c/s-3-(3-Ethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(3-Cyclobutylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-propylaminomethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopentylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; N-(5-{c/s-3-[3-(Benzylamino-methyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[3-(3-methylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol- 3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopropylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-pyrrolidin-1-ylmethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Diethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; and
N-{5-[c/s-3-(3-Azetidin-1-ylmethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide.

Claims

CLAIMSWhat is claimed is:
1. A compound of the formula
wherein R1 is a straight chain or branched (C.,-C8)alkyl, a straight chain or branched (C2-
C8)alkenyl, a straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3- 8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, or (5-11 membered) heterobicycloalkyl, and wherein R1 is optionally substituted with from one to six substituents R5 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, - NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, -NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, - OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, -OC(=0)NR7R8, -OC(=0)SR7, -SR7, - S(=0)R7, -S(=0)2R7, -S(=0)2NR7R8, and R7; R2 is H, F, -CH3, -CN, or -C(=0)OR7; R3 is -C(=0)NR9-, -C(=0)0-, -C(=O)(CR10R 1)n-, or -(CR10R11)n-; R4 is a straight chain or a branched a straight chain or a branched (C2-
C8)alkenyl, a straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, or (5-14 membered) heteroaryl; and wherein R4 is optionally substituted with from one to three substitutents R6 independently selected from F, CI, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C(=0)R8, -NR7C(=0)OR8, -NR7C(=0)NR8R9, -NR7S(=0)2R8, - NR7S(=0)2NR8R9, -OR7, -OC(=0)R7, -OC(=0)OR7, -C(=0)OR7, -C(=0)R7, -C(=0)NR7R8, - OC(=0)NR7Rs, -OC(=0)SR7, -SR7, -S(=0)R7, -S(=0)2R7, -S(=0)2NR7R8, or R7; each R7, RB, and R9 is independently selected from H, straight chain or branched (C C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C-^bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl, wherein R7, R8, and R9 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, I, -N02, -CN, -CF3, -NR10R11, - NR10C(=O)R11, -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR 0S(=O)2R11, -NR10S(=O)2NR11R12, - OR10, -OC(=0)R1°, -OC(=0)OR10, -OC(=O)NR10R11, -OC(=0)SR1°, -SR10, -S(=0)R10, -S(=0)2R10, -S(=O)2NR10R11, -C(=0)R10, -C(=0)OR1°, -C(=O)NR10R11, and R10; or, when R7 and R8 are as in NR7R8, they may instead optionally be connected to form with the nitrogen of NR7R8 to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further heteroatoms independently selected from N, O, and S; each R10, R11, and R12 is independently selected from H, straight chain or branched (Cr
C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl, wherein R10, R11, and R12 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, I, N02, -CN, -CF3, -NR13R14, -NR13C(=0)R14, -NR13C(=0)OR14, -NR13C(=0)NR14R15, -NR13S(=0)2R14, -NR13S(=0)2NR1 R15, -OR13, -OC(=0)R13, -OC(=0)OR13, -OC(=0)NR13R14, -OC(=0)SR13, -SR13, -S(=0)R13, -S(=0)2R13, -S(=0)2NR13R14, -C(=0)R13, -C(=0)OR13, -C(=0)NR13R14, and R13; each R13, R14, and R15 is independently selected from H, straight chain or branched (C C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C^bicycloalkyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl, wherein R13, R14, and R15 are each independently optionally substituted with from one to six substituents independently selected from F, CI, Br, I, N02, -CN, -CF3, -NR16R17, -NR16C(=0)R17, -NR15C(=0)OR17, -NR16C(=0)NR 7R18, -NR16S(=0)2R17, -NR16S(=0)2NR 7R18 -OR16, -OC(=0)R16, -OC(=0)OR16, -OC(=0)NR16R17, -OC(=0)SR16, -SR1S, -S(=0)R16, -S(=0)2R16, -S(=0)2NR16R17, -C(=0)R18, -C(=0)OR16, -C(=0)NR16R17, and R16 each R 6, R17, and R18 is independently selected from H, straight chain or branched (Ct-
C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C^Jbicycloalkyl,
(C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, and (5-14 membered) heteroaryl; n is O, 1 , 2, or 3; wherein R10 and R 1 in -C(=O)(CR10R11)n- and -(CR10R11)n- are for each iteration of n defined independently as recited above; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R3 is -(CR10R11)n-, -C(=0)NH- or -C(=O)(CR10R1V
3. A compound according to claim 1 , wherein R1 is optionally substituted (C3-C8)cycloalkyl or optionally substituted (Cs-C^) bicycloalkyl.
4. A compound according to claim 3, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, or bicyclo-[3.1.0]-hexyl, each optionally substituted.
5. A compound according to claim 1 , wherein R1 is optionally substituted straight chain or branched (C C8)alkyl or optionally substituted straight chain or branched (C2-
C8)alkenyl.
6. A compound according to claim 1 , wherein R4 is (C6-C14)aryl or (5-14 membered) heteroaryl, each optionally substituted.
7. A compound according to claim 6, wherein R4 is phenyl, pyridyl, naphthyl, quinolyl, isoquinolyl, pyrimidinyl, pyrazinyl, or pyridazyl, each optionally substituted.
8 A compound according to any of claims 1-7, wherein R2 is hydrogen.
9. A compound of claim 1 , selected from the group consisting of:
(5-ethyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-2-yl-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-1-yl-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-naphthalene-1 ,4-diamine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-pyridine-2,6-diamine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(6-trifluoromethyl-pyridin-2-yl)-amine; (3-benzyloxy-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethyl-phenyl)-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-benzene-1 ,3-diamine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3-methoxy-phenyl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(4-nitro-phenyl)-amine; (4-chloro-benzyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
(3-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-quinolin-2-yl-amine;
[5-(1 ,4-dioxa-spiro[4.4]non-7-yl)-1 H-pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine;
(6-chloro-pyridin-2-yl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; 3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentanone;
(5-cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-4-methyl-quinolin-2-yl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine;
(2-chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazoI-3-yl)-amine;
3-trans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentanol; (3,5-bis-trifluoromethyl-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
[5-(3-c/s-benzylamino-cyclopentyl)-1 H-pyrazol-3-yl]-(3-trifluoromethyl-phenyl)-amine; {5-[3-c/s-(4-methoxy-benzylamino)-cyclopentyl]-1 H-pyrazol-3-yl}-(3-trifluoromethyl- phenyl)-amine;
4-(5-cyclobutyl-2H-pyrazol-3-ylamino)-benzonitrile;
(5-cyclobutyl-2H-pyrazol-3-yl)-(3-fluoro-phenyl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3,5-dichloro-phenyl)-amine;
(2-brorno-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine;
N-{c/s-3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-acetamide; pyridin-2-yl-{3-frans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- amine; (5-cyclobutyl-1 H-pyrazol-3-yl)-(4-methoxy-phenyl)-amine; pyridine-2 -carboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
3-trifluoromethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yI]- cyclopentyl}-benzamide; cyclobutanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
2,2-dimethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- propionamide;
4-fluoro-N-{3-t5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- benzamide;
2,2,2-trifluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- acetamide; cyclopropanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide; N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-propionamide; cyclohexanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide;
N-[5-(3-acetylamino-cyclopentyl)-2H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide; cyclopropanecarboxylic acid {3-[5-(2-naphthalen-1 -yl-acetylamino)-1 H-pyrazol-3-yl]- cyclopentyl}-amide;
2-naphthalen-1-yl-N-{5-[3-(2,2,2-trifluoro-acetylamino)-cyclopentyl]-2H-pyrazol-3-yl}- acetamide;
N-{3-[5-(2-naphthalen-1-yl-acetylamino)-1 H-pyrazol-3-yl]-cyclopentyI}-benzamide;
N-(5-hydroxymethyl-1 H-pyrazol-3-yl)-2-naphthalen-1 -yl-acetamide; 2-naphthalen-1 -yl-N-[5-(thiazol-2-ylaminomethyl)-1 H-pyrazol-3-yl]-acetamide;
N-[5-(( 1 S)-hydroxy-ethyI)-2H-pyrazol-3-yl]-2-naphthalen- 1 -yl-acetamide; N-{5-[(1S)-(benzooxazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
N-{5-[(1 S)-(benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide; N-[5-(3-hydroxy-1 -methyl-propyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
N-[5-(benzothiazol-2-yloxymethyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
N-{5-[3-(benzothiazol-2-yloxy)-1 -methyl-propyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-[5-(2-hydroxy-(1S)-methyl-ethyl)-2H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide; N-{5-[(1 R)-(benzothiazol-2-yloxy)-ethyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-[5-(3-acetylamino-1 -methyl-propyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
3-methoxy-N-{c/s-3-[5-(2-naphthalen-1-yI-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- benzamide; N-[5-(c/s-3-acetylamino-cycIobutyl)-1 H-pyrazol-3-yl]-2-naphthalen-1 -yl-acetamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-benzamide;
2-cyclopropyl-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-acetamide;
6-chloro-pyridine-2-carboxylic acid {c/'s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; quinoline-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide; pyrazine-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide; 4-methoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- benzamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-3-nitro- benzamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-3- trifluoromethyl-benzamide;
N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- isobutyramide;
2-phenyl-cyclopropanecarboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; N-{5-[c/s-3-(benzooxazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide; 4-dimethylamino-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-ylj- cyclobutylj-benzamide;
3,5-dimethoxy-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutylj-benzamide; 2-naphthalen-1-yl-N-[5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[c/s-3-(3-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yI}-2-πaphthalen-1 -yl- acetamide; N-{5-[c/s-3-(4-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
2-naphthalen-1-yl-N-[5-(c/s-3-p-tolyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[c/s-3-(4-chloro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide; 2-(4-methoxy-phenyl)-N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yI}- acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-pyridin-3-yl-acetamide; N-{5-[c/s-3-(4-methoxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
2-quinolin-6-yl-N-[5-(c/s-3-p-tolyl-cyclobutyl)-1 H-pyrazol-3-yl]-acetamide;
N-{5-[c/s-3-(4-fiuoro-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(4-chloro-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
2-quinolin-6-yl-N-[5-(c/s-3-m-tolyl-cyclobutyl)-1 H-pyrazol-3-yl]-acetamide; 4-dimethylamino-N-{c/s-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide;
2-naphthalen-1-yl-N-{5-[c/s-3-(pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
6-methyl-pyridine-2-carboxylic acid {c/s-3-[5-(2-naphthalen-1 -yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; 2-phenyl-cyclopropanecarboxylic acid methyl-{c/s-3-[5-(2-naphthalen-1-yl- acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-amide;
N-{5-[c S-3-(3-methyl-pyrazin-2-yloxy)-cyclobutyl]- 1 H-pyrazol-3-yl}-2-naphthalen- 1 -yl- acetamide;
{5-[c/s-3-(2-methoxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-(6-methoxy-pyridin-2-yl)- amine; N-{5-[c/s-3-(3,6-dimethyl-pyrazin-2-yloxy)-cycIobutyl]-1 H-pyrazol-3-yl}-2-naphthalen- 1 -yl-acetamide;
N-{5-[c/s-3-(3-methoxy-pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1- yl-acetamide; 2-methyl-cyclopropanecarboxylic acid {c/s-3-[5-(2-naphthalen-1-yl-acetyIamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide;
2-naphthalen-1-yl-N-{5-[c/s-3-(3-trifluoromethyl-pyridin-2-yloxy)-cyclobutyl]-1 H- pyrazol-3-yl}-acetamide;
2-naphthalen-1 -yl-N-{5-[c/s-3-(3-nitro-pyridin-2-yloxy)-cyclobutyl]- 1 H-pyrazol-3-yI}- acetamide;
N-{5-[c/s-3-(benzothiazol-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
2-naphthalen-1 -yl-N-{5-[c/s-3-(4-trifluoromethyl-pyrimidin-2-yloxy)- cyclobutyl]-1 H- pyrazol-3-yl}-acetamide; 2-naphthalen-1 -yl-N-{5-[3-(5-nitro-pyridin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}- acetamide;
2-naphthalen-1-yl-N-{5-[3-(pyrimidin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
2-naphthalen-1 -yl-N-{5-[3-(5-trifluoromethyl-pyridin-2-yloxy)- cyclobutyl]-1 H-pyrazol-3- yl}-acetamide; N-{5-[3-(6-methoxy-pyridazin-3-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1 -yl- acetamide;
2-naphthalen-1-yl-N-{5-[3-(pyrazin-2-yloxy)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
N-{5-[3-(6-methy!-pyridin-2-yloxy)-cyciobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; N-{5-[3-(6-chloro-benzothiazol-2-yloxy)-cyclobutyI]-1 H-pyrazol-3-yl}-2-naphthalen-1 - yl-acetamide;
N-{5-[3-(6-methoxy-benzothiazol-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen- 1 -yl-acetamide;
N-{5-[c/s-3-(4-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[c/s-3-(3-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
2-Naphthalen-1-yl-N-[5-(c/s-3-pyridin-3-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide;
N-[5-(c/s-3-Naphthalen-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-pyridin-3-yl-acetamide;
N-(5-indan-2-yl-1 H-pyrazol-3-yl)-2-quinolin-6-yl-acetamide;
N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide; N-[5-(c/s-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yI]-2-quinolin-6-yl-acetamide;
2-(4-Methoxy-phenyl)-N-[5-(c/s-3-pyridin-4-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-{5-[3-(c/s-2-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
N-(5-{c/s-3-[3-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[2-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-[5-(c/s-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-{5-[c/s-3-(2-Fluoro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{c/s-3-[4-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazoI-3-yl)-2-(4-methoxy- phenyl)-acetamide;
N-(5-{c/s-3-[2-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyl)-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(2-methylsulfanyl-phenyl)-cyclobutyl]-2H-pyrazol-3- yl}-acetamide;
N-{5-[c/s-3-(2-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[c/s-3-(4-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-3-hydroxy-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(2-Hydroxy-ethyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
N-{5-[c/s-3-(3-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[c/s-3-(2-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[c/s-3-(3-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
4-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1 H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[c/s-3-(4-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-phenyl-acetamide; N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-acetamide;
Cyclopropanecarboxylic acid {5-[c/s-3-(2-hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3- yl}-amide; N-{5-[c/s-3-(2-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-isobutyramide;
N-{5-[c/s-3-(3-Aminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(3-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl )-acetamide; 3-(c/s-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1 H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[c/s-3-(3-Hydroxymethyl-phenyl)-cyclobutylj-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-(5-{c/s-3-[3-(1-Hydroxy-1-methyl-ethyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
N-{5-[c/s-3-(3-Ethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(3-Cyclobutylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-propylaminomethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopentylaminomethyl-phenyI)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
N-(5-{c/s-3-[3-(Benzylamino-methyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-pheny))-acetamide;
2-(4-Methoxy-phenyl)-N-{5-[3-(3-methylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol- 3-yl}-acetamide;
N-{5-[c/s-3-(3-Cyclopropylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[c/s-3-(3-pyrrolidin-1-ylmethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide;
N-{5-[c/s-3-(3-Diethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[c/s-3-(3-Azetidin-1-ylmethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
10. A pharmaceutical composition for treating a disease or condition comprising abnormal cell growth or a neurodegenerative disease or condition in a mammal comprising a compound of claim 1 in an amount effective in treating said disease or condition, and a pharmaceutically acceptable carrier. 5
11. A pharmaceutical composition for treating a disease or condition in a mammal the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission comprising a compound of claim 1 in an amount effective in treating said disease or condition or in an amount effective to inhibit cdkδ activity, and a pharmaceutically acceptable carrier. 0
12. A pharmaceutical composition for treating in a mammal a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb 6 immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency, comprising a compound of claim 1 in an amount effective in treating said disease or condition, and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a compound according to claim 1 and a second member selected from the group consisting of an SSRI, an NK-1 receptor 0 antagonist, a δHT1D antagonist, ziprasidone, olanzapine, risperidone, L-746870, sonepiprazole, RP 62203, NGD 941 , balaperidone, flesinoxan, gepirone, an acetylcholinesterase inhibitor, TPA, NIF, a potassium channel modulator such as BMS- 204362, and an NMDA receptor antagonist, wherein the cdkδ inhibitor and the second member are together in an effective amount, and a pharmaceutically acceptable carrier. δ 14. A compound of the formula
wherein Prot is a protecting group;
R2 is H, F, -CH3, -CN, or -C(=0)OR7; and n is an integer selected from 1 , 2, 3, and 4. 0
EP01958287A 2000-08-31 2001-08-24 Pyrazole derivatives and their use as protein kinase inhibitors Withdrawn EP1313710A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31
US229415P 2000-08-31
PCT/IB2001/001540 WO2002018346A1 (en) 2000-08-31 2001-08-24 Pyrazole derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
EP1313710A1 true EP1313710A1 (en) 2003-05-28

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01958287A Withdrawn EP1313710A1 (en) 2000-08-31 2001-08-24 Pyrazole derivatives and their use as protein kinase inhibitors

Country Status (38)

Country Link
EP (1) EP1313710A1 (en)
JP (1) JP2004507526A (en)
KR (1) KR20030027093A (en)
CN (1) CN1518543A (en)
AP (1) AP2001002266A0 (en)
AR (1) AR035345A1 (en)
AU (1) AU2001280009A1 (en)
BG (1) BG107455A (en)
BR (1) BR0113574A (en)
CA (1) CA2420363A1 (en)
CR (1) CR6881A (en)
CZ (1) CZ2003468A3 (en)
DO (1) DOP2001000243A (en)
DZ (1) DZ3398A1 (en)
EA (1) EA200300205A1 (en)
EC (1) ECSP034480A (en)
EE (1) EE200300085A (en)
GT (1) GT200100179A (en)
HN (1) HN2001000192A (en)
HR (1) HRP20030140A2 (en)
HU (1) HUP0302669A3 (en)
IL (1) IL154016A0 (en)
IS (1) IS6687A (en)
MA (1) MA26946A1 (en)
MX (1) MXPA03001785A (en)
NO (1) NO20030958D0 (en)
NZ (1) NZ523656A (en)
OA (1) OA12368A (en)
PA (1) PA8528101A1 (en)
PE (1) PE20020470A1 (en)
PL (1) PL360742A1 (en)
SK (1) SK2002003A3 (en)
SV (1) SV2002000618A (en)
TN (1) TNSN01132A1 (en)
UY (1) UY26909A1 (en)
WO (1) WO2002018346A1 (en)
YU (1) YU14703A (en)
ZA (1) ZA200301064B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001291013A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001297619B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1441724B8 (en) * 2001-09-27 2007-10-17 Laboratoires Serono SA Methods of increasing endogenous testosterone levels
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
MXPA04007832A (en) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aryl ureas with angiogenesis inhibiting activity.
ES2304531T3 (en) * 2002-07-17 2008-10-16 Pfizer Italia S.R.L. HETEROBICICLIC DERIVATIVES OF PIRAZOL AS QUINASA INHIBITORS.
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
EP1551842A1 (en) * 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
JP2006519234A (en) * 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション New compounds
ATE366108T1 (en) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp DIARYL UREAS FOR PDGFR-MEDIATED DISEASES
WO2005009344A2 (en) * 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
KR101204247B1 (en) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators
UA84156C2 (en) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP2006528661A (en) * 2003-07-25 2006-12-21 ファイザー・インク Aminopyrazole compounds and use as CHK1 inhibitors
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1781637A1 (en) 2004-06-29 2007-05-09 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
AU2005306458B2 (en) 2004-11-17 2011-02-17 Miikana Therapeutics, Inc. Kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
MX2007009437A (en) 2005-02-04 2007-08-16 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors.
US20090156582A1 (en) * 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
SI1853588T1 (en) 2005-02-16 2008-10-31 Astrazeneca Ab Chemical compounds
MX2007014328A (en) 2005-05-16 2008-02-12 Astrazeneca Ab Chemical compounds.
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20140025610A (en) 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. Substituted pyrazole compounds
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN103145702A (en) 2005-11-03 2013-06-12 顶点医药品公司 Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
JP5323707B2 (en) 2006-10-18 2013-10-23 ペリネス リミテッド Methods and pharmacological compositions for diagnosis and treatment of male fertility decline
RU2009119181A (en) * 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS Glycogen synthase-kinase-3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CN101641099A (en) 2007-01-24 2010-02-03 葛兰素集团有限公司 Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
MX2010000617A (en) 2007-07-17 2010-05-17 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
BRPI0816881A2 (en) 2007-09-21 2015-03-17 Array Biopharma Inc Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound.
JPWO2009130900A1 (en) * 2008-04-24 2011-08-11 日本曹達株式会社 Oxime derivatives, intermediate compounds and plant disease control agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010114928A2 (en) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
JP2013506691A (en) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole inhibitors of phosphatidylinositol 3-kinase
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP5941069B2 (en) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for kinase regulation and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
RU2016109243A (en) * 2013-08-16 2017-09-20 Мерк Патент Гмбх 3-SUBSTITUTED CYCLOPENTHYLAMINE DERIVATIVES
CN106580986B (en) * 2016-11-28 2017-09-15 王保亮 A kind of pharmaceutical composition for treating teen bra
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CN113330000A (en) * 2019-01-31 2021-08-31 辉瑞公司 3-carbonylamino-5-cyclopentyl-1 FI-pyrrole compound having inhibitory activity against CDK2
TW202229268A (en) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2 inhibitor and preparation method thereof
WO2023278326A1 (en) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Cdk2 inhibitors
WO2023274397A1 (en) * 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Cdk2 inhibitor, preparation method therefor and use thereof
TW202325280A (en) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 An aminopyrazole derivative, preparation method and use thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814374B1 (en) * 1997-12-22 2013-09-17 "Substituted heterocyclic ureas and compositions comprising them"
KR100579792B1 (en) * 1998-05-13 2006-05-12 동화약품공업주식회사 Novel 2,5-pyridinedicarboxylic acid derivatives
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
DE60024631T2 (en) * 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl UREA DERIVATIVES
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EP1202733B1 (en) * 1999-08-12 2005-10-05 Pharmacia Italia S.p.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
OA12097A (en) * 1999-11-30 2006-05-04 Pfizer Prod Inc 2,4-Diaminopyrimidine compounds useful as immunosuppressants.
JP2004501083A (en) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド Pyrazole for inhibiting protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0218346A1 *

Also Published As

Publication number Publication date
OA12368A (en) 2004-04-13
HUP0302669A3 (en) 2004-03-29
BG107455A (en) 2003-09-30
SV2002000618A (en) 2002-10-24
NO20030958L (en) 2003-02-28
TNSN01132A1 (en) 2005-11-10
CA2420363A1 (en) 2002-03-07
EE200300085A (en) 2004-12-15
NZ523656A (en) 2004-11-26
GT200100179A (en) 2002-04-22
IL154016A0 (en) 2003-07-31
UY26909A1 (en) 2002-03-22
AU2001280009A1 (en) 2002-03-13
CZ2003468A3 (en) 2004-05-12
PA8528101A1 (en) 2002-07-30
HN2001000192A (en) 2001-08-28
IS6687A (en) 2003-01-16
MA26946A1 (en) 2004-12-20
NO20030958D0 (en) 2003-02-28
AP2001002266A0 (en) 2001-09-30
KR20030027093A (en) 2003-04-03
AR035345A1 (en) 2004-05-12
WO2002018346A1 (en) 2002-03-07
CR6881A (en) 2004-03-11
ZA200301064B (en) 2004-04-19
PE20020470A1 (en) 2002-06-18
CN1518543A (en) 2004-08-04
MXPA03001785A (en) 2003-06-04
HRP20030140A2 (en) 2003-04-30
SK2002003A3 (en) 2004-04-06
ECSP034480A (en) 2003-03-31
HUP0302669A2 (en) 2003-12-29
YU14703A (en) 2006-05-25
JP2004507526A (en) 2004-03-11
DZ3398A1 (en) 2002-03-07
EA200300205A1 (en) 2003-06-26
BR0113574A (en) 2003-07-22
DOP2001000243A (en) 2002-10-15
PL360742A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
WO2002018346A1 (en) Pyrazole derivatives and their use as protein kinase inhibitors
US20050209297A1 (en) Pyrazole derivatives
JP4166084B2 (en) Imidazole derivatives
US20060149066A1 (en) Imidazole derivatives
EP1256578B1 (en) Thiazole derivatives and their use as cdk inhibitors
US8362065B2 (en) Carbazole carboxamide compounds useful as kinase inhibitors
US8124610B2 (en) Sodium channel inhibitors
US20100069348A1 (en) Novel compounds as cannabinoid receptor ligands
US20020103185A1 (en) Pyrazole derivatives
US20030083352A1 (en) Synthesis of imidazole intermediates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030218

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080301